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RNA-Seq has become the most recently and widely accepted method to evaluate gene 
expression.  Though with RNA-Seq being a fairly green technology, analytical methods for its 
output data have not been fully investigated as they have for preceding technology; such as those 
methods used in analyses of microarray data.  This is likely the result of the potential breadth of 
information that can be obtained from the different applications of RNA-Seq.  Analyses of RNA-
Seq data include: detecting differentially expressed genes, transcriptome profiling, and 
interpretation of gene functions.  As with any advanced technology medical or otherwise, the 
longer it is available, the price of the technology, in general, decreases and the technology itself 
becomes more refined.  This has been true for genomic sequencing—costs per sample have 
continued to decrease; and the accuracy and precision of results has improved greatly.  
Synchronously, more physicians have opted to have more of their patients’ genetic material 
sequenced.  This has caused both challenges in the development of accurate, efficient, and 
consistent statistical methods; and much debate regarding the ethics involved in genomic 
sequencing.  To provide insight into two statistical challenges that are common with analyzing 
RNA-Seq data, we conduct extensive simulation studies.  These simulations studies include: 1) 
investigation of fitting complex models which account for pairedness across subject’s 
measurements in terms of the power gained and control of Type I error rate; and 2) evaluation of 
clustering performance of various clustering methods in transformed RNA-Seq data.  In addition 
to investigating the aforementioned statistical challenges, we develop a protocol for a survey 
study which has the potential to provide insight into cancer patients’ opinions towards genomic 
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It is highly unlikely that Charles Darwin, Gregor Mendel, and Frederick Miescher, the 
first fathers of genetics, fully understood the greatness of their historic scientific discoveries.  
Beginning in 1859, the field of genetics was established with Charles Darwin’s discovery of 
natural selection, where generations of organisms were shown to reproduce and survive through 
evolution, mutation, migration, and genetic drift; Gregor Mendel’s experiment which revealed 
heritability in 1865; and Frederick Miescher’s detection and isolation of DNA for the first time 
in 1869 (Darwin, 1872, Fisher, 1930, Dahm, 2005, Bateson and Gregor, 1913).  Nearly a century 
later, James D. Watson and Francis H. Crick made another significant, well-known, discovery.  
With some help from X-ray diffraction images contributed by Rosalind Franklin, Watson and 
Crick discovered that the molecular structure of DNA was a three-dimensional, double helix 
(Wilkins, 1963, Watson and Crick, 1953, Heather and Chain, 2016).   
Crick furthered his research in 1970 through his documentation of the Central Dogma of 
Biology which explains the transfer of genetic information from the three major molecular 
components, DNA, RNA, and protein, which are responsible for structure and function in any 
living organism (Crick, 1970).  Figure I-1 contains a simplified version of the Central Dogma of 
Biology.  The general information transfers that can occur are: DNA transcribed into RNA, RNA 
translated into proteins, DNA and RNA replicate into copies of themselves, RNA reversed 
transcribed in DNA, and the rare phenomena of DNA to protein depending on the cellular 
environment (Crick, 1970).  As the Central Dogma of Biology became widely accepted across 
the life sciences’ research community, the race to expand its three branches began with the 
overall goal to better understand the molecular basis of life.  Thus, it became highly important to 
be able to identify genetic transcripts (i.e., read the sequence of nucleic acid), quantify genes and 
their expression values, and understand functional responsibilities of genes and proteins.  To 
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address these important topics, a collective approach needs to be taken where biological, 
statistical, and informatics techniques are heavily utilized together.  
 
Figure I-1.  The Central Dogma of Biology (Your Genome, 2016). The Central Dogma of 
Biology is the flow of genetic information.  DNA is made into RNA through a process called 
transcription; and RNA is made into proteins through translation.  Both DNA and RNA have the 
ability to replicate itself.  Both DNA and RNA are made up of four nucleic acid bases.  In DNA, 
the nucleic acid bases are Adenine (A), Thymine (T), Cytosine (C), and Guanine (G), which pair 
A to T and G to C.  In RNA, the nucleic acid bases are the same with the Thymine being 
exchanged for Uracil (U), where the new pairings become A to U and G to C (Your Genome, 




 The advent of genomic sequencing, along with its advancements, have been an integral 
part to better understand the molecular components of life.  Initially said by Frederick Sanger, 
“knowledge of sequences could contribute much to our understanding of living matter” (Sanger, 
1980).  Ideas and efforts amongst many in the molecular biology and chemistry research 
communities were focused on developing techniques to read the nucleic acid sequence present in 
DNA.  The mid 1960s gave way to the first-generation of sequencing, sequencing capable of 
reading up to approximately one killobase (kb), through paralleling work completed by Robert 
Holley and Frederick Sanger and their respective colleagues in fragments of RNA, and 
contributions of sequencing DNA fragments from Maxam and Gilbert (Heather and Chain, 2016, 
Holley, 1965, Maxam and Gilbert, 1977).  This first-generation of sequencing was termed 
Sanger sequencing (Heather and Chain, 2016).  It was this first-generation of sequencing that set 
the stage for second- and third-generations of sequencing which currently have the capability to 
sequence vast amounts of genetic material by running multiple samples at the same times, and 
even single molecule real time (SMRT) sequencing (Heather and Chain, 2016, Van Dijk et al., 
2014).   
The improvements of sequencing led to additional development of innovative technologies 
that have the ability to determine genetic expression levels.  Microarrays were invented in the 
1990s to conduct gene expression studies on a large-scale and was used religiously by the 
science community to solve a multitude of scientific problems (Zhao et al., 2014).  However, the 
mid 2000s gave rise to an updated method to quantify gene expression.  That next generation 
sequencing (NGS) method was RNA-sequencing which has come to be known as RNA-seq.  
While obtained gene expression is the end result between each of these technologies, the basis 
behind each of them is very different.  Microarray technologies utilizes relative mRNA which is 
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measured using pre-defined probe sets via fluorescence to determine expression value; whereas, 
RNA-Seq experiments measure gene expression levels from the total number of reads that fall 
into the exons of a gene.  Hence, the output data from these two technologies is dissimilar.  Gene 
expression values from microarrays are continuous and have a tendency to follow a Gaussian 
distribution, while gene expression values from RNA-Seq are count in nature and follow either 
over-dispersed Poisson or Negative Binomial distributions. 
1.1 RNA-Seq Studies 
With microarray technology having tenure amongst most of the biological research 
community, there have been debates about adoption of the newer RNA-Seq technology.  Prior to 
the mid 2000s, many, Schena (1995), DeRisi et al. (1997), Brown and Botstein (1999), Neilsen 
et al. (2002), and Monti et al. (2005) to name a few, worked extensively to quantify patterns in 
gene expression present in particular disease states, environmental or biological conditions, and 
different tissue types.  Since 2008, RNA-Seq has rapidly become a forerunner in next-generation 
sequencing (NGS) when it comes to analysis of high-throughput gene expression analysis (Reeb, 
2013). The saturation of the current literature discussing studies that use RNA-Seq and its 
applications is proof of its rise in popularity.  The RNA-Seq platform itself has the ability to 
address many applications outside of obtaining determining gene expression values.  
Specifically, scientists have used the RNA-Seq platform for discovery of novel transcripts and 
isoforms, RNA editing, alternative splicing, allele-specific expression, and exploration of non-
model-organism transcriptomes (Anders et al., 2013, Wang et al., 2009, Mortazavi, 2008).   
With the adoption and wide-spread use of RNA-Seq, new analysis methods have been 
developed.   As the implication of these analysis have the potential to play roles in treatment 
plans for patients or future diagnostics, it is important that sound, accurate statistical methods 
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need to be implemented.  That is, the statistical analysis should consider both experimental 
design and the unique characteristics of “omic” study type (Reeb, 2013).  All “omic” studies 
(i.e., genomics, proteomics, metabolomics, etc) have unique characteristics that are solely unique 
to said study.  The potential amount of information that can be derived from these types of 
studies is highly impressive.  Concurrently, the amount of physical data that is output from these 
types of studies requires much storage as sequencers for a single sample can produce more than 
500 gigabases for a single run depending on the platform used (Trapnell et al., 2012).  However, 
concerns about the difficulties involved in analyzing the massively complex gene expression 
datasets often containing expression information for 60K+ gene IDs have also been published.  
Some of the questions that arise are centered around the challenges that come with the analyses 
of RNA-Seq data, or benefit gained from the abundance of data that is provided using RNA-Seq.  
In order to move forward with the advancement of the area of genomics, statisticians and 
bioinformaticians need to work together seamlessly to insure that all of the analyses that are 
taking place are correct and computationally efficient.  Such analyses takes much practice, 
patience, careful revision, and understanding of both biological processes and statistical 
methodologies.   
To investigate some of the statistical challenges and difficulties that arise when working 
with RNA-Seq data, two extensive simulation studies were conducted.  Our first study was 
motivated by the poor overlap similarly found differentially expressed genes when comparing 
commonly used differential expression methods when using paired measurement data.  We 
sought to determine if the basic models that were fit within the differential expression methods 
controlled Type I error rate or has sufficient power when data were of a paired structure.  In our 
second study, we aim to evaluate clustering performance of RNA-Seq data that were subjected to 
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a variety of data transformations to make them “look” more normally distributed.  In planning 
these two studies, an interest in the ethics behind personalized medicine via genomic sequencing 
was sparked.   
1.2 Ethics in Precision Medicine 
According to the National Human Genome Research Institute (NHGRI) through the National 
Institutes of Health (NIH), medical science will take on an extremely personalized view in the 
next 50 years.  Their hope was to use genome-based research to develop “highly effective 
diagnostic tools”, “better understand the health needs of people based on their individual genetic 
make-ups”, and “design new and highly effective treatments for disease” (National Human 
Genome Research Institute et al., 2010).  Moreover, the goal is to have individualized analysis 
based on a given person’s genome to gather information to regarding the types of preventative 
measures that can be prescribed, lifestyle changes, and even molecular understanding of diseases 
such as diabetes, heart disease, or cancer which are make up a large portion of the amount of 
medical expenditures in any given year in the United States (National Human Genome Research 
Institute et al., 2010).  Formally defined, precision medicine, or also synonymously termed 
personalized or individualized medicine, is the tailoring of disease treatments and/or 
interventions to the unique characteristics, both genotypic and phenotypic, that an individual has 
(Ciardiello et al., 2014).  However, with the idea of using genomic sequencing to tailor medical 
treatment, concerns over the ethics behind such approach to medical care ensue.  There are 
numerous concerns regarding how incidental finds should be handled, identification of the 
individual, and many others to be mentioned in Chapter IV.  As advances in personalized 
medicine through way of genomic sequencing continue, it will be crucial to understand cancer 
patients’ opinions regarding the topic.  Thus, a protocol was developed to carry out a pilot survey 
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study which contains a 22-item survey with questions regarding patient’s demographic 
information and their opinion towards genomic testing. 
The studies involved in this dissertation are motivated by the need for accurate, efficient, 
and consistent statistical methods to analyze RNA-Seq data; as well as, the ethical concerns that 
arise with genomic sequencing.  Chapter 2 contains a comparison study of paired and unpaired 
methods for Differential Expression Analysis of RNA-Seq.  An empirical study is completed 
comparing the number of similar genes found between sets of overlapping methods.  
Additionally, we conducted a simulation study to examine consequences of improperly analyzing 
data structures common in RNA-Seq studies.  Chapter 3 is comprised of a lengthy simulation 
study which assesses data transformations and clustering methods for RNA-Seq data.  Clustering 
is completed under the assumption that the number of clusters is known or unknown.  Chapter 4 
describes the setup our patient’s opinion survey study which can potentially be extended to a 
large-scale, national survey.  This dissertation concludes with an overall discussion and possible 
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Discovery of differentially expressed (DE) genes is imperative for the understanding of 
the genomic basis of complex diseases and phenotypes.  Thus, the development of powerful 
computational methods with control of the Type I error rate for analysis is crucial.  In this study, 
we applied multiple DE analysis methods to an RNA-Seq study involving paired ovarian tumor 
samples pre- and post- treatment with carboplatin from 11 subjects.  Our objective was to 
investigate how much statistical power is gained by using a paired analysis method for RNA-Seq 
data when a generalized linear model is fit with either subject effect modeled as a covariate or as 
a random effect which can be difficult for small sample sizes.  Moreover, we wanted to gain 
insight into whether fitting a more complex model, which accounts for pairedness across 
subject’s measurements for small sample size (i.e., n = 11), is more beneficial than ignoring the 
paired data structure and proceeding with an unpaired analysis method.  Additionally, we sought 
to see how results changed between various distributional models for RNA-Seq count data—
Negative Binomial, Poisson, of Gaussian.  To accomplish these objectives, we compared the 
results between a number of DE methods that do and do not account for the paired nature of the 
study to assess the power gained and/or increase and Type I error rates using this ovarian study 
and an extensive simulation study.   Results from our empirical study found that the DE methods 
do not select the same set of DE genes, with only a few DE genes found to be in common 
between the different analyses.  To investigate the root cause of poor overlap of determined DE 
genes, a simulation study was conducted with the objective to examine Type I error rates and 
power.  The simulation study contained multiple scenarios which varied the following:  from 
which distribution the data were simulated, the sample size in each group (i.e., N = 100, 150, and 
200 samples), and the level of correlation / dependency between the measurements (i.e., 𝜌 =
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0, 0.3, and 0.5).  Data were simulated under the null hypothesis to assess the control of the Type 
I error rate, assuming correlated (paired) or uncorrelated (unpaired) data measurements from 
Bivariate Normal, Bivariate Poisson, and Bivariate Negative Binomial distributions.  Following 
the simulation of the data, two types of models where then fit to determine DE genes; method 
that account for the correlation or paired-ness of the data and ones that do not. The simulation 
results demonstrated that Type I error was controlled for all paired and unpaired scenarios where 
data were simulated from the Bivariate Normal distribution.  However, this was not the case for 
data simulated using Bivariate Poisson and Bivariate Negative Binomial Distributions.  Type I 
error rate was only controlled at the 0.05 level when data were unpaired and analyzed using a 
Generalized Linear Model (GLM).  Concurrently, fitting the more complex Generalized Linear 
Mixed Model (GLMM) resulted in controlled Type I error rate in the Bivariate Poisson and 
Bivariate Negative Binomial paired data when measurements were correlated at 𝜌 = 0.3 and 𝜌 =
0.5, respectively.  Furthermore, empirical power was calculated for those scenarios for which 
Type I error rate was controlled (Type I error < 0.05).  Overall results suggest that data structure 
should not be ignored when conducting analyses, especially if study sample size is lower.   While 
control of the Type I error rate was not affected by sample size, the power to conduct analyses 
that reached control of the Type I error rate did vary with sample size, specifically power 
increased with larger sample size regardless of simulated correlation and distribution framework 
as expected.  Additionally, our findings showed that if Type I error rate was controlled beyond < 
0.05, that power would be loss in comparison to those scenarios controlled at right around 0.05.  
In conclusion, our results advocate that it is more beneficial to fit the more complex model to 
account for pairedness of subjects’ measurements.  
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2.2  Introduction 
 
RNA Sequencing (RNA-Seq) studies can be used to address many critical research 
questions.  Most commonly, RNA-Seq studies address questions relating to the relative 
abundance of read expression counts that are present for a given gene.  One of the most 
fundamental analysis that is performed on RNA-Seq count data is differential expression (DE) 
analysis.  As its name suggests, DE analysis is the comparison of gene expression values among 
samples from varying experimental conditions.  Some examples of experimental conditions that 
might lead to genes that are differentially expressed include comparisons of: normal tissue verses 
tumor tissue; different tissue types; and tissue samples before, during or after a given treatment 
or exposure.  Inherently, one could assume that the different experimental conditions have the 
potential to produce expression differences across samples for a given gene; however, some 
genes may remain unaffected (Hardcastle, 2016).  At face value, analysis for DE seems rather 
simple.  Although, according to Trapnell et al. (2013), two major challenges exist: (1) obtaining 
gene and isoform expression values accurately from raw sequencing data, and (2) handling the 
variation that is present across biological replicates within an experiment.  The resulting goal of 
DE analysis is to determine in a gene-wise fashion those genes that are differentially expressed 
according to a specified cutoff of a given evaluation criteria (i.e., p-value or False Discovery 
Rate (FDR)) when ranked (Love et al., 2014, Trabzuni et al., 2014).   
Quantification of gene expression via read counts is based on how many reads absolutely 
or probabilistically align with the reference genome (Conesa et al., 2016).  These read counts can 
be modelled through the use of a discrete distribution; such as the Poisson distribution or the 
Negative Binomial distribution (Anders, 2010, Robinson, 2007).  However, it should be noted 
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for RNA-Seq analysis that it is important to know the background of the samples that have been 
processed.  In RNA-Seq type experiments, typically more than one sample is obtained—rather 
multiple samples, or replicates, are obtained for a given condition.  These replicates can be 
technical replicates meaning that they are from the same organism; or they can be biological 
replicates meaning that they are from different individuals.  This is relevant in selecting the 
distribution that best fit the data.  The Poisson distribution is typically chosen when the data are 
comprised of technical replicates (Marioni et al., 2008).  Though, for biological replicates, the 
Negative Binomial distribution is more appropriate as the overdispersion parameter can be tuned 
to account for the variation between people.  Additionally, data from RNA-Seq studies tends to 
be collected in a paired data structure that is represented by varying (e.g., samples from different 
tissue types) or contrasting conditions (e.g., before and after treatment) (Chung et al., 2013).  
Microarray data also have technical and biological replicates.  However, when fitting and 
analyzing microarray data the Gaussian framework is applied as expression values are 
continuous.  
Working with count distributions is often less appealing than normal distributions as the 
mathematical theory restricts “performance and the usefulness of RNA-Seq analysis methods” 
(Law et al., 2014).  Even with the rapid advancement of technology, limitations exist in the range 
of statistical tools available to handle count distributions as compared to normal distributions 
(Law et al., 2014).  While current statistical tools used to analyze RNA-Seq count data have 
attempted to incorporate many types of count distributions and models, no tool has been 
universally adopted.  The arguments when analyzing RNA-Seq data, in general, have been a 
continued debate as to whether or not the data “needs” to be analyzed using discrete distributions 
or is it possible to use a Normal distribution which is continuous.  Though, as any type of 
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sequencing experiment is highly costly, small sample sizes may be ideal for researchers 
(Hardcastle and Kelly, 2010).  However, these small sample sizes can cause major challenges 
and issues for statisticians.  Statisticians are constantly working to improve the statistical theory 
to allow for analyses that are hindered by the type of study data, sample size availability, and 
model / data assumptions.  There is evidence in statistical literature showing that correct 
modeling of the mean-variance relationship inherent in a count data generating process is key to 
designing statistically powerful methods of analysis (McCullagh and Nelder, 1989).  
Additionally, in conducting DE analysis, consideration needs to be given regarding the multiple 
testing that occurs—separate hypothesis is test for each of the thousands of genes (Trabzuni et 
al., 2014). 
Count data alone are fairly straightforward; however, the attributes of sequencing count 
data make it unique.  In sequencing data, sequencing depth and library size are taken into 
consideration when preforming analysis.  Additionally, transcripts are not independent from one 
another; and across the genome much of the information is shared (Trabzuni et al., 2014). 
However, the Generalized Linear Model (GLM) has the capability to adapt and handle the for 
mentioned sequencing attributes and ability to handle complex experiments (Anders et al., 2013).  
Linear Mixed Models (LMMs) have also been used in the analysis of gene expression data.  One 
caveat to fitting a LMM is that they are limited as they do not allow for the differences in 
expression variability that are typically present in RNA-Seq data (Trabzuni et al., 2014).  
When it comes to the analysis of paired structured count data, many have tried using 
many variations of the above listed discrete distributions.  In earlier years prior to the invention 
of the microarray or next-generation sequencing, Farwell and Sprott (1988) and Lee (1996) 
considered the use of a mixture model to handle the nuances of count data.  However, these early 
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attempts at testing paired structured data assume independence of the paired data which is 
conditioned on the samples mean (Chung et al., 2013).  In general, the Poisson model can be 
utilized when samples are independent of one another, rather no replicates are present.  However, 
in recent years it has been recognized that the paired nature of the data should be analyzed 
accordingly.  The Negative Binomial model and the Bivariate Poisson model have been proposed 
to be used when handling paired samples as they can account for correlation between 
observations (Chung et al., 2013, Karlis and Ntzoufras, 2006, Khafri et al., 2008).   
In the sections that follow, we investigate how much statistical power is gained by using 
a paired analysis method for RNA-Seq data when a generalized linear model is fit with either 
subject effect modeled as a covariate or as a random effect which can be difficult for small 
sample sizes.  Moreover, we wanted to gain insight into whether fitting a more complex model, 
which accounts for pairedness across subject’s measurements for small sample size (i.e., n = 11), 
is more beneficial than ignoring the paired data structure and proceeding with an unpaired 
analysis method.  Additionally, we seek to know how results change between various 
distributional models for RNA-Seq count data—Negative Binomial, Poisson, of Gaussian.   To 
do so, we conduct multiple comparisons between seven differential expression methods that do 
and do not account for the paired nature of the study to assess the power gained and/or increase 
in Type I error rates using an ovarian cancer study and a simulation study.  Summaries are then 
provided for both the empirical and simulation studies.  
2.3  Materials and Methods 
 
To build upon the current knowledge in the literature, we address the aims of this study 
through an empirical study of several differential expression (DE) methods to find genes that are 
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differentially expressed.  Conducting analyses that assess the differences expression, rather 
differences among the counts in transcripts or exons, across varying experimental conditions is a 
fundamental building greater understanding about the human genome (Robinson et al., 2010).  A 
consensus has yet to be reached regarding which of the developed tools for evaluating is best.  
This likely is due to the general complexities of RNA-Seq data, and in turn model variations that 
serve as the basis in each of the DE methods.  Often DE methods are capable of addressing data 
that are paired and/or unpaired.  Hence, it is important when running the methods to correctly 
specify the fit models to insure that they are consistent with the structure of the data.  This leads 
us to a second investigation.  Additionally, we explore the model basis for testing for differential 
expression for each of the DE methods.  We wanted to look at the shear basic models that are fit 
to test for differentially expressed genes without influence from any other tuning factors that are 
implemented by “black box” programs or packages.  This is accomplished through a simulation 
study which simulates paired and unpaired data structures from varying distributions and varied 
levels of pairedness, and investigates control of the Type I error rate when data structure is 
considered in test for differential expression.  All analyses for this study were conducted in R 
statistical software (R Development Core Team, 2016). 
2.3.1 Empirical Study 
To date, many studies have been completed for comparing DE methods.  Searching for 
genes that are differentially expressed when different experimental conditions have been 
exhibited, has been said to be the most popular use of transcriptome profiling (Soneson and 
Delorenzi, 2013).  In 2013, several similarly themed articles were published that compared 
analyses methods for differential expression by Rapaprot et al. (2013), Soneson and Delorenzi 
(2013), Guo et al. (2013), and Seyednasrollah et al. (2013).  However, there has been limited 
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results on comparison of methods that account for the paired-ness in the study design.  In our 
study, we chose to compare DE methods based on whether or not the method can handle both 
paired (i.e., measurements taken from the same subject at different time points) and unpaired 
samples (i.e., assuming that all samples and measurements are independent from one another). 
Currently, there are nearly 15 developed methods that can conduct differential expression 
analysis each of which use different normalization techniques, read count distribution 
assumptions, methods for estimating the over-dispersion parameter in the negative binomial 
distributional model, or in the or type of test used to determine differential expression.   
In our empirical study, we investigated seven commonly used methods to determine 
differentially expressed genes between two groups of samples (e.g, tumor-normal, treatment – 
no treatment).  These seven methods consisted of BaySeq, CuffDiff, DESeq2, EdgeR, EBSeq, 
PairedBayes, and Voom.  Most of these methods are commonly used in practice and are 
contained within packages in Bioconductor (Gentleman et al., 2004).  Methods were selected 
based on their ability to handle either or both paired (i.e., matched pairs) and unpaired (i.e., 
independent) data.  Additionally, they were selected to reflect both Frequentist and Bayesian 
theoretic backgrounds.  Table II-1 provides a summary of the aforementioned method’s design 
and theoretical attributes.  In Table II-1, it can be noticed that the DE evaluation criteria are not 
the same for all DE methods.   
By default, the evaluation criteria are the p-value, False Discovery Rate (FDR), and 
posterior probability of equal expression (PPEE).  Recall, the p-value is the probability of 
obtaining an observed or greater result assuming that given null hypothesis holds true.  FDR is a 
metric that evaluates “the proportion of errors committed by falsely rejecting the null 
hypotheses” when multiple test are conducted  (Benjamini and Hochberg, 1995).  From Bayesian 
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statistics, the posterior probability is the probability of observations being assigned to relative 
groups given the data (Gelman, 2013).  The cutoffs for each of the method’s evaluation criteria 
were determine to reflect those value which would traditionally be used for such type of analysis.  
It should also be mentioned each method was carried out using only the default codes and 
functions.  Additionally, it should be noted that baySeq, DESeq2, edgeR, and EBSeq apply 
filters to remove those  genes that are not expressed; also, in Cuffdiff genes with low expression 
are removed (Leng et al., 2013).   
 
 
Table II-1.  Summary of Differential Expression methods.  Differential Expression (DE) 
methods are summarized based upon their design capabilities (i.e., the ability to handle data that 
are paired in nature and those that are truly independent from one another); as well as, the 
theoretical backgrounds behind each method.  The DE methods use False Discovery Rate (FDR), 
p-value, or Posterior Probability of Equal Expression (PPEE). 
 
Following the analyses that used solely defaults, we extended our analysis in converting 
our evaluation criteria to be similar across all methods so that we might make stronger 
conclusions about the number of DE genes that are determined by each of the methods.  To 
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accomplish this, we needed to find an evaluation criteria that would be suitable across all DE 
methods.  For our scenarios, it was decided to change our p-values and PPEE to a FDR.  
Converting PPEE is fairly simple as the way in which it is calculated is actually an estimate for 
the FDR (Leng et al., 2013).  It is also possible to convert p-values to FDR using theory 
developed my Benjamini and Hochber (1995), Efron et. al. (2001) , Storey (2010), and Storey et. 
al. (2015).  This procedure has been simplified by the development of the qvalue package in 
Bioconductor (Storey et al., 2015, Gentleman et al., 2004).  A list of p-values can be supplies to 
the qvalue() function within the package.  Calculations are carried out to determine the local 
FDR (lFDR) which can be used as an estimation of FDR.  Specifically, the lFDR in an extension 
of the FDR developed by Benjamini and Hochberg (1995) which allows for a posterior 
probability for each feature level (Chong et al., 2015).  Details on this calculation can be found in 
Appendix A.  
2.3.1.1 Ovarian Tumor Study  
The study data that we empirically evaluated came from Dr. Jeremy Chien in the 
Department of Cancer Biology at the University of Kansas Medical Center.  In Dr. Chien’s study 
11 matched pair ovarian cancer samples were obtained.  These matched samples were obtained 
from the same patient taken pre- and post-treatment of intravenous Carboplatin.  Carboplatin is a 
chemotherapy medication that damages genetic material in cells making it harder for repair of 
any genetic material (Rozencweig et al., 1983).  Each patient was consented for tumor collection 
and DNA testing.  Tissue samples were flash frozen to preserve their attributes and further 
processed by cryosection at 20-30 micron sections.  RNA from these sections was extracted 
through the use of Trizol.  Furthermore, the Illumina RNA-Sequencing kit was used to generate 
the sequencing libraries.  Sequencing was completed using Illumina HiSeq 2000 using eight 
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samples per lane.  Running eight samples per lane helped to combat variations due to lane effects 
which include “any errors that occur from the point at which the sample is input to the flow cell 
until data are output from the sequencing machine” (Auer and Doerge, 2010).  Output for each of 
the samples contain read counts for approximately 63K Ensembl gene IDs.  Figure II-1 displays 
the relationship between the log-transformed mean and variance of this RNA-Seq data from the 
ovarian tumor study.  As we expect from RNA-Seq data, we observe that our data are 
overdispersed with respect to the mean and variance relationship.   
 
Figure II-1.  Comparison of log-transformed mean and log-transformed variance across 
samples per Ensemble gene ID from the empirical study data.  Log-mean and log-variance of 
gene express counts were calculated and plotted verses each other to show overdispersion 






Figure II-2.  Distribution of gene-wise correlation from the empirical study data.  
Histogram displays the frequency of correlations that were found in data from the empirical 
study.  Correlations were calculated for individual genes between pre- and post-treatment 
samples. 
 
The data from the ovarian tumor study are paired in nature as the RNA-Seq expression 
measurements were taken prior to the patient being treated with Carboplatin and post completion 
of the study.  The correlation between all 63K+ Ensembl gene IDs range from -1 to 1.  Seventy-
five percent of the gene correlations were seen between -0.25 and 0.5 (Figure II-2).  In our 
empirical study, we sought to conducted differential expression analysis for this study using 
methods that do or do not account for the pairedness in the measurements.  Additionally, we 
broke the relationship between the pairedness of the samples and analyzed them as if they were 
independent observations (i.e., ignoring the paired-nature of the data).  This relationship is 
broken so that we can gain a better understanding of the consequences that arise when the data 
structure is not considered in the statistical analysis. The structure of the data for the paired and 
unpaired are given below. 
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For this empirical study, let 𝑿 be the 𝐺 by 𝑁 matrix where 𝑥𝑔𝑖 is the raw RNA-Seq 
expression count for the 𝑔th gene (𝑔 =  1, … , 𝐺) and the 𝑖th sample (𝑖 =  1, … ,𝑁).  Here, 𝐺 =
62,897 Ensembl gene IDs and 𝑁 = 22 samples which reflects the 11 patients that have two 
measures recorded to reflect pre- and post-treatment expression levels 
𝑿 = [
𝑥11 𝑥12 ⋯ 𝑥1𝑁
𝑥21 𝑥22 … 𝑥2𝑁
⋮ ⋮ ⋱ ⋮
𝑥𝐺1 𝑥𝐺2 ⋯ 𝑥𝐺𝑁
]. 
In the paired analyses, we define an additional 22 𝑥 1 vector that defines when sample were 
taken say q.  Values for q are assigned as such: 
𝑞𝑖 = {
0  𝑖𝑓 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝑡𝑎𝑘𝑒𝑛 𝑝𝑟𝑒 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡


















































.  Using 𝑿, 𝒒 and 𝒔 an 
appropriate model or design matrix can be defined.  The unpaired analysis does not utilize 𝒒 as 
we assume that there is no dependency between the treatment groups and treat measurements as 
if they were independent. 
2.3.1.2 Methods Used in Differential Expression Analysis 
Testing for differentially expressed genes from two or more conditions requires 
conducting a statistical test for each gene 𝐺 = 1,… , 𝑔.  The most simple hypothesis for 
differential expression is assuming that one experimental condition which yields a “prior to” 
condition and an “after” condition.  Rather, in looking at differential expression, we test the null 
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hypothesis that the expression of a gene remains equal when comparing two or more conditions 
(i.e., equally expression regardless of experimental condition)  
𝐻𝑜: 𝜇𝑔,   𝐴 = 𝜇𝑔,   𝐵 
where 𝜇𝑔,   𝐴 or 𝜇𝑔,   𝐵 is the mean expression of the 𝑔
th gene in condition A or B.  Rejecting this 
null hypothesis results in the conclusion that the gene of interest is differentially expressed.  The 
goal with any method that conducts differential expression analysis is to minimize the number of 
type I errors (controlling at a given alpha level), while have the most power to detect a true 
difference.  
baySeq 
baySeq employs an empirical Bayesian method for identifying differential expression in 
sequence count data; and has the capability of considering more than just pairwise comparisons 
by borrowing information across the dataset unlike its counterparts, edgeR, DEGSeq, and DESeq 
(Hardcastle and Kelly, 2010).  Specifically, the empirical Bayesian method is used to estimate 
posterior likelihoods for patterns of differential expression by gene (Hardcastle, 2016).  These 
posterior probabilities are assessed through the consideration of a parametrically defined 
distribution for which some prior distribution exists (Hardcastle and Kelly, 2010).  
Determination of DE genes is based upon similarity of their prior distributions—genes that are 
similar will have the same prior distribution, while genes that are different will have different 
prior distributions (Hardcastle and Kelly, 2010).  In this approach, new estimates for the prior 
probabilities for each model can be obtained by an iterative procedure starting at an initial choice 
(Hardcastle and Kelly, 2010).  Once convergence of this iterative process is reached, the estimate 
is assumed to be found.  Through the use of this numerical Bayesian method the structure of the 
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original data is maintained (Hardcastle and Kelly, 2010).  Details of this method can be found in 
Hardcastle and Kelly (2010).   
Cuffdiff  
Cuffdiff, a program within Cufflinks, is a differential expression analysis method that 
models variability of RNA-Seq library fragments by using individual transcript and across all 
replicates (Trapnell et al., 2012, Trapnell et al., 2013).  The method seeks to test statistical 
significance of the observed change in gene expression between two or more samples for a given 
condition.  Statistical significance is tested through the use of a mixture model containing a Beta 
and Negative Binomial Distribution, a Beta Negative Binomial distribution model, which 
assumes that the number of reads per transcript is proportional to its abundance (Trapnell et al., 
2013, Trapnell et al., 2012).  The Beta distribution accounts for the uncertainty in the transcript 
fragment counts while the Negative Binomial distribution considers the overdispersion that is 
present across counts (Trapnell et al., 2013).  An advantage that Cuffdiff has is that upstream 
analysis from Cufflinks has the ability to remove the source bias that is a result of the protocol 
used in the library preparation prior to completion of assessing genes that are differentially 
expressed (Trapnell et al., 2012). 
DESeq2 
DESeq2 is another RNA-Seq method which tests for differential expressions under the 
Negative Binomial Generalized Linear Model (GLM) framework for paired samples (Love et al., 
2014, Love et al., 2016).  DESeq2 is the improved version of DESeq (Anders and Huber, 2010) 
with the addition of its capability to use shrinkage to estimate fold change and dispersion (Love 
et al., 2014).  The implementation of the DESeq2 method follows below.  Read counts are 
modeled as 𝑁𝐵~(𝜇𝑔𝑖, 𝛼𝑔) where 𝜇𝑔𝑖 = 𝑠𝑔𝑖𝑞𝑔𝑖.  𝑞𝑔𝑖 is a quantity that is proportional to the 
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concentration of cDNA fragments scaled by 𝑠𝑔𝑖 for the 𝑔
th gene and the ith sample (Love et al., 
2014).  The link function for the GLM is log2 𝑞𝑔𝑖 = ∑ 𝛽𝑔𝑟𝑥𝑖𝑟𝑟 .  Following closely to the 
empirical Bayes procedure mentioned in baySeq, empirical Bayes shrinkage is used to obtain the 
new estimates for dispersion and fold change.  Utilizing a shrinkage type estimation is highly 
beneficial for moderating “noisy estimates” that may be the result of controlled experiments with 
small sample size (Love et al., 2014).  To test for differential expression, a Wald test is used to 
compare 𝛽 coefficients. 
EdgeR 
EdgeR is a Bioconductor package that performs differential expression analysis between 
two or more groups through the use empirical Bayes estimation (Robinson et al., 2010, 
Robinson, 2008, Robinson, 2007).  One constraint that this software implements is that 
replicated measurements must be present for at least one of the groups (Robinson et al., 2010).  
EdgeR utilizes read counts from multiple unpaired or paired samples that are compiled into 
FASTQ files and later processed into BAM files.  EdgeR is highly flexible in that it can account 
for samples that are independent or paired/matched.  Raw read counts are model using an 
overdispersed Poisson model which can be written as a Negative Binomial(Robinson et al., 
2010).  Formally, the count data are model as 
𝑌𝑔𝑖~𝑁𝐵(𝑀𝑖𝑝𝑔𝑗, 𝜙𝑔) 
for gene 𝑔 and sample 𝑖; where 𝑀𝑖 is the library size or total number of reads, 𝑝𝑔𝑗 is the relative 
abundance of gene 𝑔 in experimental group 𝑗, if appropriate, to which sample 𝑖 belongs, and 𝜙𝑔 
the dispersion for the gene 𝑔 (Robinson et al., 2010).  It follows that the mean and variance for 
this parameterization are 𝜇𝑔𝑖 = 𝑀𝑖𝑝𝑔𝑗 and 𝜇𝑔𝑖(1 + 𝜇𝑔𝑖𝜙𝑔), respectively.  It should be noted that 
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when the dispersion parameter is equal to zero, the model becomes Poisson.  The combination of 
the overdispersed Poisson or Negative Binomial distribution to model the data and the empirical 
Bayes estimation procedure help to account for the technical and biological variability present 
across genes and allow for information to be borrowed between genes (Robinson, 2007).  
EBSeq 
EBSeq is another empirical Bayesian approach to determining differential expression.  
Though this method is not limited to solely DE in genes, it has the ability to identify DE 
isoforms when inputs are estimates of isoform expression (Leng et al., 2013).  Prior to testing, 
expression values are normalized using Median Normalization which accounts for the variability 
across samples (Anders and Huber, 2010).  Following the empirical Bayes process mentioned 
above in baySeq and DESeq2, posterior likelihoods are estimated to determine genes that are 
differentially expressed (Seyednasrollah, 2013).  Specific details can be found in Leng et al. 
(2013). 
pairedBayes 
The last of the Bayesian methods investigated is paired Bayes.  As the name suggests, 
this method utilizes a Bayesian hierarchical approach that is capable of handling paired gene 
expression data—both within and between sample variation are accounted for in this method 
(Chung et al., 2013).  The over-arching goal is to determine differential expression through the 
estimation of the posterior probability of a given gene (Chung et al., 2013).  The Poisson-Gamma 
mixture model that is used has priors assigned to some of its parameters.  Following Chung et al. 
(2013), we start with the paired design we have two observations (𝑌𝑔𝑖1, 𝑌𝑔𝑖2) where 𝑌𝑔𝑖1 is the 
observed expression level before treatment, 𝑌𝑔𝑖2 is the observed expression level after treatment,  
𝑔 = 1,… , 𝐺 genes and 𝑖 = 1,… , 𝑛 samples.  When conditioning 𝑌𝑔𝑖1 and 𝑌𝑔𝑖2 on their true 
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baseline relative expression to the library size (i.e., 𝜆𝑔𝑖), and the expression level fold chance 
after treatment (i.e., 𝒳𝑔), the basis of our mixture model, the Poisson portion, takes shape as: 
𝑌𝑔𝑖1|𝜆𝑔𝑖, 𝒳𝑔~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 (𝑁𝑖1𝜆𝑔𝑖) 
𝑌𝑔𝑖2|𝜆𝑔𝑖, 𝒳𝑔~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 (𝑁𝑖2𝜆𝑔𝑖𝒳𝑔) 
where 𝑁𝑖1 and 𝑁𝑖2 are the sizes of the libraries.  Here, the goal is to test if there is any treatment 
effect, or rather, where 𝒳𝑔 ≠ 1.  Furthermore, the Gamma portion of the mixture model which is 







where the shape and rate parameters are 𝛼𝑔 and 𝛽𝑔, respectively.  In this two-component mixture 
model we are able to describe the fold change distribution through a latent variable 𝑧𝑔.  
𝑧𝑔 = {
0 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑒𝑞𝑢𝑎𝑙 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 (𝐸𝐸), 𝜋0
1 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 (𝐷𝐸), 𝜋1
}. 
Within the model hierarchy above, prior distributions are assigned to many of the parameters.  
Those priors are as follows: log(𝒳𝑔)|(𝑧𝑔 = 0)~𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝜎𝑜
2) ; log(𝒳𝑔)|(𝑧𝑔 =
1)~𝑁𝑜𝑟𝑚𝑎𝑙(𝜇1, 𝜎1
2);  non-informationve priors for 𝛼𝑔 and 𝛽𝑔; (𝜋0, 𝜋1 )~𝐷𝑖𝑟𝑖𝑐ℎ𝑙𝑒𝑡(1,1); 𝜇1 has 
an improper prior; 𝑝(𝜎0
2) ∝  1
𝜎0
2⁄ ; and 𝑝(𝜎1
2) ∝  1
𝜎1
2⁄ .  It should be noted that joint 






Variance modeling at the observation level, termed Voom, is a method located within the 
limma software package (Smyth, 2005, R Development Core Team, 2016) which aims to 
conduct differential expression while considering the mean-variance relationship that exists 
among counts (Law et al., 2014).  Voom does so by applying precision weights to normalized 
counts while considering the trend of the mean-variance (Law et al., 2014).  Estimation of the 
mean-variance trend of log transformed reads is completed non-parametrically (Law et al., 
2014).  Once the estimates are obtained, they are used to predict the variance of each of the log 
counts per million (cpm) values (Law et al., 2014).  The predicted variance is then incorporated 
into inverse weights for corresponding log-cpm values (Law et al., 2014).  A summary of the 
procedure to find the associated weights continues as such: using the normalized log-cpm values 
gene-wise linear models are fitted; residual standard deviations for each gene are produced and a 
robust trend is fitted; results from the linear model and standard deviation trend produce 
predicted count and count size, respectively; and weights for a given observation are specified by 
the inverse squared predicted standard deviation for said observation (Law et al., 2014).  From 
here, the information, log-cpm values and associated weights, can be put into the limma pipeline 
to for differential expression. 
2.3.2  Simulation Study  
In this section, we describe the setup of the conducted simulation which investigates 
controlling Type I error rate when testing for differential expression of paired and unpaired data 
with methods that account for the study design / repeated measurements nature of the data.  
Conduction of this type of simulation study to determine the validity of a statistical model for 
differential expression has become the most popular method used (Reeb, 2013).  The following 
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simulation study extends from a recent study conducted by Reeb and Steibell (2013).   In our 
simulation study, we simulate both paired and unpaired data from Normal, Poisson, and the 
Negative Binomial distributions.  These distributions were specifically selected as each have 
been used to simulated gene expression data at some point in history.  The Normal distribution 
has been used in the past to simulate continuous microarray data; whereas, the Poisson, and 
Negative Binomial distributions have been used to simulate RNA-Seq data.  Though, some 
researchers apply data transformations to the count data with the aim to make the count data 
more normal which allows for the use of methods that suitable for continuous data.  One of the 
data transformation that is used is log(“expression count value” + 1). 
Recently, the most common way to simulate RNA-Seq data has been through use of 
variations of the Negative Binomial distribution.  In addition to simulating data from different 
distributions, we further consider different sample sizes (i.e., N = 100, 150, and 200 subjects).  
As an aside, it should be mentioned that smaller sample sizes were attempted in our simulation 
study prior to settling on the aforementioned sample sizes.  The initial smaller sample sizes we 
used were N = 5, 10, and 25.  However, when fitting the Generalized Linear Mixed Models 
(GLMM) using these smaller sample sizes caused convergence issues.   
In addition to simulating data with different sample sizes, we varied levels of pairedness 
through variations in correlation (i.e., 𝜌 = 0, 0.3, and 0.5).  Correlation of 𝜌 = 0 means that the 
data have no link with each other and can be considered to represent an “unpaired design”.  
When correlation is present, data have the potential to be deemed as paired in nature depending 
on the context of the research study.  Each scenario undergoes analysis to test whether a 
treatment effect is present (i.e., differential gene expression between the two conditions/groups).  
Paired (or repeated measures or correlated) data are analyzed using both paired and unpaired 
31 
 
statistical methods.  Similarly, unpaired simulated data are also analyzed using both paired and 
unpaired statistical methods.  In doing so, we further address the aims of this study to determine 
how well the Type I error rate is controlled and statistical power considering relationships 
between the data structure and capabilities of statistical methods.  Data corresponding to a single 
gene for N subjects were simulated for each scenario, with 1,000 datasets simulated for each 
simulation scenario.  Though it should be mentioned that the original goal of this study was to 
address the same aim mentioned above in small sample sizes (i.e., Is there a loss of control of 
Type I error rate or loss of power?).  Due to convergence issues, sample sizes were increased.  In 
Section 2.5, we discuss some of the future work that may combat the convergence issue.  
2.3.2.1  Data Simulation 
 For purposes of this study, data were simulated gene-wise (i.e., one gene at a time) for N 
= 100, 150, and 200 subjects for paired and unpaired data structures.  Utilizing information from 
the ovarian tumor study conducted at KUMC, we observed that nearly 70% of correlation 
between the paired samples were between the vales of -0.25 and 0.5.  Hence, it was decided to 
use correlations values of 𝜌 = 0, 0.3, and 0.5 as more positive correlation was exhibited in the 
genes pre- and post-treatment in the empirical study.  Those data that are simulated to have 𝜌 = 0 
are considered as unpaired data, while those simulated at 𝜌 = 0.3 and 0.5 are referred to as paired 
data in this study.  To simulate the desired correlations, we used Cholesky Decomposition 
developed by André-Louis Cholesky and Trivariate Reduction depending on which distributional 
framework is being used (Rencher and Christensen, 2012, Mardia, 1970).  Data for all 
distributions were simulated bivariately to account for the pairedness between pre- and post-
treatment observations we wish to induce for each gene.  Under the null, genes are simulated to 
have equal means between repeated measurements.  Conversely, when investigating power, 
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genes are simulated with unequal means between pre-and post-treatment measurements—one of 
the treatment measurements is simulated with the addition of a given effect size. 
Normal Distribution 
 Following a similar approach used to simulate pairwise single nucleotide variants (SNPs), 
we are able to simulate paired gene expression data while using the Normal distribution and 
assistance from a Cholesky Decomposition matrix (Liu et al., 2010, Rencher and Christensen, 
2012).  To do so, we first simulate a vector of two groups of independent Standard Normal 
random variables, 𝑍.  The groups follow to identify those expression values pre- and post-
treatment.  We then define a 2x2 correlation matrix (𝑅), 𝑅𝜌 = [
1 𝜌
𝜌 1
],  to reflect the pairedness 
that we would like to simulate.  In our study, we have 𝑅𝜌=0.3 = [
1 0.3
0.3 1




] which are positive definite (i.e., 𝑅 is symmetric and 𝑥𝑇𝑅𝑥 > 0 for all 𝑥) (Rencher 
and Christensen, 2012).  𝑅𝜌=0.3 and 𝑅𝜌=0.5 undergo Cholesky Decomposition to obtain a lower 
triangular matrix, 𝐿, which can be multiplied by 𝑍 to obtain the correlated, or paired, random 
variables 𝑋.  𝐿 is calculated as [
1 0
𝜌 √1 − 𝜌2
], which implies 𝐿𝜌=0.3 = [
1 0





] and 𝐿𝜌=0.5 = [
1 0




].  Thus, the correlated random 









].  The end result when 
simulating data under the null is a bivariate normal distribution 𝒁~𝑁2(𝟎, 𝜮).  Conversely, 
simulation of the unpaired data (𝜌 = 0) was done so solely using the Standard Normal 
distribution (i.e., 𝑁~(0,1)) for each of the group of subjects.  For those data simulated until the 
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alternative hypothesis that the mean gene expression values are different, an effect shift, ∆, of 







] ,  𝜮].  
Poisson Distribution 
 Simulation of paired and unpaired data from the Poisson distribution for two groups has 
most commonly been done through the use Trivariate Reduction proposed by Mardia (1970).  
Many other researchers have implemented this type of simulation in their count data simulation 
studies (Barbiero and Ferrari, 2014, Yahav and Shmueli, 2011, Johnson et al., 1997).  This 
elegant method of simulation relies on the theoretical property that a sum of independent Poisson 
random variables is also distributed as a Poisson (Casella and Berger, 2002).  Following 
Mardia’s Trivariate Reduction, we begin by generating three independent Poisson (i.e., 
𝑍1~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆1), 𝑍2~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆2), and 𝑍12~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆12)).  These variables are combined to 
generate two new dependent random variables--𝑋1 = 𝑍1 + 𝑍12 distributed 𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆1 + 𝜆12) 
and 𝑋2 = 𝑍2 + 𝑍12 distributed (𝜆2 + 𝜆12).  Correlation between these two new dependent 






√(𝜆1 + 𝜆12)(𝜆2 + 𝜆12)
 
(Yahav and Shmueli, 2011).  However, prior to any data simulation using this approach, we 
needed to determine the rates, the λs, for each of the three Poisson random variables to relate this 
simulation to simulations from the other distributions used.  Through some basic algebra, the 
rates were determined.  Rates used in this simulation are found in Table II-2.  By plugging in the 
respective rates into the three Poisson random variables, we achieve the desired correlation 
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within our pre- and post-treatment data for 1,000 genes.  It should be mentioned that the rate 
values are not unique.  There are many other rate values that would satisfy the correlations that 
are utilized throughout our simulation study. 
 
Table II-2.  Rates for Poisson random variables.  Table contains a summary of the rates that 
are required to be used in the simulation of the three Poisson random variables to achieve desired 
correlation through the Trivariate Reduction. 
 
 Similarly to simulating data under the alternative for the normal distribution, an effect 
shift was added to a portion of the simulated Poisson distributed data.  It follows 
𝑍1~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆1 + ∆), 𝑍2~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆2),  and 𝑍12~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆12) were generated.  Though 
Mardia’s Trivariate reduction, we are left with 𝑋1~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆1 + ∆ + 𝜆12) and 
𝑋2~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆2 + 𝜆12).  The same rates from Table II-2 were used for this simulation of data 
under the null.   
Negative Binomial Distribution 
 While simulation of Bivariate Negative Binomial data can also be accomplished using 
Trivariate Reduction, the method is not as straightforward due to number of parameters that are 
involved in calculating the mean and variance.  To simulate our Bivariate Negative Binomial 
data, we use an approach that uses conditional sampling that is based on decomposition of two 
dimensional distribution of bivariate copulas (Erhardt and Czado, 2008).  The use of the copulas 
aid in setting up the dependency (i.e., correlation) between the simulated random variables; as 
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well as, help to obtain multivariate count distributions (Erhardt and Czado, 2008).  The desired 
correlations remain the same as in above simulations (i.e., 𝜌 = 0, 0.3, and 0.5).  Specific details 
of this simulation approach can be Erhardt and Czado (2008).  Fortunately, Erhardt and Czado 
have created an R package, corcount, that easily allows for the implementation of this type of 
simulation of bivariate data (Erhardt, 2009).  
2.3.2.2  Application of Statistical Analysis Methods to Simulated Data  
Completion of the simulation study looking at the statistical analysis of the paired verses 
unpaired data can be broken into two sections: 1) control of Type I error rate and 2) power.  
Once simulated data were generated, we were able to conduct analyses to evaluate how well the 
various statistical tests controlled the Type I error rate in settings where observations were 
uncorrelated and correlated.  Additionally, if the Type I error rate ended up being controlled for a 
given scenario, we proceeded to determine the empirical power.   
In this portion of the simulation, we assume the null hypothesis where the means of pre- 
and post-treatment expression values are the same (i.e., 𝐻𝑜: 𝜇𝑔,   𝐴 = 𝜇𝑔,   𝐵).  For data simulated 
from the Bivariate Normal distribution, we use the T-Test or Linear Model (LM) and the paired 
T-Test or Linear Mixed Model (LMM) (assuming equal variances) to test if there is a difference 
in the mean gene expression.  For data simulated from the Bivariate Poisson and Bivariate 
Negative Binomial distributions, we use Generalized Linear Models (GLM) and Generalized 
Linear Mixed Models (GLMM).  In the GLM, expression count values and treatment group were 
the response and predictor variables, respectively.  In the GLMM, the response variable was also 
expression counts; however, treatment group and paired sample relation were modeled as fixed 
and random effects, respectively.  The use of the generalized-type linear models allow us to 
describe how the mean depends on the linear predictor through some link function, 𝑔 (i.e., 
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𝑔(𝜇𝑖) = 𝜂𝑖, and how variance depends on the mean.  In our scenarios where the generalized 
models are used, the log link function is used.  All statistical test, were set to test for a difference 
in treatment effect.  A summary of the tested models (i.e., LM, LMM, GLM, and GLMM) and be 
found in Table II-3. Control of the Type I error rate was established if the empirically calculated 
Type I error rate was <  𝛼 where 𝛼 = 0.05.  By setting 𝛼 = 0.05, we are in acceptance that five 
percent of the time we end up with a false positive result--rejecting the null hypothesis given that 
the null hypothesis is true. 
 
 
Table II-3.  Unpaired and paired models fit in simulation study.  Table summarizes the 
models that are fit to conduct the paired and unpaired simulation study and corresponding Type I 
error rate and power analyses.  Models are presented in vector notation. 
 
 
Once results for all of the scenarios are evaluated to determine their Type I error rate is 
controlled, we can continue by conducting an empirical power analyses.  Power analyses can 
only be conducted if scenarios have control over the Type I error rate.  The empirical simulation 
of power is nearly identical to the setup of the simulation for the empirical Type I error rate.  
However, in the empirical simulation, one of the treatment measurements, either pre- or post-
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treatment is simulated to have a shift applied to it’s mean expression values.  Essentially, an 
effect size is introduced between treatment measurements in the simulations.   
2.4  Results 
 
2.4.1 Comparison of Differential Expression Methods in Empirical Study 
In comparing the results from all seven of the DE methods, we begin by looking at how 
many genes were determined to be DE based upon set cutoff values for each method’s default 
evaluation criteria.  All methods determined that the ovarian cancer samples contained genes that 
are DE in both a paired and unpaired design capability (Table II-4).  The number of DE genes 
range from 20 genes to ~ 4,600 genes, with the most and fewest DE genes being determined by 
DESeq2 and BaySeq, respectively.  An FDR of <  0.2 was selected as an equivalent evaluation 
criteria cutoff for DE genes for comparing methods with evaluation criteria of p-value and PPEE 
of <  0.05.  The cutoff value for methods using the FDR criteria needed to be set higher as it is 
more stringent due to the way it accounts for multiple testing.  We also observe that when 
comparing methods that are capable of both paired and unpaired designs that the unpaired design 
calls an increased number of DE genes verses the paired design (e.g., EdgeR unpaired design 





Table II-4.  Number of genes found to be differentially expressed (DE) based on evaluation 
criteria cutoff.  Each of the seven differential expression (DE) methods were executed for their 
respective design capabilities.  The number of DE genes were determined by those genes which 
met the respective evaluation criteria cutoff.  The DE methods use False Discovery Rate (FDR), 
p-value, and Posterior Probability of Equal Expression (PPEE) for their evaluation criteria. 
 
 Furthermore, to assess how well each of these seven methods performed in terms of 
selecting the same DE genes, comparisons of the intersection of similar DE Ensembl gene IDs 
were completed in both a pairwise and a multi-way manner.  We began by making comparisons 
between those methods that were capable of paired and unpaired designs which include BaySeq, 
DESeq2, and EdgeR.  Both DESeq2 and EdgeR contain an overlap of the DE genes that are 
selected; however, no overlap exists in the BaySeq comparison (Figure II-3).  We also see that 
EdgeR resulted in the greatest proportion of DE genes found between the paired and unpaired 
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designs (Figure II-3). 
 
Figure II-3. Comparison of Differential Expression (DE) methods capable of paired and 
unpaired designs.  The Venn diagrams above are contain of the number of DE genes that were 
determined by each method.  The overlapping portion of the Venn diagrams represent the 
number of DE genes that were selected by both design context—unpaired verses paired.  A) 
depicts DE genes found using BaySeq, B) depicts DE genes found using DESeq2, and C) depicts 
DE genes found using EdgeR. Criteria for DE genes in A) was FDR<0.2, and for B) and C) 
criteria was p-value<0.05. 
 
 Without altering the evaluation criteria to be similar across all methods, we proceeded in 
making comparisons across all unpaired and paired methods.  Paired methods initially have less 
DE genes found (Table II-4).  As the number of intersecting methods increase, we see that the 
number of DE genes that are the same between all methods reduce in number significantly for all 
multi-way comparison scenarios.  The number of same DE genes found between all paired 




Another comparison was also made to consider the number of same DE genes found between the 
overlap of Bayesian and Frequentists methods.  This resulted in zero and 14 genes, respectively 
for the Bayesian and Frequentists methods (Figure II-5).  Lastly, combinations of five DE 
methods were compared.  After combinatorically looking at all combinations of any five DE 
methods while using default evaluation criteria, it was found that the greatest number of same 
DE genes to overlap was 35 DE genes (Figure II-6).  The five methods that determined 35 of the 
same DE genes were paired EdgeR, unpaired EdgeR, Paired DESeq2, Cuffdiff, and Voom.  
Although, when we continued to compare more than five DE methods, we noticed that with each 
additional DE method added to the comparison that there was a decrease in the number of genes 
that were determined to same as was also previously mentioned.  When comparing all of the DE 




Figure II-4.  Comparison of Differentially Expressed (DE) genes found in unpaired and 
paired methods.  The Venn diagrams above contain the number of Differentially Expressed 
(DE) genes that were determined by each method.  The overlapping portions of the Venn 
diagrams represent the number of DE genes selected to be the same between the compared DE 
methods.  A) contains comparisons of DE gens found using paired designs; and B) contains 
comparisons of DE genes found using unpaired designs minus results from unpaired BaySeq.  




Figure II-5.  Comparison of Differentially Expressed (DE) genes found Bayesian and 
Frequentist theoretical backgrounds.  The Venn diagrams above contain the number of 
Differentially Expressed (DE) genes that were determined by each method.  The overlapping 
portions of the Venn diagrams represent the number of DE genes selected to be the same 
between the compared DE methods.  A) contains comparisons of DE gens found using Bayesian 
methods; and B) contains comparisons of DE genes found using Frequentist methods without 





Figure II-6.  Comparison of Differential Expression (DE) methods which find the most 
overlapping DE genes.  The Venn diagrams above contain the number of Differentially 
Expressed (DE) genes that were determined by each method.  The overlapping portions of the 
Venn diagrams represent the number of DE genes selected to be the same between the compared 
DE methods.  The five methods in this figure produce the highest number of similar DE genes 
between comparison of all combinations of five DE methods. 
 
In addition to conducting comparisons based off of default evaluation criteria.  We 
converted all evaluation criteria to estimated FDR. While we would expect the number of DE 
genes that meet the criteria to decrease somewhat in using FDR, we notice that there are some 
extreme differences.  The pattern that the unpaired designs contained larger numbers of DE 
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genes verses that of the paired designs remains the same.  Similar comparisons to those found 
using the default evaluation criteria were investigated.  However, the results ended up being very 
poor in terms of methods selecting the same DE genes after re-evaluation.  Most multi-way 
comparisons resulted in few to no DE genes that were selected to be the same.  This was also the 
case for some two-way comparisons. 
 
 
Table II-5.  Summary of genes that meet re-evaluation criteria of False Discovery Rate 
(FDR) < 0.2.  Each of the seven Differential Expression (DE) methods were executed for their 
respective design capabilities.  All evaluation criteria, p-values, and Posterior Probability of 
Equal Expression (PPEE), were converted to False Discovery Rates (FDR).  No conversion took 





2.4.2 Simulated Data 
In our simulation study, data were simulated in paired and unpaired structures from the 
following Bivariate distributions: Normal, Poisson, and Negative Binomial distributions.  Prior 
to conducting any analyses, we verified that our simulated data contained the desired correlations 
between our repeated measures of 𝜌 = 0, 0.3, and 0.5.  Each of the simulated data scenarios 
under the null resulted in having average correlations matching those which were desired (Figure 
II-7(A) and Table II-6) with acceptable standard deviations (Figure II-7(B) and Figure II-A3).  
As there are no extreme deviations from the average correlations when compared to the desired 
correlations, we can assume that the distribution from which the data are simulated does not 
affect the outcome of the correlated data as long as the data simulation algorithm is set up 
correctly.  An example for one gene with similar correlations to 𝜌 = 0, 0.3, and 0.5 is plotted in 
Figure II-7(C).  The solid red line that is plotted through the panels of Figure II-7(C) depict the 




Figure II-7.  Correlation summary for simulated data from the Bivariate Normal 
distribution under the null.  Figure contains numeric and graphical summary of the correlations 
found in the simulation study for 𝜌 = 0, 0.3, and 0.5.  Data are simulated from the Bivariate 
Normal distribution.  A) contains a table summarizing the average correlations from the 
simulated data for N = 100, 150, and 200 for correlations 𝜌 = 0, 0.3, and 0.5. B) depicts the 
variability of correlations in simulated data for N = 100, 150, and 200 and 𝜌 = 0, 0.3, and 0.5.  
C) Simulated data for one gene are plotted for N = 100 samples for 𝜌 = 0, 0.3, and 0.5.  





Table II-6.  Correlation summary for simulated data from the Bivariate Poisson and 
Negative Binomial distributions under the null.  Table contains a summary of average 
correlations from the simulated data N = 100, 150, and 200 for simulated correlations of 𝜌 =
0, 0.3, and 0.5. 
 
2.4.3 Comparison of Paired Verses Unpaired Analyses Techniques 
With confirmation that our simulated data contained the correlations that we desired to 
allow for both paired and unpaired data structures, we proceeded with our analyses.  Our 
objective of our simulation study was to determine if paired and unpaired analysis techniques 
controlled the Type I error rate when corresponding data structures were paired and unpaired, 
respectively.  Likewise, we investigated whether or not Type I error rate was controlled if 
analyses were conducted where the data structure and analyses methods were not the same.  
Furthermore, if Type I error rate was controlled for a given scenario, we continued our 
simulation and analyzed empirically how well powered are analyses were.  Rather, we wanted 
investigate the potential power gained from using a paired analysis method when the simulated 
study data are also paired; and to see if results varied based on the distribution that was used to 
simulate the data. 
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Beginning with our simulation results from the Bivariate Normal distribution simulated 
data, we observe that the empirically calculated Type I error rate is relatively controlled for all 
scenarios at the 𝛼 = 0.05 level (Table II-7).  As correlation, or pairedness, is introduced into the 
simulated data, 𝜌 = 0.3 and 𝜌 = 0.5, we see that when using the LM to test for mean differences 
in gene expression values that the Type I error rate is over controlled or conservative in nature 
(Table II-7).  For 𝜌 = 0.5, the Type I error rate becomes very small under analysis using the LM 
framework—much less than the control threshold that was previously set to be < 0.05.  
However, analyses of the simulated paired data while using a LMM seems to provide control of 
the Type I error rate.  Although it should be noted that Type I error rate control is slightly missed 




Table II-7.  Empirical Type I error rates from paired and unpaired analyses using the 
Bivariate Normal distribution under the null.  Table contains a summary of empirical Type I 
error rates from the simulation study were the Bivariate Normal distribution was used to simulate 
study data.  Error rates were calculated from 1,000 simulations.  Cells shaded in green and blue 




  Next, we examine the results for data that were simulated from discrete distributions.  
Recall from above, GLMs and GLMMs are fit to model the dependency of both the linear 
predictors and variance with respect to the mean in our unpaired and paired analyses, 
respectively.  Some of the same trends regarding control of the Type I error rate exist in the 
paired and unpaired analyses of the simulated count data.  Particularly, in the Poisson and 
Negative Binomial results we observe that when the simulated correlation was 𝜌 = 0 and 
analysis was completed using a GLM, Type I error rate was controlled at the <  0.05 level 
(Table II-8).  Though, no control was observed for 𝜌 = 0 when the GLMM was implemented—
all empirically calculated Type I error rates are greater than 0.05.   Additionally, we observe that 
control of the Type I error rate occurs 𝜌 = 0.3 and 𝜌 = 0.5 for in the scenarios using GLM for 
the Poisson and the Negative Binomial distributions used to simulate the paired data (Table II-7).  
Though, the same issue still arises that was seen in the Normal results found in Table II-6.  The 
empirically calculated Type I error rate becomes very small in the aforementioned scenarios 
where 𝜌 = 0.5.  Control over the Type I error rate also exists for 𝜌 = 0.5  using GLMM for 
analyses of data simulated from Poisson, and it is nearly controlled for the Negative Binomial.  




Table II-8.  Empirical Type I error rate from paired and unpaired analyses using the 
Bivariate Poisson and Bivariate Negative Binomial distributions under the null.  Table 
contains a summary of empirical Type I error rates from the simulation study.  Bivariate Poisson 
and Bivariate Negative Binomial distributions were evaluated for N = 100, 150, and 200 for 
simulated correlations 𝜌 = 0, 0.3, and 0.5.  Error rates were calculated from 1,000 simulations.  
Cells shaded in green, blue, and red have Type I error rate controlled near 0.05,<  0.05, 𝑎𝑛𝑑 >
 0.05, respectively. 
 
 For those scenarios in which the Type I error rate was controlled, we calculated the 
empirical power for such tests.  Under all distributional frameworks, simulated correlation and 
all N, there was at least one scenario which contained a Type I error rate that was controlled.  
Thus, we simulated data under the alternative hypothesis (i.e., 𝐻𝑎: 𝜇𝑔,   𝐴 ≠ 𝜇𝑔,   𝐵).  
Consideration was given for two mean shifts in all pre-treatment gene expression simulated 
values.  The two mean shifts that were considered were 0.3 and 0.5.  Similarly to the null 
scenarios, correlations of the simulated data were examined to see how closely they matched the 
desired correlations.  The mean correlations in the simulated data resembled the desired 
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correlations for both mean shifts (Table II-9 and Table II-A1).  Here, the mean correlation again 
does not appear to be affected by distributional framework.  Thus, we are confident that the 
applied mean shifts were implemented in the simulation correctly. 
 
 
Table II-9.  Correlation summary for simulated data from the Bivariate Normal, Bivariate 
Poisson, and Bivariate Negative Binomial distributions under the alternative with one 
measurement having a shift of 0.3.  Table contains a summary of average correlations for the 
simulated data for N = 100, 150, and 200 for simulated correlations 𝜌 = 0, 0.3, and 0.5.  Data 
were simulated to reflect unequal means by the addition of a mean shift of 0.3. 
 
 As the desired correlations have been met on average, we continued with our empirical 
power simulation for those scenarios in which Type I error rate was controlled.   Observed able 
in Table II-7, we see that all of the scenarios resulted in a Type I error rate that was controlled 
which allows us to determine the empirical power to conduct such test.  Using the Normal 
framework, we first observe that the empirical power is highly variable among all simulations.  
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Most notably, we notice that as the number of samples increases for all simulated correlation 
values that the empirical power also increases (Table II-10).  This is also the case when the mean 
shift was increased from 0.3 to 0.5 (Table II-10).  Another comprehensive observation we 
observe is found when keeping the fitted model constant across the simulated correlation values, 
we notice that the empirical power decreases as simulated correlation increase (e.g., LM with 
𝜌 = 0, 0.3, and 0.5 yields empirical power of 0.548, 0.26, and 0.097 for N = 100) (Table II-10). 
In the scenarios when 𝜌 = 0, there are only minimal differences between statistical test that 
utilize a LM verses that of a LMM with respect to the calculated empirical power (Table II-10).  
This is not apply for 𝜌 = 0.3 or 𝜌 = 0.5.  When comparing LM verses LMM, we see that the 
empirical power is greater for all sample sizes when fitting a LMM when the structure of the data 
are simulated in a paired way (Table II-10).  Reaching 80% power is almost always obtained for  
a mean shift of 0.5 with exceptions at 𝜌 = 0.5 for N = 100 and N = 150 samples. 
In reviewing the simulation scenarios for the discrete distribution framework which 
controlled for Type I error rate above, it was determined that not all scenarios were controlled.  
Therefore, empirical power simulations only needed to be run for those scenarios in which Type 
I error rate was controlled.  The results for the discrete distribution framework scenarios for both 
mean shifts are provided in Table II-11.  The grayed out cells present in the table are 
representative of those scenarios where the Type I error rate was not controlled (Table II-11).  
According to the empirical simulation results using discrete distribution frameworks found in 
Table II-11, we observe that only a few scenarios reach 80% power.  These scenarios that have 
empirically calculated power of at least 80% exist only for a mean shift of 0.5.  When fitting a 
GLMM using the Poisson distribution, 81.4% and 90.8% power is reached when 𝜌 = 0.3 for N = 
150 and N = 200, respectively (Table II-11).  Additionally, for 𝜌 = 0.5 and GLMM model 
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greater than 80% empirical power was achieved when N = 150 and N=200 (Table II-11).  
Concurrently for 𝜌 = 0.5, the Poisson and GLM distribution framework and fit model resulted in 
86.2% power (Table II-11).   None of the scenarios for 𝜌 = 0 reached 80% empirical power for 
either the Poisson or Negative Binomial distributional frameworks (Table II-11).  Lastly, 
empirical power was obtained for all 𝜌 = 0.5 scenarios when the model fit was a GLMM and the 
distribution from which the data were simulated was the Negative Binomial for all sample sizes 
(Table II-11).  The only other combination of simulation components that yielded at least 80% 




Table II-10.  Empirical power for paired and unpaired analyses using the Bivariate Normal 
distribution with varying mean shifts under the alternative.  Table displays a summary of 
empirical power from the simulation study where the Bivariate Normal distribution was used to 
simulated the study data.  Data sere simulated to reflect mean shifts of 0.3 and 0.5 applied to on 
of the treatment measurement’s gene expression values.  Cells shaded in green have reached 





Table II-11.  Empirical power for paired and unpaired analyses using the Bivariate Poisson 
and Bivariate Negative Binomial distributions with varying mean shifts under the 
alternative.  Table displays a summary of empirical power from the simulation study were the 
Bivariate Poisson and Negative Binomial distributions were used to simulate the study data.  
Data were simulated to reflect mean shifts of 0.3 and 0.5 applied to one of the treatment 
measurement’s gene expression values.  Those scenarios that do not contain power information 
did not have control of the Type I error (< 0.05) in the null scenarios (Table II-7). 
 
2.5  Discussion 
 
Differential expression (DE) analysis has become a very popular type of analysis among 
researchers that work with RNA-Seq data.  However, current comparison studies of DE 
methods do not seem to explain the rationale behind why certain methods were used verses 
other methods.   To that, there is very little information regarding the impact that different data 
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structures (i.e., paired and unpaired data) have within DE methods that are capable of 
accommodating varying data structures when selecting genes that are truly differentially 
expressed.   
From our empirical study, our results provide insight to the considerations that research 
may need to make when conducting DE analyses.  First, we recognize that comparison of DE 
methods, with default setting used, perform poorly in determining the same genes to be 
differentially expressed.  This was the case for all types of comparisons that were made—
comparisons between Frequentists and Bayesian theoretical backgrounds; as well as, looking at 
the comparisons between methods capable of handling all paired or unpaired data structures.  
Although, when comparing the paired verses unpaired DE methods, we found that more DE 
genes that were similar between the methods are found in the paired context.  This is a result 
that was expected as the structure of our original ovarian tumor data was paired in nature.  The 
study DE methods does not utilize statistical models that account for the pairedness by using 
models that allow for mixed effects—fixed or random.  It is more common for the pairedness to 
be modeled as a fixed covariate.  In terms of the theoretical background behind the DE methods, 
we observed that few DE genes overlapped between any two methods, let alone in the 
comparison of all Bayesian methods; these are crucial finding.  It is expected that the Bayesian 
methods would find different DE genes as the Bayesian approaches can highly vary from one 
method to another due to set up of prior distributions and other model parameters.  After 
summarizing the results, we think that it is fair to add to the challenges mentioned by Trapnell 
et al. (2013).  An additional challenge of conducting DE analyses is that the varying attributes 
found in the different DE methods make it difficult to determine similar genes that are DE. 
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As the results from our empirical study using the ovarian cancer data were poor in terms 
of the number of similar overlapping DE genes that were found when comparing the many DE 
methods, we decided to conduct a simulation study to determine if our findings from the 
empirical study were inhibited by data structure and/or the model which was fit.  Our simulation 
study was solely conducted from a Frequentist viewpoint and sought to determine how well 
varying scenarios through sample size, correlation values between repeated measures, and fit 
model controlled the Type I error rate.  Furthermore, if the Type I error rate was controlled, we 
investigated if the statistical test performed had adequate power by introducing a mean shift in 
the simulated expression values (i.e., 𝐻𝑜: 𝜇𝑔,   𝐴 ≠ 𝜇𝑔,   𝐵).  Both portions of this simulation study 
were done in an empirical matter, and we purposefully analyzed data structures in correct and 
incorrect fashions.  The latter, helped to provide insights to the consequences that arise when 
performing incorrect analyses. 
The results for the portion of the simulation which explored control of the Type I error 
rate were as expected, especially for the analyses using the Bivariate Normal distribution.  For 
the Bivariate Normal scenarios, we observed that as the simulated correlation increased Type I 
error rate remained controlled right around the 0.05 value when a Linear Mixed Model (LMM) 
was fit and tested.  This is likely due to the fact that in fitting the mixed model we are able to 
account for the pairedness between observations that is a result of the simulated correlation.  We 
observe that the empirically calculated Type I error rate when fitting a Linear Model (LM) for 
data simulated using the Bivariate Normal distribution decreases drastically as the correlation in 
the simulated data increases.  While having a small Type I error rate according to its statistical 
definition is ideal, here it is probably a result of not have enough power to detect a difference in 
some given difference in mean expression values which we will discuss later. 
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Similar trend exists in the Bivariate Poisson and Bivariate Negative Binomial distribution 
scenarios in terms of control of the empirically calculated Type I error rate.  For the Poisson and 
Negative Binomial scenarios, when data  had no correlations, or were unpaired, the fit 
Generalized Linear Model (GLM) had control over the Type I error rate for all sample sizes.  
Type I error rate was not controlled at the 0.05 level for the aforementioned scenarios when a 
paired model, a Generalized Linear Mixed Model (GLMM), which is designed to account for 
paired data was fit.  Again as correlation increases, for all GLM scenarios, it is observed that the 
empirically calculated Type I error rate decreases likely for the same rationale explained for the 
Bivariate Normal distribution scenarios.  These results are what one would expect.  If data are 
unpaired or without correlation between observations (i.e., pre- and post-treatment), then the 
models fit to test such data likely should not contain paired capabilities.   
The simulation results for all scenarios which fit a GLMM are not as aligned with what 
we would expect for 𝜌 = 0.3 and 𝜌 = 0.5.  When considering the Poisson scenarios, it was 
observed that Type I error was controlled at 𝜌 = 0.3; however, at 𝜌 = 0.5 it becomes slightly 
less than 0.05 with empirically calculated Type I error rates ranging between 0.013 and 0.017.  
The results at 𝜌 = 0.3 are as expected a mirror the correspond scenario from the Bivariate 
Normal.  Though, at 𝜌 = 0.5, not having control at the 0.05 level not as expected.  For the 
Bivariate Negative Binomial scenarios, Type I error rate control was only nearly obtained when 
𝜌 = 0.5 using the GLMM—no Type I error rate control was attained at the 0.05 level for 𝜌 =
0.3.  These results are also not as expected as one would expect.  Fitting a model that accounts 




In those scenarios for which Type I error rate was controlled at 0.05 or lower, the portion 
of the simulation which calculated empirical power provided some logic as to the values which 
were obtained.  For those conservative Type I error rate values significantly lower than 0.05 for 
scenarios that simulated data using the Bivariate Normal distribution, it was notice that the 
empirical power is extremely low.  Hence, conducting statistical tests using a model which does 
not agree with the structure of the data has been shown to have low power.  Empirical power 
increased with both an increase in mean shift and sample size which is typical in any simulation 
study of this type.  When the sample size was large enough, empirical power was achieved 
regardless of which type of model was fit to any of the data structures in the Normal scenarios.  
However, when sample size was smaller, modeling the data structure correctly becomes more 
important in reaching a desired power to conduct such test.  This was a result that we expected 
to observe across scenarios where Type I error rate was controlled.  
With multiple testing of numerous genes, there is potential for statistical significance 
failing to lead to meaningful clinically relevant findings.  Thus, it should be advised that once 
differential expression analysis is completed that supplementary investigations should be 
completed. Empirical Type I error rates that are significantly lower than 0.05 are said to be 
conservative as the probability of rejecting the null hypothesis when the null hypothesis is true 
is very low.  This translates to a decrease of statistical power.   
In general, several types approximations are considered for the statistical methods 
developed for RNA-Seq studies (Law et al., 2014).  One of the prevalent issues we discovered 
when fitting the GLMM model when we decreased our sample size was that our models did not 
converge in their analyses.  This is likely due to the fact that many statistical tests that are only 
asymptotically valid or theoretically accurate only when the dispersion is small which is not the 
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case in RNA-Seq data types (Law et al., 2014).  This is problematic as many RNA-Seq studies 
contain smaller sample sizes due to funding constraints.  Thus, methods that allow for analysis 
of paired RNA-Seq data that have small sample sizes need to be investigated.  Moreover, these 
smaller sample size studies would need further investigate Type I error rate and power for 
conducting tests; as well as, adapt models and method approaches to handle small sample sizes.  
Within the scope of our study, we tried to troubleshoot why our models in the paired Poisson 
and Negative Binomial context would not converge at sample sizes less than 100 samples.  A 
simple fix that was suggested in many forums, was to increase the number of iterations in the 
optimizer.  Implementing this method provided no increase in performance.  Additional 
limitations for our simulation study exists-- we only investigated negative correlation present in 
our simulated data and only considered gene expression values measures pre- and post-
treatment.  Future studies may seek to extend our study by using smaller sample sizes, a greater 
range of correlations (negative and positive) within the data, and including data that are have 
additional replicates. 
Other methods that can be used for future work include implementing (1) a sandwich 
estimator, or (2) use method of moments as the estimator.  The sandwich estimator would be 
able to better handle the paired structure of the data through the use of a robust covariance 
matrix estimator or the empirical covariance matrix estimator (Kauermann and Carroll, 2000).  
We propose implementing the sandwich estimate from Kaurman and Carroll as it has already 
been implemented for Poisson type data (Kauermann and Carroll, 2000).  Further adjustments 




Findings from our empirical study may be a result of our small sample size of N = 11 
subjects, our approach of using only default stings in DE methods, and number of measures 
taken on each subject. Others have found higher numbers of DE genes that were similar across 
methods they compared.  There is also evidence that by increasing the number of replications, 
other have seen through simulation that the percentage of DE genes that are called also increase 
(Robles, 2012).  Additionally, this study, specifically the simulation study, is limited as only 
positive correlation values were considered when simulating the data.   
In conclusion, we determined that differential expression analysis methods, when 
multiple are compared, lack precision in determining similar genes that are differentially 
expressed for small sample size and low number of replicates.  Our results suggest that EdgeR 
and DESeq2 are most robust to incorrect specification of data structure in terms of determining 
differentially expressed genes.  All-in all, we agree with the conclusion that was made by 
Rapaport et al. (2013) and have results that suggest that no individual DE method appears to be 
best in determining DE genes.  However, taking in combination the results from our empirical 
study and the simulation study, our recommendation (as expected based on statistical theory) is 
to use analysis techniques that coincide with the study design as Type I error rate is more likely 
to be controlled.  Additionally, we conclude that statistical test will have greater power when 
study design and statistical model for analysis align with one another.  
While statisticians have the ability to fit numerous statistical models to RNA-Seq data, it 
is crucial for them to keep in mind how to interpret their findings so that researchers can know 
the clinical implications.  This is also the case when RNA-Seq data are transformed.  
Furthermore, it is fundamental that any analysis complete be evaluated and validated in terms of 
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its performance and accuracy.  All-in-all with any type of research study, there needs to be a 
















An Assessment of Transformations and Clustering Methods Using RNA-Seq Data 

















 The analysis of RNA-Seq data comes with some different and additional challenges, as 
compared to microarray based data.  In contrast to microarray based mRNA data in which 
relative mRNA is measured for pre-defined probe sets via fluorescence, RNA-Seq experiments 
measure the gene expression levels from the total number of reads that fall into the exons of a 
gene. Therefore, the quality control, global biases, normalization and analysis methods for RNA-
Seq data are quite different than those for microarray based data. In particular, where the 
assumption of normality was a reasonable assumption for microarray based data, RNA-Seq data 
tends to follow an over-dispersed Poisson or Negative Binomial distribution.  Little research has 
been done to assess how cluster methods perform for analysis of RNA-Seq data and if 
transformation of the data can improve the performance.  Hence, we conducted an extensive 
simulation study to assess the performance of combinations of data transformations and 
clustering methods with respect to clustering performance and accuracy in estimating the correct 
number of clusters. Data were simulated based on RNA-Seq data collected on 56 serous ovarian 
cancer tumor samples.  In total, 192 unique scenarios were investigated with variations in data 
transformation, clustering method, number of simulated clusters, and size of clusters.  Within 
these scenarios, considerations are given to whether or not the number of clusters found in the 
data are known or unknown. Each scenario’s performance was evaluated by the adjusted rand 
index, clustering error rate, and concordance index.  Evaluation results revealed that data 
transformations which cause the data to look more normal in combination with model-based 
clustering methods perform better with respect to all performance evaluation metrics when the 
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number of clusters is said to be known.  The K Unknown simulation branch revealed the 
difficulty in algorithmically selecting the number of clusters present in a given dataset when no 
expert advice is available.  Globally, we conclude that model-based clustering (MC) approach 
may be the best starting place for exploratory clustering analysis of RNA-Seq data types when 
the number of clusters is backed by prior knowledge.   






 The analysis of RNA-Seq data comes with some different and additional challenges, as 
compared to microarray based data.    In contrast to microarray based mRNA data, in which 
relative mRNA is measured for pre-defined probe sets using fluorescence, RNA-Seq experiments 
measure the gene expression levels from the total number of reads that map to the exons of a 
gene.  Furthermore, RNA-Seq experiments have the potential, in theory, to answer many more 
research questions as compared to mRNA microarray studies, such as splicing, fusion detection 
and allelic specific expression (ASE).  Additionally, the quality control, global biases, 
normalization and analysis methods for RNA-Seq data are quite different than those for 
microarray based data.   
Microarray data are continuous verses that of sequencing data which are count-based.  
Microarray data can be simulated using continuous distributions with varied parameters and 
many have accepted that microarray data can be measured using the Normal, or Gaussian, 
distribution.; whereas, sequencing data needs to be simulated from discrete distributions such as 
the Poisson (or over-dispersed Poisson) or the Negative Binomial distribution. Within the last 
few years, several researchers have evaluated and compared clustering methods in microarray 
analysis (Jiang et al., 2004, Shannon, 2003, Quackenbush, 2001, Eisen et al., 1998, Sorlie et al., 
2001, Makretsov et al., 2004, Allison et al., 2006, Qu and Xu, 2004).  Applications of clustering 
in microarray data were completed through the use of unsupervised classification as no 
hypotheses or data assumptions were needed (Allison et al., 2006).  One of the earliest studies 
using hierarchical clustering in microarray data showed that genes with common role and 
function in the cellular process would cluster together (Eisen et al., 1998).  Others have found 
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that unsupervised, hierarchical clustering has the capability to determine prognostic clusters, 
clusters that are based upon some marker of health status; as well as, identify subtypes of 
invasive cancers (Makretsov et al., 2004, Sorlie et al., 2001).  Despite that other studies support 
genes that share common function cluster together, clustering outcomes can be greatly affected 
by the dependency of a particular method used relative to the clustering algorithm used for 
classification, normalization across and within experiments, and the measure of similarity or 
dissimilarity that is used (Quackenbush, 2001).  Some have also argued that if you have some 
prior insight as to what cluster may be, that using supervised model-based clustering algorithms 
is superior (Qu and Xu, 2004). Knowledge of these variations have suggested that researchers 
should select a couple clustering methods to summarize their results (Jiang et al., 2004, Shannon, 
2003).    
A common practice in statistics is to apply transformations to a given set of data to make 
the analysis methodologies more efficient and induce better statistical properties.  RNA-Seq data 
have been said to have three problematic properties when it comes to statistical analysis--a 
skewed distribution, variability among the read counts for individual genes, and likelihood of 
extreme values (Zwiener et al., 2014).  Two of these problematic properties can be addressed 
using simple algebraic approaches.  The skewness of the distribution can be addressed by using a 
data transformation.  Likewise, the variability can be handled through many types of 
normalization procedures.  While this study will not cover types of normalization, a 
comprehensive procedure can be found by Dillies et al. (2012).     
Clustering analysis can be viewed as one of the first steps when exploring data.  Clustering 
analysis is purely exploratory and for hypothesis building as clustering methods will form 
clusters even in data that is unrelated and completely independent (Quackenbush, 2001, 
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Shannon, 2003).  The challenge for clustering analysis lies in obtaining a “good” clustering 
method and in turn coming up with the “correct” number of clusters (Yeung, 2001).  The 
collective goal of clustering methods is to accurately group data objects of interests based on 
some type of mathematical calculation of similarity or dissimilarity to assess whether the object 
belongs to a cluster (Eisen et al., 1998).  Common measures of similarity that are used in 
clustering methods for a variety of data domains include: Euclidean distance, cosine similarity, 
Jaccard correlation coefficient, and relative entropy (Huang, 2008).   
Clustering methods tend to fall into two categories—supervised clustering and 
unsupervised clustering.  Supervised clustering methods use algorithms that cluster objects into 
some pre-defined category.  Whereas, unsupervised clustering methods aim to discover 
categories by grouping objects by one of the similarity measures mentioned above (Allison et al., 
2006).  Nevertheless, both of these clustering methods’ categories seek to reduce the data to be 
able to better explain potential relationships that may exist.  Selection of the most appropriate 
clustering method is not always straightforward and is often driven by the context of the specific 
study (Chalise et al., 2014). Within the different clustering methods, analyses have been 
completed to cluster based upon genes (i.e., gene-based clustering) or clustering based upon 
subject samples (i.e., sample-based clustering) (Liu and Si, 2014).   
 In the early era of the microarray, many researchers sought to apply clustering analysis to 
the gene expression data as the importance to identify specific patterns of gene expression and 
groups of genes or groups of participant samples for that could provide greater insight into 
biological function (Quackenbush, 2001).  The pioneered reports of researchers executing 
clustering analysis in expression data date back to 1997 (Weinstien, 1997).  Weinstien et al. 
(1997) implemented a hierarchical clustering approach to a set of targets that contained different 
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compounds and ordered them based upon Pearson correlation coefficients relating activity and 
target patterns.  As time progressed, clustering methods for microarray data included: 
hierarchical clustering, graph-theoretical approaches, model-based clustering, K-Means, density-
based hierarchical clustering, and self-organizing maps (SOMs) (Jiang et al., 2004, 
Quackenbush, 2001).  A comprehensive evaluation and comparison of clustering methods for 
microarrays was completed in 2006 by Thalamuthu et al..  They compared six different gene 
clustering methods and found that model-based clustering outperformed non-model based cluster 
methods in a simulation study and applied to real data (Thalamuthu et al., 2006). 
When it comes to the analysis of RNA-Seq data the literature is saturated with studies 
regarding differential expression as it relates to varied experimental conditions.  The trend in 
clustering analysis followed thereafter.  After reviewing the available literature, it was apparent 
that the evaluation and comparison of clustering methods has only been completed in microarray 
analyses--microarray technology predates RNA-Sequencing by approximately 10-15 years.  
Moreover, little research has been done to assess how cluster methods perform for analysis of 
RNA-Seq data and if transformation of the data can improve the performance.  The current 
literature contains three closely related studies to this topic that have looked at performance of 
clustering methods—one investigates classification and clustering of sequencing data using a 
variety of methods (Witten, 2011), another used clustering analysis to identify features of the 
gene space in RNA-Seq and microarrays (Sibru et al., 2012), and the other study provides an in 
depth look at model based clustering for RNA-Seq data (Si, 2013).    
In this paper, we aim to assess four data transformations applied to count data (RNA-Seq 
data type) and up to five clustering methods to provide insight into clustering using RNA-Seq 
data.  Using an extensive simulation study that contains 192 simulation scenarios, we investigate 
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several previously purposed data transformations and clustering methods that have been used in 
microarray analysis.  Data for this simulation were simulated from parameters obtained from an 
actual RNA-Seq dataset.  We limited the number of genes in our simulated datasets to account 
for the significant computational resources that were needed for our methods.   
All simulation scenarios fit into four parent categories depending on how the genes were 
selected to be included in the clustering analyses. The factors varied in the simulation studies 
include: (1) how genes were selected to be included in the clustering analyses (top 100 genes 
according to their median absolute deviation (MAD), or random sample of a 100 genes); (2) size 
of the clusters (equal cluster sizes or extremely unequal cluster sizes); (3) number of clusters; (4) 
data transformations; (5) clustering methods; (6) whether K was known or unknown.  The 
simulation scenarios assessed the following data transformations: naïve, logarithmic base 2 
(Log), Blom (Beasley et al., 2009), and variance stabilizing transformation (VST) (Durbin et al., 
2002).  Concurrently, using the transformed datasets the following clustering methods were 
assessed: Hierarchical Clustering (HC), Model-based Clustering (MC), Non-Negative Matrix 
Factorization (NMF), Recursively Partitioned Mixture Model Clustering (RPMM), and K-Means 
Clustering (KM).   Each of the clustering methods carried out a sample based clustering 
approach (i.e., interested in clustering patient tumors to determine molecular subtypes).   
In the following sections of this paper, we will describe how our data were simulated 
using Negative Binomial maximum likelihood estimation (MLE), provide details of our 
simulation study, and further discus the data transformations and clustering methods used.  We 
then summarize the normality and performance findings from all simulation scenarios.  To our 




3.3 Materials and Methods 
 
To address the aims of this study, an extensive simulation study was conducted.  This 
simulation study has four major components—1) simulating data that is similar to actual RNA-
Seq data collected from a set of ovarian tumors, 2) implementing various data transformations, 3) 
utilizing many clustering methods when the number clusters within the data is either 
approximately known by an expert or completely unknown requiring the use of model-based 
algorithms or the Gap Statistic (Tibshirani, 2001), and 4) evaluating all simulation scenarios 
using the Adjusted Rand Index (ARI), Clustering Error Rate (CER), and Concordance Index (C-
Index).  The schematic in Figure III-1 provides a brief overview of the entire simulation study.  It 
should be noted that for scenarios in which the number of clusters is known and set a priori will 
be referred to as “K Known” scenarios; whereas, those scenarios where the number of clusters in 
the data is completely unknown will be denoted as the “K Unknown” scenarios.  All analysis for 




Figure III-1.  Simulation schematic to assess aims of study.  Prior to simulating our data, we 
began by obtaining Negative Binomial (NB) parameters from 100 top genes and 100 randomly 
selected genes based upon Median Absolute Deviation (MAD) of expression values.  Data were 
then simulated for both an equal number of samples in each cluster and an unequal number of 
samples in each cluster for three classes of 𝐾 (𝐾 = 1, 2 and 3) using the NB parameters for D = 
100 datasets.  Furthermore, data transformations were applied to all data sets; and K Known and 
K Unknown clustering methods were applied.  Data transformations were evaluated according to 
normality measures (i.e., skewness and kurtosis) and clustering methods were assessed by 




Before assessing our data transformations and clustering methods, great consideration 
was given to the way in which the data are simulated to ensure that data are similar to what 
would be found in a real RNA-Seq experiment to ensure our results are robust and relevant.  
Most often researchers have simulated RNA-Seq count data from either an overdispersed 
Poisson distribution or a Negative Binomial distribution. The usage of both of these distributions 
can be found throughout the literature as they are able to deal with the unique challenges that 
arise when simulating RNA-Seq data.  These difficulties include the nonnegative, integer-valued 
structure of RNA-Seq data; as well as, the highly variable total number of sequence reads across 
different samples (Witten, 2011).  Recently more researchers have preferred the use of the 
Negative Binomial distribution when it comes to RNA-Seq studies.  The Negative Binomial 
distributions allow for two distributional parameters to be controlled—the mean and shape 
parameters.  Controlling the mean and shape parameters allow researchers to model the 
overdispersion, which typically exists in sequencing data.  Overdispersion occurs when there is 
greater observed variance in the data than expected (e.g., under the Poisson distribution 
assumption the mean and variance are equal).  In this simulation study we chose to simulate the 
data from a Negative Binomial distribution, in which we used parameter estimates for simulation 
based on the RNA-Seq data from an ovarian cancer study out of the Mayo Clinic (Rochester, 
MN) headed by Dr. Ellen L. Goode in the hope that our simulated data will better resemble that 
of “real-life”.   
3.3.1 Mayo Clinic Ovarian Cancer Study 
The Mayo Clinic data contains data collected on 56 patients with invasive epithelial 
ovarian cancer.  Women who were eligible for the study needed to have a diagnosis that was less 
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than one year prior and be ≥20 years of age.  All participant samples were of Serous (SER) 
histology as confirmed by re-review by a gynecologic pathologist (GLK).  RNA was extracted 
from these samples at the Tissue Microarray facility at the Mayo Clinic and sent to be sequenced 
by BGI Americas.  Prep for the sequencing of the samples included riboZero treatment of 1 𝜇g 
of RNA and using the Illumina TruSeq Stranded Total RNA kit to make libraries.  After samples 
were prepped, sequencing was completed using the Illumina HiSeq 2000 with 100bp paired end 
reads, six samples were multiplexed per lane.  The resulting FASTQ files were sent to Dr. 
Fridley’s lab at The University of Kansas Medical Center (KUMC).  At KUMC, the FASTQ 
files were aligned to the human genome (G = 63,152 ensemble gene IDs) using TopHat2, 
followed by application of HTSeq to generate gene count.  To further understand the behavior of 
this study data, we calculated the mean and variance for each of the ~63K Ensemble genes across 
all participant samples.  In computing the log transformations on the count data, an additional 
count of 1 was added avoid undefined values.  Figure III-2 displays the relationship between the 
transformed mean and variance of the RNA-Seq data.  It can be noticed that the data are over-




Figure III-2.  Comparison of log-transformed mean and log-transformed variance across 
samples per Ensemble gene ID.  It is common among RNA-Seq data that overdispersion will 
be present.  That is, the variance is greater with respect to the mean.  The red 45 degree line is 
representative of equal log-mean and log-variance. 
 
3.3.1.1 Data Selection 
The Mayo Clinic data contains gene abundance estimates for 𝐺 = 63,152 Ensembl genes 
on 𝑁 = 56 participants.  Let 𝑿∗ be the 𝐺 by 𝑁 matrix where 𝑥∗𝑔𝑖 is the raw RNA-Seq count for 



















As with any sequencing dataset, data size is often a concern for statistical analysis and 
computational processing time. Additionally, we have the classic “small n, large p” phenomena 
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that is often encountered in RNA-Seq studies (i.e., there is a much lower number of samples (i.e., 
small n) with respect to the large number of covariates or genes (i.e., large p) that are taken for a 
given sample).  Hence, we decided to reduce the size of our data, specifically reduce the number 
of genes that whose attributes we would use to simulate our datasets.  This was accomplished 
using two fairly intuitive ways: 1) selecting 100 of the top most variable genes according to the 
Median Absolute Deviation (MAD) (most common practice in selecting genes for clustering), 
and 2) selecting a random sample of 100 genes. 
The top 100 most variable genes were selected by calculating each gene’s median 
absolute deviation (MAD).  The MAD is calculated by obtaining the median count value across 
all 𝑁 samples, subtracting it from each of the sample’s counts for a given gene, and further 
taking the median of all those differences.  Rather, MAD is defined as:  
𝑀𝐴𝐷(𝒙𝑔.
∗ ) = 𝑀𝑒𝑑𝑖𝑎𝑛𝑖(|𝑥𝑔𝑖
∗ − 𝑀𝑒𝑑𝑖𝑎𝑛(𝒙𝑔.
∗ )|). 
The MADs for all of the genes were then ordered in decreasing value and subset to those 100 
genes with the highest deviations.  Here, let the subset of data be 𝑿𝑇, a 𝐺𝑇
∗
 by 𝑁 matrix where 
𝐺𝑇
∗ = 100 Ensembl gene IDs, similar to 𝑿∗.  It follows: 
𝑿𝑇 = [
𝑥11 𝑥12 ⋯ 𝑥1𝑁
𝑥21 𝑥22 … 𝑥2𝑁
⋮ ⋮ ⋱ ⋮
𝑥𝐺𝑇∗1 𝑥𝐺𝑇∗2 ⋯ 𝑥𝐺𝑇∗𝑁
], 
where 𝑥𝑔𝑖 is the raw RNA-Seq count for the 𝑔
th top 100 most variable gene (𝑔 =  1, … ,  𝐺𝑇
∗
) 
and the 𝑖th sample (𝑖 =  1, … , 𝑁).  The creation of the dataset that contains 100 randomly 
selected genes follows similarly to that of the dataset containing the top 100 MAD genes.  
Though, prior to obtaining a random sample of 100 genes, we filtered out the lower 50% MAD 
genes, ordered in decreasing order, as a majority of them have zero counts for all 𝑁 samples.  
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Thus, from the residual 50%, 100 genes were randomly sampled using a random number 
generator within R (R Development Core Team, 2016).  For this subset, let the data be 𝑿𝑅, a 𝐺𝑅
∗
 
by 𝑁 matrix where 𝐺𝑅
∗ = 100 Ensembl gene IDs.  It follows: 
𝑿𝑅 = [
𝑥11 𝑥12 ⋯ 𝑥1𝑁
𝑥21 𝑥22 … 𝑥2𝑁
⋮ ⋮ ⋱ ⋮
𝑥𝐺𝑅∗1 𝑥𝐺𝑅∗2 ⋯ 𝑥𝐺𝑅∗𝑁
], 
where 𝑥𝑔𝑖 is the raw RNA-Seq count for the 𝑔
th top 100 most variable gene (𝑔 =  1, … ,  𝐺𝑅
∗
) 
and the 𝑖th sample (𝑖 =  1, … , 𝑁).   
The resulting selections of genes are plotted in blue against the original Mayo Clinic data 
along with their corresponding expression levels in Figure III-3 A) and Figure III-3 B), 
respectively.  The distinct way in which the data were selected can be observed.  In Figure III-3 
A) observe that all of the selected genes contain the highest log means and log variances.  
Additionally, notice the completely ransom selection of the genes in Figure III-2 B).  For both 
types of data selections, there is a lack of distinct patterns of expression (Figure III-3: A and B). 
Though it should be noted that the distributions for the color breaks in the heatmaps in Figure 
III-3 are very different between the different ways the data were select.  This was purposely done 
to allow for the variation in expression to be better depicted.  Even though the scale for the color 
breaks differ from one another, genes with lower read counts are represented in red and those 




Figure III-3.  Gene selection for both the top 100 genes and random 100 genes according to 
their Median Absolute Deviation (MAD).  Highlighted in blue are the top 100 most variable 
genes in both panel A) and B).  A) contains the top 100 MAD genes, and B) contains the random 
subset of 100 genes. 
 
Figure III-4:  Heatmaps of most variable genes.  Each heatmap represents low, moderate, and 
high expression count values through the use of red, yellow, blue color scheme, respectively for 
one of the 100 simulated datasets.  The color breaks that were used for the red, yellow, blue color 
scheme differed depending on the category of gene selection.  Panel A) contains the top 100 
MAD genes had color breaks corresponding the following gene expression values [0, 500, 1000, 
5000, 9000, 14000, 25000, 50000, 75000, 100000, 500000, 1000000, 1789200].  Similarly panel 
B) contains the 100 randomly selected MAD genes at [0, 0.5, 1, 2, 3, 5, 10, 20, 50, 100, 500, 




3.3.1.2 Maximum Likelihood Estimators for the Negative Binomial Parameters  
Vector Generalized Linear Models (VGLMs) are an inclusive class of models of various 
multivariate response types that are highly generalizable (Yee, 2003, Yee, 1996).  VGLMs are 
able to handle problems that stem from uni- and multivariate distributions, categorical analysis, 
generalized estimating equations and many more (Yee, 2003).   VGLMs are models of the form 
𝑓(𝒚|𝒙; 𝑩) = ℎ(𝒚, 𝜂1, … , 𝜂𝑀, 𝜑) 
for some known function ℎ(∙), where 𝑩 = (𝛽1𝛽2 …𝛽𝑀) is 𝑝 𝑥 𝑀, 𝜑 is an optional scaling 
parameter, and 𝜂𝑗 = 𝜷𝑗
′𝒙 = 𝛽(𝑗)1𝑥1 + ⋯+ 𝛽(𝑗)𝑔𝑥𝑔 is the 𝑗th linear predictor (Yee, 2003).  The 
only assumption for VGLMs is that the regression coefficients must be comprised of a set of 
linear predictors.  Once the form of the model is established, the log-likelihood function can be 
obtained and Maximum Likelihood Estimates (MLEs) can be found for the parameters in the 
parent distribution through Iteratively Reweighted Least Squares (IRLS) using either the 
Newton-Raphson or Fisher-scoring algorithm(Green, 1984, Yee, 2003).  Details of this process 
can be found in the Yee and Hastie paper from 2003.  In 2015, Yee has made available an R 
package to that carries out the MLE process above for a specified distribution—the VGAM 
package.  To obtain data that reflect that of “real-life”, we will utilize VGLMs to obtain MLEs 
from fitted NB models for each gene, and use those MLEs in the simulation of the datasets. 
For each of the resulting datasets from the gene selections, 𝑿𝑇 and 𝑿𝑅 above, we fit 100 
vector generalized linear models (VGLMs), one for each gene, using a Negative Binomial 
parameterization.  The NB parameterization that was used to fit each of the models in both gene 
selection datasets was 
𝑃(𝑋 = 𝑥;  𝜇,  𝑘) =  (












, 𝜇 > 0,  𝑘 > 0  
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with mean 𝜇, variance 𝜇 +
𝜇2
𝑘
, and dispersion parameter 
1
𝑘
.  Additionally, the linear predictors for 
our VGLM are log(𝜇) =  𝜂1 = 𝜷1
′ 𝒙 and log(𝑘) =  𝜂2 = 𝜷2
′ 𝒙 where the log link is used here due 
to the range restrictions that are present for 𝜇 and 𝑘.  Utilizing the IRLS method, the MLEs for 𝜇 


















] from the dataset containing 100 randomly selected genes.    
 
3.3.2. Simulation Study  
 To address the specific aims proposed, an extensive simulation study was conducted. The 
simulation of the data in this study has many unique attributes to insure that our scenarios and 
results are generalizable.  We further simulated these data to include exploring different numbers 
of clusters and clusters on different sizes.  In our simulation study, we simulate data that 
considers one (i.e. no clusters) to three clusters (i.e., 𝐾=1 cluster, 𝐾=2 clusters, and 𝐾=3 
clusters).  Additionally, given the behavior of some clustering methods wanting to cluster so that 
cluster sizes are equivalent, we simulate data that is of equal cluster size and extremely unequal 
cluster sizes.  The cluster sizes for K=2 clusters and K=3 clusters for equal and unequal cluster 




Table III-1.  Cluster sizes for different number of clusters.  Equal and Unequal cluster sizes 
were used in the simulation study.  𝑐𝑘 for 𝑘 = 1, 2, or 3 designate the number of samples in a 
given cluster. 
 
For organizational purposes of this simulation, we utilize the way data were selected to 
obtain the MLEs (i.e., top 100 MAD genes or Random 100 MAD genes) and the size of the 
clusters (i.e., equal or unequal cluster sizes) to define four parent categories of scenarios for all 
K.  The 4 parent categories will be defined as: 1) Top 100 MAD Genes with Equal Cluster Sized 
(TE); 2) Random 100 MAD Genes with Equal Cluster Sizes (RE); 3) Top 100 MAD Genes with 
Unequal Cluster Sizes (TX); and 4) Random 100 MAD Genes with Unequal Cluster Sizes (RX). 
3.3.2.1 Datasets Simulation 
We generate 100 datasets (D=100 datasets) for each of the 4 parent categories previously 
mentioned.  The data for these datasets were simulated from a NB distribution using the 
respective sets of MLEs (i.e., ?̂?𝑇 and ?̂?𝑇, or ?̂?𝑅 and ?̂?𝑅).  Specifically, 
𝑥𝑔𝑖~𝑁𝐵(?̂?𝑔, ?̂?𝑔) 
where ?̂?𝑔 is the MLE of the mean and ?̂?𝑔 is the MLE for the dispersion parameter for the 𝑔th 
gene.  The data are simulated under the assumption that subjects are independent from one 
another and that the gene expression between genes is also independent.  Though, in order to 
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simulate data that resembled different clusters, we incorporated effect size shifts to ?̂?𝑔 and ?̂?𝑔 to 
a proportion of genes which would represent genes that were up-expressed in this cluster group.  
We set 10% of the genes in any dataset up-expressed for 𝐾 = 2 and for 𝐾 = 3 there would be a 
step progression for the percentage of genes that were up-expressed—10% for 𝑐2  and 20% for 
𝑐3 of which 10% would be simulated with the same effect size as that of 𝑐2 .  Figure III-5 depicts 
specifically how genes were simulated for each cluster and up-expressed genes. 
 
 
Figure III-5.  Data simulation with clusters and up-expressed genes.  Datasets were 
simulated so that clusters would be present (i.e., 𝑐1, 𝑐2, and 𝑐3) through a shift to make certain 
percentages of genes up-expressed.  A) depicts how data were simulated for 𝐾 = 2, and B) 
depicts how data were simulated for 𝐾 = 3. 
 
 
3.3.2.2 Empirical Power Simulation to Determine Effect Size 
The effect size shifts for the mean and dispersion parameters, parameters from the 
Negative Binomial distribution, were determined through an empirical pilot study.  Data were 
simulated for the K=2, TE parent category using ranging combinations of shifts for each of the 
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parameters.  The rationale behind adding shifts to the mean and the dispersion parameters is to 
reflect the behavior that is present in simulating data from a Negative Binomial distribution—as 
mean values increases, so to do the variance, or overdispersion, values increase.  Additionally, it 
should be noted that caution should be taken when specifying these shifts.  The shifts applied to 
both the mean and overdispersion parameters needed to be substantial enough so that the 
clustering method would have the ability to distinguish clusters.  Shifts too large would lead to 
the clustering method always obtaining the “truth” or correct cluster assignment for a given 
sample.  Conversely, the shifts could not be too minimal which would result in no clusters being 
determined by the clustering method.   
After determining a set range of shifts for the parameters, one hundred datasets were 
simulated for each unique combination of shifts.  These datasets then underwent model-based 
clustering to determine which percentage of samples clustered identically with their simulated 
cluster.  Adequate power was said to be achieved if the 100 datasets for a given combination of 
effect size shifts resulted in clusters that had samples that perfectly matched the simulated 
sample-cluster assignment at least 80% of the time.  The empirical simulation showed that a 
mean shift of exp(3.375) and a dispersion shift of 1.01 would yield correct cluster assignment 
~80% of the time.  Additionally, it was determined for the K=3 simulation scenarios that in 
addition to the K=2 effect size shifts that exp(5.5) and 1.03 would be used for a percentage of 
genes in 𝑐3 .  For our simulation proposes, let ∆?̂?1= exp(3.375) , ∆?̂?2= exp(5.5) , ∆?̂?1= 1.01, and 
∆?̂?2= 1.03 for the simulation of datasets. 
3.3.2.3 Data Transformations 
In a similar fashion to Zwiener et. al. (2014) and Witten (2011), we explore many RNA-
Seq data transformations in regards to their performance in non-parametric and model-based 
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approaches. The following sections describe the four data transformations that have been applied 
to all of the scenarios for of the simulated data prior to clustering.  Even though, clustering 
methods can be executed using raw count RNA-Seq, clustering methods may run more 
efficiently and have higher accuracy in assigning samples to clusters when they are transformed 
(Shannon, 2003).  The four data transformations assessed were: Naïve transformation, Log 
transformation, Blom transformation, and Variance Stabilizing Transformation (VST).  The data 
transformations were evaluated in terms of skewness and kurtosis to assess which transformation 
yielded the “most normal” transformed RNA-Seq data.  Skewness is the measure of symmetry 
and kurtosis measures flatness or peakedness for a distribution of values (Casella and Berger, 
2002).  When data are normally distributed, skewness equals zero (i.e., 𝑆𝑘 = 0) and kurtosis 
equals three (i.e., 𝐾𝑡 = 3) (Rencher and Christensen, 2012).  𝑆𝑘 > 0 denotes positive skewness; 
whereas 𝑆𝑘 < 0 denotes negative skewness (Rencher and Christensen, 2012).    Similarly, 𝐾𝑡 >
3 means that kurtosis is positive or more peaked; whereas 𝐾𝑡 < 3 means negative kurtosis or a 
flatter distribution (Rencher and Christensen, 2012).  Following the clustering analyses, the data 
transformations in combination with each different clustering method were further considered for 
how they may have played a role in the results. 
Naïve Transformation 
The naïve transformation is the untransformed or null, simulated RNA-Seq data.  
Denoted as  
𝑥𝑔𝑖
𝑛𝑎𝑖𝑣𝑒 = 𝑥𝑔𝑖 , 
the naïve transformed data contains all of the original attributes of the raw simulated data.  This 
transformation often times does not yield accurate results in any type of statistical analysis when 
the dataset of interest includes highly variable data that span a wide range of values or are 
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skewed.  The naïve transformation will be used as a baseline to compare all other 
transformations with.  
Log Transformation 
Logarithm transformations are very useful when it comes to scaling a dataset that has a 
skewed wide range of data values; such as that of RNA-Seq data (Zwiener et al., 2014).  
Following suit from the popular Bioconductor Package, edgeR (Robinson et al., 2010), the 
specific logarithm transformation that will be used is the log base 2 data transformation.  The log 
base 2 transformation is applied to the data plus some constant c as follows:  
𝑥𝑔𝑖
𝑙𝑜𝑔2 = 𝑙𝑜𝑔2(𝑥𝑔𝑖 + 𝑐) 
Here, we are using 𝑐 = 1 to allow for the transformation of those zero count values to be non-
infinite.   
Blom Transformation 
 In the realm of statistical genomics, Blom transformations have become popularized as 
they allow for the data to be converted back to more or less the standard normal distribution 
(Beasley et al., 2009).  This is accomplished through the use of an Inverse Normal, ϕ−1, rank-
based algorithm where 𝑐 = 3/8. 
𝑥𝑔𝑖
𝐵𝑙𝑜𝑚 = ϕ−1(𝑟𝑎𝑛𝑘(𝑥𝑔𝑖) − 𝑐)/(𝑛 − 2𝑐 + 1) 
Variance-Stabilizing Transformation 
The Variance-Stabilizing Transformation (VST) is carried out in the DESeq2 R package 
in Bioconductor, and was initially proposed by Anders and Huber (Anders and Huber, 2010).  
VST allow for covariates with variances independent of the mean value to be obtained (Zwiener 











where 𝜇𝑖 are the mean expression values and 𝑉(𝜇𝑔) is defined as the variance of the Negative 
Binomial distribution (i.e., 𝑉(𝜇𝑔) ≔  𝜇𝑔 + 𝑎𝑔𝜇𝑔




where 𝑎0 and 𝑎1 are specific estimates based on the GLM (Zwiener et al., 2014). Furthermore, 
the delta method used with a Taylor expansion which considers squared Euclidean distances 
between pairs of samples (Durbin et al., 2002).  Details of this transformation can be found in the 
DESeq2 R package documentation (Love et al., 2014, Love et al., 2016).  Utilization of the VST 
transformation lends itself while to RNA-Seq data as it based on the Negative Binomial 
Distribution (Witten, 2011). 
3.3.2.4 Clustering Methods K Known and K Unknown Scenarios 
 In this section, we will describe each of the clustering methods that will be assessed in 
terms of how well they perform in terms of their accuracy in assigning samples to clusters.  The 
clustering analysis portion of this simulation study can be divided into two branches.  Branch 1 
consist of those scenarios where the number of cluster(s) is considered “known” based upon 
expert’s knowledge and literature.  These scenarios will be denoted as “K known” scenarios.  To 
know the number of clusters in a given dataset would be ideal.  However, this is rarely the case.  
Thus, branch 2 consists of simulation scenarios where the number of cluster(s) is entirely 
unknown.  Not knowing the number of clusters tasks the researcher to either make a subjective 
guess about the number of clusters based on graphical representations (i.e., a dendrogram or a 




3.3.2.4.1 Clustering Methods for the K Known Scenarios 
 The K Known scenarios utilizes three clustering methods—Hierarchical Clustering (HC), 
Model-Based Clustering (MC) through the mclust package in R, and Nonnegative Matrix 
Factorization (NMF).  For each of these clustering methods, the number of clusters, 𝐾, was 
purely determined by how many clusters were simulated in a given simulated dataset.  Rather, if 
a dataset were simulated using 𝐾 = 2 clusters, then the 𝐾 fed to the clustering method would be 
two.  By specifying a particular 𝐾 for the clustering method, we force the method to partition the 
samples of the data into 2 clusters.   
Hierarchical Clustering 
One of the most common nonparametric clustering methods that is used in this study is 
Hierarchical clustering (HC).   HC was developed by Eisen et al. in 1998 (Eisen et al., 1998). 
The HC utilizes all of samples and proceeds to divide them into smaller groups in an iterative 
manner.  HC is a relatively simple type of clustering approach which provides a graphical 
representation of the results assuming that some hierarchical structure of the data exists 
(Shannon, 2003, Quackenbush, 2001).  HC consists of two different variations—agglomerative, 
a type of bottom up approach, and divisible, a top-down approach.  Furthermore, HC can be 
classified by the way in which clusters are formed or distance between clusters (Chalise et al., 
2014).  The formation of clusters is commonly termed as linkage which can be complete, 
average, and single.  In this study, we use only the agglomerative variation with a complete 
linkage where all samples begin as their own cluster.  Specifically, we let each sample be defined 
as 𝑆𝑖, it’s own cluster, for 𝑖 = 1,… ,𝑁.  From the individual clusters, pairwise distance 
comparisons are made in terms of the linkage.  Since we use complete linkage in our method 
which seeks to maximize the distance between any pair (i.e, {𝑆𝑖, 𝑆𝑖+1}) of individual clusters, the 
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algorithm goes through all pairs and separates samples based upon furthest distance between 
them so that samples of 𝑐1 are furthest from any sample in 𝑐2 (Chen et al., 2002, Chalise et al., 
2014).  This procedure has been written into an R function, hclust in the basic stats package (R 
Development Core Team, 2016).  Within this function, set up our parameters to reflect the prior 
type of HC clustering that we would like to use. 
Model-Based Clustering  
Model-Based Clustering (MC) comes in many different forms from methods that use 
mixture models (McLachlan et al., 2002, Yeung, 2001, Fraley et al., 2012, Farley and Raftery, 
2002) to Bayesian model-based methods (Medvedovic and Sivaganesan, 2002, Medvedovic et 
al., 2004).  Though, in clustering the incorporation of a “well-grounded” statistical model into a 
clustering method may serve to be beneficial in determining the best, most accurate clustering 
method (Yeung, 2001).  In MC the data is assumed to be from some finite mixture of probability 
distributions (i.e., a mixture of Gaussian models) (Chalise et al., 2014, Yeung, 2001).  Moreover, 
the likelihood of the mixture model can be written as:  






where 𝐾 is the number of clusters or components in the data, 𝒙𝒊 are the independent multivariate 
observations, 𝑓𝑐 is the density of the some multivariate normal distribution distributional model 
with mean of 𝜇𝒄 and covariance matrix ∑𝑐, 𝜃𝑐 are the parameters for the 𝑐
th component which 
can be thought of as the kth cluster, and 𝜏𝑐 is the probability that an observation belongs to the 
𝑐th component-- 𝜏𝑐 has two restrictions 𝜏𝑐 ≥ 0 and ∑ 𝜏𝑐
𝐾
𝑐=1 = 1 (Yeung, 2001).  Through, 
eigenvalue decomposition and an EM algorithm the number of clusters, 𝐾, is estimated.  Within 
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the eigenvalue decomposition, different parameterizations are used to define the model type that 
is being used.  A wide range of model types exists: equal and unequal volume spherical models, 
unconstrained models, and elliptical models.  Utilizing the mclust package in R, we are 
seamlessly able to implement this model-based clustering approach as proposed by Farley and 
Raftery in 2002 (Fraley et al., 2012, Farley and Raftery, 2002).  As we wanted to optimize 
clustering performance in every method that we used in the simulation, we selected to use the 
mclustBIC() which determines the most optimal model characteristics (R Development Core 
Team, 2016, Fraley et al., 2012).  This function has the flexibility to have the number of clusters 
specified or not specified. 
Non-negative Matrix Factorization 
 Non-negative Matrix Factorization (NMF) is a parts-based machine learning technique 
that uses a series of matrix manipulations to determine potential groups or likeness among 
objects (Devarajan, 2008, Lee and Seung, 1999).  NMF has primarily been used to detect 
patterns in faces and text documents (Lee and Seung, 1999).  However, recently NMF has been 
applied gene expression data from microarrays to discover molecular patterns (Brunet et al., 
2004). The aim of NMF is to reduce the dimensionality of the data to find a small number of 
genes which are defined as a nonnegative linear combination of 𝑝 genes (Devarajan, 2008).  For 
our clustering analysis, we let our 𝑁 𝑥 𝐺 transformed matrix of counts be 𝑉 which is 
decomposed into two matrices with non-negative counts (i.e., 𝑉~𝑊𝐻). 𝑊 and 𝐻 are matrices 
that are 𝑝 𝑥 𝑘 and 𝑘 𝑥 𝑛, respectively. The algorithm look for rank 𝑘 of the factorization which 
represents the number of clusters (Lee and Seung, 1999).  The rank is chosen to satisfy  
(𝑝 + 𝑛)𝑟 < 𝑝𝑛 (Lee and Seung, 1999).  It should be mentioned that the NMF algorithm may not 
always converge to the same solution for any given run (Brunet et al., 2004).  To combat this 
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challenge, Brunet et al. amended the initial NMF method proposed by Lee and Seung (1999) by 
adjusting the algorithm so to avoid numerical underflow (Brunet et al., 2004). 
Some of the data transformations that were applied to the simulated datasets resulted in 
negative values which are unacceptable in NMF.  Values for the NMF algorithm need to be 
nonnegative as the name suggests—a restriction that is unique to NMF.  Hence, the minimum 
absolute value count in the dataset was added to all values of the dataset.  NMF will not perform 
well if the dataset contains too much sparseness or values that are 0.  Thus, for those dataset from 
the RE and RX categories, we added an additional count to all of the data values in the data set. 
Furthermore, for the NMF clustering method, the standard NMF method was used, “Brunets” 
method.   
3.3.2.4.2 K Unknown Scenarios 
The K Unknown scenarios would be most representative to that which would be faced in 
“real-life” when conducting a cluster analysis as the number of clusters is rarely known.  The 
clustering analysis for K Unknown branch utilize all of the clustering methods that were used in 
the K Known clustering analysis with the addition of two different clustering methods.  The two 
additional clustering methods include Recursive Partitioned Mixture Model (RPMM) clustering, 
and K-Means (KM) clustering.  RPMM is a relatively new clustering methodology in 
comparison to KM which has been around for quite some time.  The addition of these two 
clustering methods to the common exploratory analyses, K Unknown-type analyses, allows for a 
more comprehensive evaluation of available clustering methods.  In this K Unknown scenarios, 
the number of clusters is unknown.  Here we are ignoring how  the data were simulated in 
clusters and use a data driven - algorithmic approach in combination with each of the five K 
Unknown clustering methods to estimate the number of clusters.   
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Recursively Partitioned Mixture Model Clustering 
Recursively Partitioned Mixture Model (RPMM) clustering is another method that relies 
on mixture models to aid in the clustering of samples similarly to MC.  Additionally, RPMM 
clustering also assumes that the data have some hierarchical structure as in HC.  The 
combination of these two attributes make allow for model-based hierarchical clustering method 
for high-dimensional data; such as, RNA-Seq data (Houseman et al., 2008, Koestler, 2013). One 
caveat to this clustering method is that it will only cluster to a maximum of 2𝑟 where 𝑟 is the 
number of partitions algorithmically determined.  In R, the rpmm() was used from the RPMM 
package (Houseman, 2014, R Development Core Team, 2016). 
K-Means Clustering  
K-Means (KM) clustering is one of the older clustering methods dating back to its first 
application nearly 40 years ago.  KM groups objects into (𝑘) fixed number of clusters so that the 
within-cluster sum of squares is minimized (Hartigan, 1979). The algorithm essentially shuffles 
all samples around searching for 𝐾 clusters that have which have their respective within-cluster 
sum of squares minimized.  For this type of clustering 𝐾 must be known.   Similarly to all other 
clustering methods mentioned above, the KM also has a function in R that will complete the 
procedures—kmeans() (R Development Core Team, 2016). 
3.3.2.4.2.1 Selection of K Number of Clusters 
Few formally defined algorithmic approaches have been developed to determine the 
number of clusters to be selected in clustering analyses.  Most studies select 𝐾 in a subjective 
manner as previously mentioned.  Determination of the number of clusters for a specific analysis 
is a difficult task.  Number of clusters are typically approximated based upon an experts advice 
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or information from prior studies.  Although, when no prior information is known about the data 
to be clustered, we turn to algorithmic approaches.  In our study, we use two algorithmic 
approaches to estimate the number of clusters: (1) the Gap Statistic (Tibshirani, 2001), and (2) a 
model-based approach through using the best Bayesian Information Criterion (BIC) from the 
mclust package in R (Farley and Raftery, 2002, Fraley et al., 2012).  When implementing the 
Gap Statistic, we developed code that would allow for the algorithm to work seamlessly with 
each of the five K Unknown clustering methods.  The code modifications let the Gap Statistic 
select the number of appropriate clusters for the data while keeping the innate clustering method 
unaltered.  However, execution of the model-based approach was conducted slightly different; 
rather than utilizing all of the five K Unknown clustering methods, only MC was used.  In this 
instance, MC can determine the best BIC from the results of its EM (expectation-maximization) 
algorithm.  The BIC that resembles the first decisive local maximum is indicative of the best 
model and in turn an estimation for the number of clusters that are present in the data (Fraley and 
Raftery, 1998). 
Gap Statistic 
Tibshirani et al. (2001) came up with a method that would select K such that the Gap 
Statistic would be optimized.  The Gap Statistic is a measure that compares the within-cluster 
dispersion to that of the dispersion under the null (Tibshirani, 2001).  According to Tibshirani, 
calculation of the Gap Statistic begins by clustering the data by varying the range of values for 
K; as well as, the within-dispersion measures (𝑊𝑘) for 𝑘 = 1, 2, … , 𝐾.  From here, 𝐵 reference 
datasets (𝑏 = 1,… , B) are generated where the features are from a uniform distribution.  Each 
dataset is then clustered to produce new within-dispersion measures (𝑊𝑘𝑏
∗ ).  The formula for the 
Gap Statistics becomes: 
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𝐺𝑎𝑝 𝑆𝑡𝑎𝑡𝑖𝑠𝑡𝑖𝑐 = 𝐺𝑎𝑝(𝑘) = (1 𝐵⁄ )∑ log(𝑊𝑘𝑏
∗ ) − log(𝑊𝑘)
𝑏
. 
For this particular study, we restricted the range K to 1 − 10 clusters and the number of 
bootstraps, B, to 10.  Once, the Gap Statistic is calculated for all variations of 𝐾, the estimated 
number of clusters can be calculated as:  
?̂? = 𝑠𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑘 𝑠𝑢𝑐ℎ 𝑡ℎ𝑎𝑡 𝐺𝑎𝑝(𝑘) ≥ 𝐺𝑎𝑝(𝑘 + 1) − 𝑠𝑘+1 
where 𝑠𝑘 = 𝑠𝑑𝑘√(1 + 1/𝐵) and 𝑠𝑑𝑘is the standard deviation of the Gap Statistic for k.  ?̂? is the 
new estimated number of clusters for a given dataset. For each of our transformed datasets from 
the four parent categories, we conducted a small simulation for each of the D datasets with 𝐵 =
10 bootstraps of the reference datasets for the calculation of the Gap Statistic for each of the 
clustering methods used in the K Unknown scenarios.  This small simulation generated 100 
values of ?̂? –one for each of the D datasets for any given combination of data transformation and 
clustering method.  For each distinct combination mean ?̂? was calculated and used as the 
specified number of clusters.  K Unknown clustering methods were then reran with the 
corresponding mean ?̂?. 
K Selection using Mclust 
 A model-based algorithm is another option to use to determine the number of clusters in a 
particular dataset.  Recall from the MC section above, the 𝑓𝑐 density from some multivariate 
normal distribution model with mean of 𝜇𝒄 and covariance matrix ∑𝑐.  Using different 
parameterizations for ∑𝑐, allows for different models to be passed through the EM algorithm as 
the number of clusters are varied (Fraley and Raftery, 1998).  BICs are calculated for every 
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possible combination of number of clusters and covariance matrix parameterization (Fraley and 
Raftery, 1998).  The combination with the highest BIC yields the estimation of the number of 
clusters, say ?̂?𝑀𝐶 , as previously mentioned above.  Unlike the Gap Statistic implementation, we 
were only able to determine the number of clusters for each of the 100 simulated datasets that 
had been transformed.  The estimated ?̂?𝑀𝐶  were then also re ran through all K Unknown 
clustering methods and evaluated.   
3.3.2.5 Clustering Evaluation Methods 
 To summarize and compare the transformations and clustering methods, the following 
three evaluation criteria were used: Adjusted Rand Index (ARI) (Hubert and Arabie, 1985), 
Clustering Error Rate (CER) (Witten et al.), and the Concordance Index (CI or C-Index) (Harrell 
et al., 1996).  The ARI ranges in value between 0 and 1 and is computed as a measure of cluster 
similarity (Sibru et al., 2012, Hubert and Arabie, 1985). The decision to use the ARI instead of 
the Rand Index (Rand, 1971) was made because a constant value is not allowed for the expected 
value of two clustering (Rokach and Maimon, 2005).  Values near 0 represent a lack of samples 
clustering to their “true” cluster; whereas, 1 indicates that samples cluster perfectly.  ARI can be 
easily implemented using adj.rand.index() function in the fossil package in R (R Development 
Core Team, 2016, Rand, 1971, Hubert and Arabie, 1985).  The CER is similar to the ARI; 
however, it is essentially the complimentary calculation without the adjustment. Lastly, the CI 
the probability that Sample 1 will cluster to 𝑐1 if the sample was initially from 𝑐1.  Formally it is 
the probability between the predicted and the observed cluster assignments (Harrell et al., 1996).  
A CI value equal to 0.5 means that the probability of predicting the correct cluster assignment is 
no better than that of random chance or that there is no predictive ability.  Values of CI that are 
94 
 
closer to 1 indicate high predictive ability for objects to be clustered perfectly (Harrell et al., 
1996).  All of the distinct formulas or steps for each of these three evaluation criteria can be 
found in Appendix D. 
3.4 Results 
 
3.4.1 Simulated Data 
For all simulation scenarios, data were simulated from a Negative Binomial distribution 
to represent four parent categories.  As a reference, the four parent are: Top 100 MAD Genes 
with Equal Cluster Sized; 2) Random 100 MAD Genes with Equal Cluster Sizes; 3) Top 100 
MAD Genes with Unequal Cluster Sizes; and 4) Random 100 MAD Genes with Unequal Cluster 
Sizes, abbreviated TE, RE, TX, and RX, respectively.   Within each panel of Figure III-6, the x-
axis contains the 𝑁 samples and the y-axis the 𝐺 genes.  Each of the heatmaps are ordered by the 
correlation that is present between the different genes.  Figure III-6 displays the variation 
between the parent scenarios; in addition, to the distinction of the clusters which are represented 
by the vertical dashed red lines.  The varying number of clusters are a direct result of the effect 
size shifts that were applied to the mean and overdispersion parameters of the Negative Binomial 
distribution.  As expected those parent categories that were selected randomly (RE and RX) from 
the Mayo Clinic data show more variation among the read counts that are present globally in the 
simulated datasets; whereas, less variation is present in the parent categories that were selected 




Figure III-6.  Heatmaps for all four parent categories and for all 𝑲.  Heatmaps from each of 
the four cateegories are plotted with each of the three different number of clusters (i.e., 𝐾 = 1 as 
no clusters, 𝐾 = 2 as two clusters, and 𝐾 = 3 as three clusters).  The dashed red lines help to 




3.4.1.1 Comparison of Data Transformations  
To compare the data transformations, we first looked at the measures of skewness and 
kurtosis, where data sampled from a Gaussian distribution would be around 0 and 3, 
respectively. All data transformation which numerically changed the data (i.e., Blom, Log, and 
VST) had on skewness values that more similar to that of a Gaussian distribution as compared to 
the naïve transformation (Table III-2).  Though, the corresponding kurtosis values to those 
skewness values that are more normal all are platykurtic or have kurtosis values ≤ 3.  Skewness 
values were closest to 0 for the RE and RX parent scenarios came from the Blom transformation 
and from the VST transformation for the TE and TX scenarios (Table III-2).  This can also be 
visually seen in Figure III-7 where the best results of skewness are listed as the following 
combinations for the four parent categories: TE--VST transformation and 𝐾 = 1; RE--Blom 
transformation and 𝐾 = 3; TX--VST transformation and 𝐾 = 1; and RX--Blom transformation 
and 𝐾 = 1.  We see that the Q-Q plots only minimal deviation from the theoretic quantile line 
which is an indication that data are approximately normal (Figure III-7).  Figure III-7 also shows 
that the tails of the distribution are heavy, which correspond to the case when kurtosis value ≤ 3.  
Values for both skewness and kurtosis remained the same when 𝐾 = 1 across all transformations 
selection-based parent scenarios of TE and TX, and RE and RX implying that method of data 
selection does not play a role in determining normality.  For simulated clusters of 𝐾 = 2 or 𝐾 =
3, it is likely that the combination of varied cluster sizes and the effect shifts implemented in the 





Table III-2.  Normality summary of data transformations.  Mean skewness (Sk) and mean 
kurtosis (Kt) values were calculated for each of the data transformations for each of 𝐾 simulated 
clusters in the four parent categories.  Those values that are bolded in red represent the closet 





Figure III-7.  Q-Q plots from data transformations whose skewness was most similar to 
Gaussian distribution.  All Q-Q plots are from a sample of data from the scenario of those best 
skewness values highlighted in red in Table III-2.  A) Q-Q plot for parent category TE, VST 
transformation, and, 𝐾 = 1. B) Q-Q plot for parent category RE, Blom transformation, and, 𝐾 =
3. C) Q-Q plot for parent category TX, VST transformation, and, 𝐾 = 1. D) Q-Q plot for parent 
category RX, Blom transformation, and, 𝐾 = 1.  The red 45 degree line present in each panel 
provides a reference to where points should fall if from Gaussian distribution. 
 
3.4.1.2 Comparison of Clustering Methods 
Clustering method performance was measured for both the K Known (Table III-3 and Table 
III-4) and K Unknown (Table III-5) simulations.  Assessment of 𝐾 = 1 scenario for K Known and 
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K Unknown scenarios are not presented in either of the summary tables as there were no clusters 
to compare sample assignment.  This is due to the way in which 𝐾 = 1 datasets were simulated to 
not reflect any clusters.  However, we calculated the proportion of times in which the clustering 
algorithm selected the correct number of simulated clusters.  This was completed for not only K 
Unknown for K=1, but for all other scenarios as well.  Comparisons between the Gap Statistic’s 
findings and the MC based selection for K were also made. 
K Known Scenarios 
For the K Known simulation scenarios, combinations of all clustering methods for most 
data transformations and known 𝐾 values had performance values that were better than random 
chance.  That is, their mean CI values are greater than 0.5.  Conversely, for the NMF clustering 
method, there are only minimal differences from 0.5.  The small variations ranged between CI 
values or 0.48 to 0.55.  When looking at the ARI and CER it is apparent that differences do exists 
between the pairing of data transformation and type of clustering method used.  Notably, model-
based clustering does not perform well in regards to selecting the correct clustering assignment 
when the Blom transformation is used with data that are highly variable prior to the transformation 
or rather for those data that represent the top 100 MAD genes (Table III-3 and Table III-4).  The 
best overall performance was observed when model-based clustering was carried out on data that 
were simulated with three clusters and when a log transformation was applied (Table III-3, Figure 
III-8 and Figure III-9).   For this combination of simulation parameters, parent category did not 
play a role. 
Model-based clustering on average appears to have the greatest performance when it comes 
to correct cluster assignment evaluated by our clustering metrics.  In Figure III-8 and Figure III-9, 
corresponding clustering evaluation metrics are present on the y-axis and data transformations on 
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the x-axes.  We can see that the model-based clustering (MC) line, in red, tends to be higher than 
the other clustering methods for ARI and CI and lowest for CER (Figure III-8 and Figure III-9).  
On the contrary, it appears that NMF performs the worst across data transformations.  Though, 
there are a few instances where NMF works better when the data have not been transformed (i.e., 
the naïve transformation).  This may also be due to the lack of assumptions required to carry out 
non-parametric methods--the assumption of normality is not needed.  For all of the clustering 
performance metrics, there are drastic differences when comparing the Naïve transformation to the 
other data transformations.  The Blom, Log, and VST transformations have similar results across 
the evaluation metrics for HC and MC clustering methods for data that were simulated from the 
selected random 100 MAD genes.  Additionally, it appears that the performance of HC follows 




Table III-3. Summary of evaluation metrics by clustering method and data transformation 
for K Known TEK and TXK parent categories.  Three different evaluation metrics were used 
to evaluate the performance of the data transformation paired with clustering method..  The 
evaluation metrics include: Adjusted Rand Index (ARI), Clustering Error Rate (CER), and 
Concordance Index (CI). Mean (𝜇) and standard deviation (sd) values were calculated for each 
metric. Fields with gray represent the highest performing transformation for K and clustering 




Table III-4. Summary of evaluation metrics by clustering method and data transformation 
for K Known REK and RXK parent categories.  Three different evaluation metrics were used 
to evaluate the performance of the data transformation paired with clustering method..  The 
evaluation metrics include: Adjusted Rand Index (ARI), Clustering Error Rate (CER), and 
Concordance Index (CI). Mean (𝜇) and standard deviation (sd) values were calculated for each 
metric.  Fields with gray represent the highest performing transformation for K and clustering 




Figure III-8.  Metric evaluation summary for all parent categories for 𝑲 = 𝟐.  Mean 
Adjusted Rand Index (ARI), Clustering Error Rate (CER), and Concordance Index (CI) are 
plotted for each of the four parent categories for 𝐾 = 2.  The Hierarchical Clustering (HC), 
Model-based Clustering (MC), and Non-Negative Matrix Factorization (NMF) are represented 





Figure III-9.  Metric evaluation summary for all parent categories for 𝑲 = 3.  Mean 
Adjusted Rand Index (ARI), Clustering Error Rate (CER), and Concordance Index (CI) are 
plotted for each of the four parent categories for 𝐾 = 3.  The Hierarchical Clustering (HC), 
Model-based Clustering (MC), and Non-Negative Matrix Factorization (NMF) are represented 







K Unknown scenarios  
For the K Unknown branch of the simulation, the same clustering performance metrics 
were used.  Two additional clustering methods were also assessed— Recursively Partitioned 
Mixture Model (RPMM) and K-Means (KM).  Prior to evaluation of the clustering methods, two 
algorithms were implemented.  Both the Gap Statistic and model-base clustering via Bayesian 
Information Criteria (BIC) values were used to determine the optimal K.  Results from the Gap 
Statistic and model-based approach can be found in Table III-5, and Table III-6, respectively.  
The Gap Statistic method often resulted with the choice of the data having no clusters ?̂? = 1 
regardless of the simulated number of clusters across all of K Unknown clustering methods the 
exception was for 𝐾 = 1 the Gap Statistic tended to select ?̂? = 1 correctly.  At most, the Gap 
Statistic errored 23% of the time for the 𝐾 = 1 scenarios.  For 𝐾 = 2 and 𝐾 = 3, the Gap 
statistic failed in determining the correct number of simulated clusters nearly 100% regardless of 
parent category, clustering method, or data transformation.  With the performance being so poor 
for the Gap Statistic in selecting the simulated K, we knew that our evaluation methods would 
not provide any useful additional information.  This proved to be the case after brief evaluation.  
The mean CER and CI values for HC, MC, NMF, RPMM, and KM were very poor at values of 
0.51 and 0.68 for 𝐾 = 2 and 𝐾 = 3, respectively.  This was the case across all combinations of 




Table III-5. Summary of the percentage (%) of times the Gap Statistic incorrectly selected 
the number of K simulated clusters.  Percentages are given for each of the K Unknown 




 The poor performance of the Gap Statistic led us to explore other methods that are 
capable of algorithmically selecting the number of clusters present in a given dataset.  We 
proceeded by implementing the model-based method for selecting K through the mclust R 
package.   The results in terms of how often the algorithm selected the correctly the number of 
clusters were also discouraging.  For all parent scenarios and all K, the algorithm incorrectly 
selected the number of clusters 100% of the time.  We observe that the algorithm selects ?̂?𝑀𝐶  
higher than the simulated number of clusters in the datasets.  For 𝐾 = 1, 𝐾 = 2, 𝐾 = 3,  ?̂?𝑀𝐶  
ranged from 2 clusters to 7 clusters, 3 clusters to 9 clusters, and 4 clusters to 9 clusters, 
respectively.  While the algorithm does not directly pick up the exact number of clusters that 
were simulated in the datasets nor does the algorithm select ?̂?𝑀𝐶  to be equal to one nearly 
always, we can proceed with cluster evaluation as the as the greater value of ?̂?𝑀𝐶  still contains 
the number of simulated clusters.  Rather, if ?̂?𝑀𝐶 = 4 and our simulated datasets has 𝐾 = 3, 
cluster assignments have the possibility to pick up all three clusters with potential that an 
outlying sample would be assigned to the fourth cluster.    
Figure III-10 and Figure III-11 summarize the mean values of the clustering evaluation 
metrics similarly to Figures III-8 and III-9 for the K Known scenarios.  K-Means, represented as 
the black line, clustering appears to perform the best when the number of optimal clusters is 
selected using the model-based clustering method’s built in approach for 𝐾 = 2 𝑎𝑛𝑑 𝐾 =
3 (Figure III-10 and Figure III-11).  Conversely, Recursively Partitioned Mixture Model 
clustering performed worse than all other methods.  We can also observe that HC, MC, and NMF 
clustering methods followed similar trends that were observed in the K Known scenarios. 
Specifically, for values of ARI and CER, we see drastic differences for the Naïve data 
transformation (Figure III-8, Figure III-9, Figure III-10, and Figure III-11).  For the other three 
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data transformations, it is difficult to select the one that might yield the most benefit to RNA-Seq 
in terms of clustering.  According to the evaluation metrics that we used, different parent 
categories suggest that different data transformations are most beneficial.  Another notable 
difference in these summaries is the lack of trends that exist across parent categories for all 
clustering methods; whereas, trends did exist in in the K Known clustering evaluation summary.  
We speculate that this is an artifact of carrying over ?̂?𝑀𝐶  from the MC selection algorithm 
applied to the transformed datasets and directly imputing it into each of the K Unknown 
clustering methods.  No information was incorporated into the model-based algorithm regarding 
unique attributes present in each of the individual clustering method which may lead to the semi-
irregular results.  An interesting result of the 𝐾 = 2 Unknown scenarios comes from comparing 
evaluation criteria across TX and RX (Figure III-10).  KM, in black, has the highest performance 
when looking at ARI and CER.  However, when looking at CI, we see that KM remains flat at 
0.5 meaning the probability that the sample will cluster correctly is no greater than chance alone.  
This is a result that we wouldn’t expect to have considering the mean values plotted for ARI and 
CER.  KM evaluation criteria behavior in the K Unknown scenarios for 𝐾 = 3 does not appear to 
have this drastic of a disagreement between any of the methods.   




Figure III-10.  Metric evaluation summary for all parent categories for 𝑲 = 𝟐 for model-
based clustering selection of K.  Mean Adjusted Rand Index (ARI), Clustering Error Rate 
(CER), and Concordance Index (CI) are plotted for each of the four parent categories for 𝐾 = 2.  
The Hierarchical Clustering (HC), Model-based Clustering (MC), Non-Negative Matrix 
Factorization (NMF), Recursively Partitioned Mixture Model (RPMM), and K-Means (KM) are 





Figure III-11.  Metric evaluation summary for all parent categories for 𝑲 =3 for model-
based clustering selection of K.  Mean Adjusted Rand Index (ARI), Clustering Error Rate 
(CER), and Concordance Index (CI) are plotted for each of the four parent categories for 𝐾 = 3.  
The Hierarchical Clustering (HC), Model-based Clustering (MC), Non-Negative Matrix 
Factorization (NMF), Recursively Partitioned Mixture Model (RPMM), and K-Means (KM) are 








3.4.1.3 Computational Resources 
 All K Unknown scenarios required much more computational time in comparison to K 
Known scenarios.  The average time for the K Known scenarios was approximately 6,224.80 
seconds or ~1.73 hours with standard deviation of .16 hours; whereas, the average time for the K 
Unknown scenarios was approximately 136,806.70 seconds or ~38 hours with standard deviation 
of ~4.3 hours.  These average times were computed over all simulations in each of the given 
categories.  In general, it was also true that as the simulated number of clusters in the simulation 
increased so did the amount of time it took to complete all of the calculations (Figure III-12).  
Additionally, there were no differences in computational time if the cluster sizes were equivalent 
or not.  Computational time for simulations scenarios from both types of the data selection were 
similar to one another in both the K Known and K Unknown scenarios (Figure III-12).  Rather, 
the amount of time for TE and TX scenarios and the scenarios from RE and RX were similar.  
RE and RX scenarios for the K Unknown had longer computational time than the TE and TX 
scenarios (Figure III-12).  In the K Known scenarios the opposite is true—the TE and TX 




Figure III-12.  Computational time for 𝑲 𝒌𝒏𝒐𝒘𝒏 and 𝑲 𝑼𝒏𝒌𝒏𝒐𝒘𝒏 scenarios.  Plots show 
the computational time that was taken to complete the simulations for each of the four parent 
scenarios. A) depicts the computational time for the 𝐾 𝐾𝑛𝑜𝑤𝑛 scenarios; whereas, B) the 
𝐾 𝑈𝑛𝑘𝑛𝑜𝑤𝑛 scenarios.  
3.5 Discussion 
 
 For RNA-Seq data there have not been many studies that have looked at the clustering 
performance of multiple clustering methods in combination with data transformations.  Hence, 
there is little guidance for researchers as to which data transformations should be used for RNA-
Seq data when conducting clustering analyses.  Even if clustering analyses are exploratory in 
nature, they can provide valuable information regarding the relationship between genes or 
samples.  In order to provide this information, it is important to have accurate and efficient 
statistical methods.  In light of the minimal information and studies that are currently available, 
we conducted and compared the results of an extensive simulation study to assess clustering 
method performance when data selection, data transformations, number of simulated clusters, 
and clustering method were varied.  Results from our simulation study provide insight to what 
could potentially be done to increase correct cluster assignment for samples; with or without 
prior information about how many clusters there might be.  Additionally, the simulation study 
has revealed some of the challenges and difficulties that still remain for completing clustering 
analysis in RNA-Seq data.  To combat biasing our performance results for our clustering 
methods, datasets were simulated to represent four parent categories that considered the way in 
which the data were selected and the size of the clusters. 
 We feel that the structure of the simulated data was improved upon from the Witten study 
from 2010 as parameters were obtained from “real-life” dataset.  In Witten’s simulation study, 
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the distributional parameters appeared to be arbitrarily selected.  Values for the over-dispersion 
parameter, ϕ, appear to reflect values which are typically used to show over-dispersion within the 
data.  Additionally, the mean of her model was composed of a multiplicative mixture of 
Uniform, Exponential, and Log-Normal distributions.  While this way of approaching such 
simulation is typical, unique attributes from “real-life” data are missed.  To better preserve the 
unique attributes that are present in actual RNA-Seq data samples, we obtained the NB MLEs to 
be used to simulate our datasets.  Looking at Figure III-2 and Figure III-3 in Section 3.3, our 
simulated data appear to match the Mayo Clinic data well. 
 As RNA-Seq data do follow a NB distribution with high variability among gene read 
counts, implementation of data transformations are warranted.  Without data transformations, the 
overdispersed nature of RNA-Seq create problems with many types of statistical methods.  
Moreover, many statistical methods, clustering methods included, are better adapted to handle 
data that follow more of a normal distribution.  Hence, we applied the Blom, Log, and VST 
transformations to our simulated RNA-Seq data.  In terms of skewness, we determined that all 
simulations made the data more normal.  Specifically, the Blom transformation on average 
obtained the most normal data according to the mean skewness values (Table III-2).  The data 
transformations; however, did not provide any benefit in handling tail behavior as denoted by 
mean kurtosis values presented in Table III-2. 
 Each data transformation was used for each of our clustering methods for the K Known 
and K Unknown simulation branches.  In the assessment of clustering method performance in 
combination with the data transformations, we observed many expected results based off of 
previous literature from Witten, Yeung et al., and Thalamuthu et al..  While these authors’ 
studies were completed in microarray data, model-based clustering (MC) was found to produce 
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higher quality of clusters (Witten, 2011, Yeung, 2001, Thalamuthu et al., 2006).  Notably, 
model-based clustering using mclust out-performed all other clustering methods in the K Known 
branch across all data transformations and evaluation metrics.  Since the primary model used for 
MC is the Gaussian mixture model, it is reasonable that transforming data to look more normal 
would be highly beneficial for the performance of the MC method.  Contrariwise, NMF lacks the 
level of performance in comparison to HC and MC.  However, there does appear to be some 
benefit in using NMF when no transformation is made to the data.  NMF does not use any model 
constraints to assign clusters as it is nonparametric, rather it seeks to minimize the generalized 
Kullback-Leibler divergence which is similar to conventional least squares.  HC falls in the 
middle regarding its performance in comparison to MC and NMF.  Though, performance could 
potentially be gained from using single linkage verses complete linkage especially in our parent 
scenario categories where the data selected were based on the top 100 MAD genes.  Single 
linkage is better when outliers are present as the outliers are merged into clusters last rather than 
first (Chalise et al., 2014).  The presence of potential outliers can be seen in Figure III-3. 
 Results from our K Unknown simulation branch revealed the difficulty in algorithmically 
selecting the number of clusters present in a given dataset when no expert advice is available.  
Implementation of the Gap Statistic purposed by Tibshirani et al. (2001) to determine the optimal 
number of clusters, ?̂?, did not prove to provide any benefit in performance of any of the 
clustering methods assessed.  In our Gap Statistic analysis to determine what the optimal ?̂? 
would be for any scenario, we nearly always ended up with the algorithm selecting our data to 
have no clusters, ?̂? = 1, even when the data were purposefully simulated to have 𝐾 = 2 and 𝐾 =
3 clusters.  After reviewing why this pneumonia was occurring, it was determined that the results 
are likely due to the fact that our data our data are not standardized nor may the effect shifts used 
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to simulated the clusters in our datasets be large enough.  This is likely the reason for the poor 
performance evaluation metrics in our clustering methods’ analysis. 
 In addition to the Gap Statistic results for the K Unknown scenarios, the results from the 
second approach which used a model-based algorithm in combination with BIC, verified that any 
transformation to RNA-Seq data to make it more normal will be beneficial for downstream 
clustering analyses.  Though, the utilization of an additional algorithm to select optimal K, did 
not provide much evidence regarding best practices when there is no information available 
regarding potential number of clusters.  We can, however, say that our results suggest that using 
K-Means clustering is highly robust to missed assignment of clusters as it consistently performed 
better than all other clustering methods across our evaluation metrics.  K-Means was also the 
only clustering method that had a relatively consistent performance trend across all parent 
categories.  This is an interesting finding as K-Means clustering tends to perform best when 
clusters are of equal size.  However, further investigation into the evaluation criteria of the 𝐾 =
2 Unknown scenarios for TX and RX is needed to fully understand why the mean concordance 
index has such low performance for K-Means.  Overall, the K Unknown performance results 
compared to the K Known performance results were worse for the mutual clustering methods 
used, HC, MC, and NMF, which is not unexpected.  It would not be expected that by increasing 
uncertainty, which is present in our K Unknown branch of the study, that clustering performance 
would improve.  Thus, not knowing the number of clusters in a given dataset is a challenge that 
researchers and statisticians will continually have to navigate.    
 This study does provide similar results to those which were found in microarray studies 
that looked at performance of clustering methods when the number of clusters is known.  In 
particular, that model-based clustering demonstrates the highest level of performance when it 
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comes to correctly assigning samples to their said clusters.  Additionally, our results highly favor 
the use of the Log, base 2, transformation when it comes to conducting clustering analysis of 
RNA-Seq data.  However, at this point, we feel that the results of the K Unknown simulation 
branch are inconclusive.  The data and clustering performance would likely benefit from adding 
an additional step that would further standardize the data.  Furthermore, there would be an 
opportunity to improve upon the Gap Statistic algorithm to better handle data that are not 
standardized.  Likewise, there is room to advance those clustering methods used in this study, 
aside from MC, by developing algorithms to select the optimal number of clusters in a way that 
considers the method’s theoretical background. There is also the potential to re-engineer MC’s 
prominent Gaussian framework into a framework that is capable of handling discrete based 
distributions.  More specifically, to design a model-based clustering algorithm that was built 
using a mixture of negative binomial distributions.   
Other limitations of this study include that only a subset of data transformations and 
clustering methods are assessed.  It is highly likely that there is not one best data transformation 
or clustering method for all scenarios.  Additionally, this study is limited in that NB MLE 
parameters were only obtained from one type of cancer and histology type, ovarian cancer of the 
Serous histology, which many slightly bias the generalizability of the results across clustering 
methods for all types of genes or samples from different tissue or cancer types.   Also, our study 
does not consider if selected features were linked or unlinked to producing inherit clusters.  
Future work to extend this study include: examining different effect sizes to apply to parameters 
of the NB distribution, varying 𝑁 and 𝐺, normalizing the RNA-Seq data so that they are more 
standardized, and implementing any new clustering methods that have been adapted for count-
type data.  Furthermore, a natural extension of this study would be to look at clustering 
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performance at the isoform level as it has the potential to further advance the knowledge behind 
different cancer signatures.   
 In conclusion, we found that RNA-Seq data requires caution when conducting clustering 
analyses.  This is supported by our efforts to improve the performance of clustering methods 
through data transformations and common methods used to determine the number of clusters in a 
dataset.  Our results suggest that a model-based clustering (MC) approach may be the best 
starting place for exploratory clustering analysis of RNA-Seq data types when the number of 
clusters is backed by prior knowledge.  However, if no information is known about the number 
























Ethical Considerations for Precision Medicine— A Survey Protocol to Investigate Patient’s 
Opinion Towards Genomic Sequencing 











 The technologic advancements, specifically in high-throughput sequencing, that have 
recently occurred in the field of genomics have changed the way in which providers approach 
making treatment decisions.  Phenotypes and clinical information are no longer are the primary 
determinant in the treatment decision process.  By taking phenotypic and genotypic information 
together, more tailored treatments can be precisely selected.  This approach to the treatment of 
cancer is becoming increasingly popular as in many cases the personalized treatments exhibit 
higher efficacy and provide patients with better quality of life.  However, there is much ethical 
controversy that surrounds genomic sequencing in terms of patient privacy and security of the 
large amounts of data collected.  Many survey studies have been completed to assess cancer 
patients’ attitudes and perspective towards genomic sequencing and the ethics involved in the 
topic.  Though, only few have been targeted solely towards cancer patients.  As cancer patients 
are the largest population that has the potential to be affected by personalized medicine through 
genomic sequencing, it is critical that researchers and providers alike understand their opinions.  
We have developed a protocol to conduct a survey-based pilot study within the local University 
of Kansas network.  We propose to conduct 8 one-on-one interviews and a focus group with 10 
participants to aid in revision of a survey prototype.  Upon revision of the pilot survey prototype, 
we hope to recruit approximately 32 participants, or more, who will attend a Saturday morning 
survey session.  Participants will be given an approximately 22-item survey to complete which 
contains questions regarding their knowledge and opinion of genetic testing and its applications.  
Subsequently within the survey, participants will be asked demographic questions and be 
provided with a brief, educational overview of cancer and genomic sequencing.  Results from 
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this pilot study can later be used in defining and implementing a larger-scale, potentially national 
study. 
Keywords: Precision Medicine, Genetic Sequencing, Medical Ethics, Sporadic Cancer, 






The big “C”, as cancer is often referred to, has become one of the hallmark diseases that 
has impacted nearly every individual in some way or another—a family member, oneself, or 
otherwise.  There are likely many reasons this is the case; some of those reasons include risk 
factors such as tobacco, obesity, alcohol, infectious agents; as well as, potential environmental 
exposures (American Cancer Society, 2016).  Although, potentially the number one reason for its 
high impact within the population is the sheer number of people have cancer or who were 
previously diagnosed with cancer and are in remission or disease free. 
According to the World Health Organization (WHO), cancer has been recorded as one of 
the leading causes of death worldwide (World Health Organization, 2014).  The trends of 
incidence and prevalence of cancer among the top three most populated countries in the world 
are very interesting.  In China, the most populated country in the world, cancer is listed as the 
leading cause of death with an estimate of ~3 million cancer deaths having occurred in 2015 
(Chen et al., 2016).  However, in India, cancer does not even rank within the top 10 causes of 
death (Centers for Disease Control and Prevention1, 2015).  The estimated cancer mortality in 
India reported from GLOBOCAN 2012 was only 683,000 individuals (Ferlay et al., 2013).  
Continuing to the third highest populated country in the world, the United States, cancer again 
makes its way onto the list of leading causes of death.  Several nationally recognized reports for 
the top leading causes of death in the United States rank cancer as the second most frequent 
causes of death (Centers for Disease Control and Prevention2, 2015).   
In 2013, in the United States there were 14,140,254 people living with cancer according 
to the latest published prevalence numbers (National Cancer Institute1, 2016).  While the national 
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surveillance programs have not updated the prevalence numbers for 2016, they do provide 
estimates for the estimated number of new cases and deaths per 100,000 people.  The estimated 
incidence, or new, cases of cancer and cancer deaths for 2016 are 448.7 per 100,000 and 168.5 
per 100,000 people, respectively regardless of sex or type of cancer (National Cancer Institute1, 
2016).  This translates into ~1,604,000 cancer incidence cases and ~617,000 cancer deaths 
(Ferlay et al., 2013).  Furthermore, the estimated number of people in the United States that will 
have cancer or previously had cancer is approximately 19 million by the year 2024 (National 
Cancer Institute2, 2016).  The aforementioned collection of people have cancer types that are 
numerous and vast, and vary in terms of stage, grade, and histology.  As there are so many cases 
associated with cancer, the costs that are associated with treatment of all of those patients is very 
high.  The National Cancer Institute (NCI) estimated expenditure for cancer care in the United 
States increase by approximately $31 billion from 2010 to 2020 (National Cancer Institute2, 
2016).  The estimated costs of cancer in the United States in 2010 was $124.57 billion (Mariotto 
et al., 2011).  In addition to the dollar amount associated with cancer care, are both the difficult 
to quantify emotional and physical burden of the patient.  Thus, there is a great need to research 
cancer from all aspects from cancer care treatment to performing good research, and to ensuring 
that patients, providers, and researchers have the best possible information available to them at 
any given cross section of time. 
To promote collective efforts within the United States to reduce and prevent threats to the 
health in the general public, the government publishes an agenda of national topics and 
objectives for critical health related issues to be addressed (Office of Disease Prevention and 
Health Promotion, 2016).  The overall goal of this agenda is to “attain high-quality, longer lives 
free of preventable disease, disability, injury, and premature death; achieve health equity, 
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eliminate disparities, and improve the health of all groups; create social and physical 
environments that promote good health for all; and promote quality of life, healthy development, 
and healthy behaviors across all life stages” (Centers for Disease Control and Prevention: 
Division for Heart Disease and Stroke Prevention, 2014).  The most recent agenda, Healthy 
People 2020, includes both “cancer” and “genomics” in its list of topics to be addressed (Office 
of Disease Prevention and Health Promotion, 2016).  Specifically, for cancer the goal is to 
“reduce the number of new cancer cases; as well as, the illness, disability, and death caused by 
cancer” (Office of Disease Prevention and Health Promotion, 2016).  Additionally, for genomics 
the goal is to “improve health and prevent harm through valid and useful genomic tools in 
clinical and public health practices” (Office of Disease Prevention and Health Promotion, 2016).  
The topic of genomics was never previously included in list of topics nor did it show up in any 
objectives to be addressed prior to the current rendition of the agenda.  We believe this is directly 
related to the recent advancements of genomic technologies and understanding of the vast realm 
of genomics.  While the two agenda topics items mentioned above can stand alone, the two have 
in recent years become fittingly married together as the field of cancer genomics.  Though to 
better understand this marriage, we first look at each agenda item separately. 
DNA is not a stagnant nor unchanging molecule. DNA is a forever changing molecule,  
in a person’s lifetime their DNA can undergo a multitude of changes from repairs (i.e., DNA 
repair) to mutations (i.e., single nucleotide polymorphisms (SNP), insertions, deletions, etc.) and 
structural changes (i.e., chromosome duplication or altered chromosome structure) which results 
in variations of genetic material (Aguilera and Garcia-Muse, 2013).  These variations taken 
together are often referred to as the hallmarks of cancer (Figure IV-1).  Nearly all cancers found 
in humans can be categorized by these hallmarks (Negrini et al., 2010).  The list of hallmarks 
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proposed by Negrini et al. (2010) provide a fairly comprehensive overview of possible rationales 
which leads to the development of cancer.   
Cancer is a very complex disease which utilizes a great amount of research hours and 
personnel.  There are three groups which classify a majority of the cancers: familial cancers, 
hereditary cancers, and sporadic cancers.  Familial cancers are caused by multiple variants that 
are often difficult to define.  Those variants range from a unique combination of multiple genes, 
family history of cancer, and environmental stimuli (Coriell Personalized Medicine 
Collaborative, 2016, Sijmons, 2010).  While the relationships between the hallmarks are not 
specifically depicted in Figure IV-I, we would expect there to be multiple hallmarks that had 
directional arrows pointing to other hallmarks as high variation of causes is characteristic of 
familial cancer.  Families with familial cancer exhibit trends in cancer type greater than that 
expected by chance alone due to genetic syndromes and mutations in known cancer genes 
(Coriell Personalized Medicine Collaborative, 2016, National Cancer Institute3, 2016). 
Sporadic cancer are slightly easier to define as there are not as many components that are 
linked to its cause.  Although, not all causes of sporadic cancers can be determined.  Sporadic 
cancers (i.e., non-hereditary cancers) are classified by the lack of family history of given cancer 
and the absence of the individual having any type of genetic risk factor through an inherited gene 
mutation (National Cancer Institute6, 2016).  The genetic alterations that are found in these types 
of cancers are called somatic mutations (i.e., mutations which are observed in the tumor’s 
genetic material but not in a person’s inherited genetic material) and occur after conception 
(National Cancer Institute7, 2016).  The pathway in which these types of cancers develop is 
through an activation of the cell grow signaling which leads to DNA damage and DNA 
replication stress (Figure IV-1: Panel C) (Luo et al., 2009, Negrini et al., 2010).  This causes 
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downstream problems with genomic instability and  reproduced cells evading cell death and 
senescence (Figure IV-1: Panel C) (Luo et al., 2009, Negrini et al., 2010).  The initial activation 
of the cell grow signaling can be the result of a lifetime of genetic damage. Sporadic cancers 
account for approximately 60% of all cancers and tend to occur later in life (Coriell Personalized 
Medicine Collaborative, 2016, Anderson, 1992). 
Hereditary cancers are different than sporadic cancers in that they are linked to genetic 
inheritance from parents (i.e., genomic instability, mutations in key cancer causing genes) 
(Figure IV-I: Panels A and B).  Rather, hereditary cancers are associated with a mutation in 
determined susceptible germline gene that cause an individual to have an increased risk to 
develop cancer (Coriell Personalized Medicine Collaborative, 2016).  If an individual develops 
cancer that has been determined to be linked to such mutation of a gene, likely through genetic 
sequencing, is termed a hereditary cancer.  Cases of hereditary cancers are generally found in 
younger individuals (Anderson, 1992).  Unfortunately, some of the susceptible germline gene 
mutations have been tracked and shown to have a lifetime risk up to an 85% chance of 
developing cancer (Coriell Personalized Medicine Collaborative, 2016).  The most published 
hereditary cancers occur from mutations in BRCA1 and/or BRAC2 resulting in breast and 
ovarian cancer (National Cancer Institute4, 2015, Walsh et al., 2010, King et al., 2003).  A 
summarized list of mutated genes and the related cancer types of the identified 50 hereditary 
cancer syndromes can be found on the National Cancer Institute’s website (National Cancer 
Institute5, 2013).  While the actual percentage of hereditary cancers is small, the syndromes 
which arise from them is consistently growing (Strahm and Malkin, 2006).  It should be noted 
that it is not always the case that if an individual has a germline mutation that if they get cancer 
that it will be a direct result of the germline mutation.  A different mutation may be linked to the 
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cause of the cancer.  Moreover, on occasion genes that are inherited and mutated through the 
germline, genes which predispose an individual to cancer, also play a role in pathogenesis in 





Figure IV-1.  Overview of the hallmarks of cancer (Luo et al., 2009, Negrini et al., 2010).  
Found within the sections of the circle are many of the identified hallmarks that play a role in the 
development of cancer (Panel A).  Those hallmarks that lack shaded backgrounds are those 
hallmarks that were added in 2010.  The arrows in the inner circle of panel B) and Panel C) 
depict the relationships hallmarks have with each other in hereditary and sporadic cancers, 
respectively (Luo et al., 2009, Negrini et al., 2010).
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Cancer is fueled by changes in an individual’s genetic material that occur irregularly or 
changes that are prompted by the environment (i.e., radiation exposure, smoking, sun exposure, 
etc.).  Hence, it is fitting that a large component to understanding and treating cancer would be to 
understand the variations present in genetic material.  The field of study which studies genes, 
gene function, and their technologies is genomics (World Health Organization2, 2002).  To gain 
insight into genetic material, genetic sequencing, can be performed which determines the 
combination of the nucleic acids in DNA and/or RNA.  Together, these combinations make up 
the genetic sequence, which provides genes that are present and information about the structure 
and function of those genes (National Human Genome Research Institute2, 2015).  However, it 
should be noted that genetic testing is not exclusively limited to DNA and RNA, analyses can be 
performed on chromosomes, proteins, and metabolites.  Also, there are also three different types 
of DNA sequencing that are utilized—whole genome and targeted (i.e., sequencing of specific 
areas and exome). 
Sequencing technologies have improved greatly over the years.  Prior to 2004, microarray 
technology was used to determine genetic sequence, but it was drastically limited in the amount 
of sequencing information that could be output.  Recent advancements in technology have led to 
the popularity of using Next-Generation Sequencing (NGS) for genetic sequencing.  The advent 
of NGS technologies has not been around for that long of a time frame, but it has already enabled 
researchers to study genetic material at a level that surpassed early expectations (Van Dijk et al., 
2014).  It wasn’t until 2004 that NGS became commercially available (Mardis, 2008).  
Sequencing technology has improved greatly over the years in terms of increased speed, 
efficiency, lower costs, and higher accuracy to provide “exquisite sensitivity and resolution” 
(Walsh et al., 2010, Mardis and Wilson, 2009).  Currently, cost for whole genome sequencing 
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(WGS) is ≤ ~$1,000 which make it available for smaller labs, research centers, clinics, and 
population-wide (Van Dijk et al., 2014, Shen et al., 2015, Ku et al., 2013).  Addressing the 
objective listed in Healthy People 2020 for genomics, it is fitting that in the near future providers 
and patients would be encouraged to utilize the application of genomics in the treatment of 
common diseases. 
The fields of genomics and cancer are projected to weave together more so in coming 
years than they are currently.  Today our understanding of the molecular nature of cancer is due 
largely in part to next-generation sequencing (NGS) techniques (Yang et al., 2012).  
Additionally, some of the largest advancements in the field of genomics have been in the area of 
cancer biology (Balmain et al., 2003).  More specifically, genomic sequencing and molecular 
profiling gained popularity as their results led to better understanding of the complexities of 
cancer (Balmain et al., 2003).  As put by Catenacci et al. (2014), we are at a “critical point” in 
modern-day medicine where cancer treatment and care decisions are being driven by the plethora 
of data produced by NGS.  With the costs of sequencing becoming more reasonable, more 
providers are regularly using it for purposes of cancer diagnostics in both a discovery and 
confirmatory context (Shen et al., 2015, Ku et al., 2013).  In familial cancer, researchers are able 
to conduct WGS within the family to determine if offspring have germline mutations of genes 
which predisposed them to cancer (Shen et al., 2015, Ku et al., 2013).  Furthermore, sequencing 
can determine single changes in a nucleic acid base of a portion of DNA which can disrupt 
proteins responsible for normal cell function (The Cancer Genome Atlas, 2010).  However, the 
primary goal of genomic sequencing is to identify those somatic or germline mutations that 
might be candidates for targeted drug therapies (Gingras et al., 2016). 
130 
 
This is a form of precision medicine.  As its name suggests, precision medicine, or also 
synonymously termed personalized or individualized medicine, is the tailoring of disease 
treatments and/or interventions to the unique characteristics, both genotypic and phenotypic, that 
an individual has (Ciardiello et al., 2014).  Next-Generation Sequencing is becoming more 
commonly used to determine “best” drug therapy through a data-informed decision when it 
comes to placing a patient on a treatment that they will likely benefit from based upon given 
molecular biomarkers (Yang et al., 2012, Gingras et al., 2016).  The goals of personalized 
medicine are to “increase the probability of efficacy and/or decreasing the probability of serious 
adverse events”(Vicini et al., 2016).  Cancer is at the “frontline” of personalized medicine as 
additional considerations are now being given to molecular biomarkers and not solely 
phenotypes when developing eligibility criteria in clinical trials (Ciardiello et al., 2014).  Many 
clinical therapies in development are largely associated with defined biomarkers (Ciardiello et 
al., 2014).  As more cancer therapeutics are being developed specifically for certain biomarkers, 
it is essential that researchers document their findings to allow other researchers to further 
advance personalized medicine in the cancer patient population.  In the last 10 years, few 
databases (i.e., The Genomics of Drug Sensitivity in Cancer (GDSC) database, Mutations and 
Drugs Portal (MDP) database, and canSAR) have been created to keep track of which molecular 
features influence a drug response in cancer cells through a combination of cell line drug 
sensitivity data, genomic data, and data from the analyses of genomic features (Yang et al., 2012, 
Taccioli et al., 2015, Bulusu et al., 2014).   
While great progress has been made in the area of precision medicine for cancer, it has 
not been without challenges—scientific challenges do to cancer’s complexity, and otherwise due 
to ethical considerations.  There is much controversy that surrounds genetic testing.  At the 
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center of the controversy is that genomic sequencing has the ability to identify an individual, 
reveal if the individual is at an increased risk of developing certain types of cancer, expose other 
diseases that the individual may have which leads to valid concerns of patient privacy, 
discrimination, and security of the large amounts of data (Ciardiello et al., 2014).  More 
specifically, whole genome and exome sequencing produces large-scale data of which has the 
potential to have both medical and social influence as levels of result’s uncertainty can still be 
present (Fiore and Goodman, 2015).  While much genetic data has been released and stored in 
publicly available databases without any direct link to individuals, there are still some medical-
Sequencing databases that contain patient identifying variables such as: demographic 
information, clinical information, etc. (Foster and Sharp, 2006).  That being said, data that is 
obtained from sequencing should be stored using the same degree of security that is used to 
protect other entities that house personal health information (i.e., electronic medical records and 
some databases).  
Fortunately and unfortunately with genetic sequencing there is no way to tune the results.  
Rather, intermittently sequencing reveals a medical finding that is different from that which a 
researcher was looking for—referred to as “an incidental finding”.  Incidental findings can 
expose information about paternity, risks of certain diseases or syndromes, etc. which may have 
drastic implications mental health, well-being, or even how an individual proceeds care.  The 
question that often arises with these incidental findings is, “Do you tell your patient of them?”  
This has created much controversy in recent years with genomic sequencing becoming more 
readily used in diagnosing patients.  In general, there are two sides to this argument.  Side one, 
should providers only present results and findings for the current medical issue that a patient has; 
or side two, should a provider lay out any findings from medical tests.  Previously proposed 
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guidelines in general seem to advise patient providers to communicate such findings when they 
are found, especially if results are analytically valid and clinically significant (Fabsitz et al., 
2010, Wolf et al., 2012, Zawati and Knoppers, 2012).   
In general, current practice for reporting and communicating incidental findings to 
patients is dependent on the following subjective criteria: “variant frequency, the potential for 
medical intervention to mitigate disease, the strength of association between specific gene 
abnormalities and the condition, and penetrance (i.e., proportion of individuals carrying a 
particular variant of a gene) of those genes” (McGuire et al., 2013, Green et al., 2013, Middlelton 
et al., 2016).  Following this recommendation, only approximately 1% of patients would have a 
qualifying incidental finding (Green et al., 2013).  However, much debate is still had about those 
incidental findings that are of uncertain significance (Hofman, 2016).  When patients were asked 
whether or not they would want to know about any incidental findings, the consensus was to 
allow the individual patient to decide based upon their moral, political, and religious values 
(Townsend et al., 2012, Freedman, 1987, Foster and Sharp, 2006). 
Several other ethical concerns that arise from genetic testing are: adequacy of patient 
consent; familial genetic testing; additional germline testing for individuals with early onset 
sporadic cancers (i.e., if patient was diagnosed prior to age 55); targeted vs. whole genome 
sequencing; unnecessary treatment due to false positive results of testing; 
stereotyping/stigmatization; disparities in access to additional testing, counseling, and the way in 
which insurance companies reimburse; and additional privacy and discriminatory concerns 
(Fiore and Goodman, 2015, Foster and Sharp, 2006).  Although, governmental bodies are 
helping address some of the ethical concerns that have developed surround genetic sequencing.  
In 2008, the Genetic Non-Discrimination Act (GINA) was passed which forbids employers and 
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health insurance companies to discriminate against individuals based on genetic test or family 
history (Fiore and Goodman, 2015).  While GINA was a step in the right direction, there is still 
work to be done to protect patients and address ethics associated with genomic sequencing.  It is 
highly likely that as the general community becomes more educated about genomic sequencing 
as a whole, acceptance of its implementation will increase.  
4.3 Motivation and Objectives for the Survey 
 
Understanding cancer patients’ opinions regarding precision medicine in terms of 
genomic sequencing is critical, especially as there are many ethical concerns that arise.  By 
obtaining patients’ opinions, providers can potentially deliver better, more efficacious treatment 
to their patients.  Additionally, it provides insight to surveillance groups that develop guidelines 
which address approaches to care of patients.  Current literature is saturated with surveys that 
have been given to providers regarding their opinion to the use of genomic sequencing in 
patients with varying types of cancer.  This is likely due to the fact that providers have acquired 
some education regarding genomic testing.  Other surveys that seek individuals’ opinions 
towards genomic sequencing in cancer care utilize participants that are from some type of health 
care profession or science researcher area, or participants that from the general public 
(Middlelton et al., 2016, Henneman et al., 2013).  The few published studies that use patients’ 
opinion towards genomic sequencing, are not enough to fully gain a consensus of the general 
cancer patient population.  Hence, we propose a protocol for implementing a local patient 
opinion survey targeting cancer patients, which could later be evaluated for content validity, 
reliability, and duplicity.  Upon this evaluation, the survey could be revised and executed in a 
larger population at a later date.  Prior to the development of the survey, we plan to conduct a 
134 
 
series of one-on-one interviews and a host a focus group with various types of cancer patients.  
The primary objective of the survey would be to determine basic cancer patients’ opinions 
towards genomic sequencing in a pilot study with the hopes conduct a larger-scale study.  
Additionally, we would like to gain some insight to patient opinions regarding targeted drug 
therapies, and briefly germline sequencing. 
4.4  Proposed Pilot Study Design 
 
 In developing a protocol to implement our survey, there are many topics that needed to be 
addressed; such as, what are the concerns that patients have, who the study will be given to, how 
many participants will take the survey, participant recruitment, questionnaire development, and 
potential statistical analyses.  For this pilot survey study, we plan to use a convenience sample of 
cancer patients being treated within the University of Kansas network of providers.  Using a 
small sample of varied providers, we will aim to schedule up to 8 one-on-one interviews or a 
focus group which contains up to 10 people as recommended.  Once data is summarized from 
those participants in either the one-on-one interviews, we will recruit participants to take our 
pilot survey study. Those participants that agree to participate in a morning survey session group 
will be given a survey questionnaire to complete.  After completion of the survey questionnaire, 
participants will also be given the opportunity to voice opinions and discuss with other survey 
participants about their questions and concerns of having genomic testing completed, and in turn 






4.4.1  Pilot Study Approval 
Prior to moving forward with the conduction of the one-on-one interviews, focus group, 
and future pilot survey study, approval needs to be attained from the Institutional Review Board 
(IRB).  This protocol, interview/focus group questions, supplementary documents including the 
consent form, recruitment “Save the Date”, and potential survey questionnaire will be submitted 
to the electronic IRB system to be reviewed by the IRB committee.  We assume that since this 
study would involve “no more than minimal risk” that it would receive an expedited review by 
the committee.  Once approval is given from the IRB to proceed with the study, we would begin 
reaching out to providers to help recruit participants for our study.  This pilot survey study will 
be conducted in compliance with this protocol and Good Clinical Practice (GCP) guidelines.  
Any changes to this protocol or study documents will be submitted to the IRB as an amendment 
for review and approval.  All copies of completed consent forms and survey questionnaires will 
be securely retained for five years after the completion of the study the Principal Investigator 
(PI).  Furthermore, the master electronic data will be encrypted with password protection.  Only 
necessary members of the research team will be given data files.  No patient identifying 
information will be collected on the survey.  Lastly, all survey administrators and research team 
members will undergo brief training and detailed instruction regarding to insure that everyone is 
competent in their respective roles. 
4.4.2  One-on-one Interviews and Focus Group 
 In order to develop a survey that accurately obtains patients’ opinions towards the 
previously mentioned topics, we propose to conduct multiple one-on-one interviews and/or a 
small focus group to gain deep insight into areas where cancer patients have concerns in terms of 
the ethics behind precision medicine and genetic sequencing.  The use of one-on-one interviews 
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and a focus group, we hope, will provide a comfortable environment for participants to 
thoughtfully respond to our questions or ask for clarification; and provide awareness to areas or 
domains that we may need to consider to be addressed in our questionnaire.  Recruitment of 
participants for either the one-on-one interviews or focus groups will be recruited from other 
principal investigators that we have worked with in the past.  These providers will discuss with 
their patients about the opportunity to be a part of our study.  Depending on the patient’s interest 
level, the provider will attempt to schedule a 30 minute interview with a member from our 
research team at their next follow-up appointment or they will be given a “Save the Date” 
(Appendix E) regarding when the focus group session would be help.  The exact date of the 
focus group will be determined by research team upon approval from the IRB. 
4.4.3  Sample Frame and Sample Size Justification 
 Participants for these one-on-one interviews, focus group, and future survey will be 
obtained from a convenience sample made up from cancer patients within the University of 
Kansas network.  Providers within the University of Kansas network will be asked to aid in our 
recruitment effort of patients by discussing our on-going study and handing their eligible patients 
one of the “Save the Date” cards to attend our focus group or survey session depending on where 
we are at in our study timeline (Appendix E).  In the early stages of our study, providers will also 
be responsible for scheduling one-on-one interviews at an agreeing patient’s next follow-up visit 
with a designated research team member interviewer.   As we are targeting recruitment of cancer 
patients, we plan to reach out to previous PIs that our research team has worked with for filling 
out one-on-one interviews and focus groups.  For our pilot survey portion of the study, we plan 
to recruit from providers from The University of Kansas Cancer Center (KUCC), the Medical 
Oncology Division in the Department of Internal Medicine at the University of Kansas Medical 
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Center (KUMC), and the Hematology/Oncology Division at KU’s Westwood campus.  We 
assume that we will have adequate success in recruiting from previous PIs that we have worked 
with to fill our one-on-one interviews.   
Our justification for recruiting providers and in turn participants from three different 
locations is to reach the widest range of cancers amongst pilot survey participants.  Within each 
of the three recruitment locations that we will utilize to recruit patients from, there are 
approximately 80 listed providers with credentials of M.D. (i.e., medical doctor), O.D. (i.e., 
osteopathic doctor), or P.A. (i.e. physician assistant).  Reaching out to these providers to see if 
they would be willing to assist us in completing this pilot survey study will be fairly feasible as 
e-mail, phone number, and/or office location are available through either the KUMC website 
(www.kumc.edu), KUMC email directory through Microsoft Outlook, or through “Find a 
Doctor” on the health grades website (www.healthgrades.com).  However, we believe that not all 
internet-listed providers see patients in the clinic or if the websites includes the most up-to-date 
list of providers which would reduce our sample of providers, say to 40 providers if we are being 
conservative.  Furthermore, due to the busy schedule of providers, we assume that only half of 
those providers that see patients in the clinic will be able and willing to take on the additional 
responsibility in helping us recruit participants.  Assuming during a one week period a provider 
sees at least two patients that have been diagnosed within the last year, our potential sample size 
of individuals over the course of four weeks would be 160 individuals.  Our hopes are that up to 
20% of those patients whom received the information from their provider and “Save the Date” 
card will actually attend the scheduled pilot survey session (Appendix E).  This equates to ~32 
participants, or more.  Ideally, both the focus group and pilot survey session would be held on a 
Saturday morning around 10:00 a.m. at a University of Kansas facility that had easy-assessable 
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parking near the facility.  The exact date of the survey session would be determined by research 
team following the study approval from the IRB. 
4.4.4  Eligibility Criteria and Compensation 
  For a patient to be eligible to participate in any portion of our study, they must meet two 
criteria.  First, the patient must have been diagnosed with any stage of cancer within the last year 
from the date of the study event they are attending.  Secondly, the patient must be at least 20 
years of age.  Any participant in either a one-on-one interview, the focus group, or in the pilot 
study will receive $50 for their time.   
4.4.5  Questionnaire Development for Interviews, Focus Group, and Pilot Study 
 The study questionnaires for this research study includes questions asked to the patient 
regarding the following: demographics, understanding of genomics and genetic testing, and 
opinions related genomic sequencing.  Questions used in the initial one-on-one interviews and in 
the focus group will follow closely to those found in Appendix F.  However, the both the 
research team member interviewer and the focus group moderator will be trained to inquire 
further to facilitate more discussion on topics that participants fill strongly about.  Specifically 
the survey questionnaire will be divided into three sections to better facilitate the flow of the 
survey.  Section one contains only basic demographic questions that address the background of 
the individual filling out the survey.  Section two will briefly educate the individual about 
genetics, cancer, and genetic testing.  Lastly, section three will contain questions to obtain 
patient’s opinion which will be broken into appropriate domains in our pilot survey study (i.e., 
education, precision medicine ethics, etc.).  Responses to each of the survey questions were 
designed to be highly inclusive and provide insight.  To minimize non-response to questions, 
most questions are given the response option “Prefer Not to Answer”.  The proposed prototype 
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of the survey questionnaire can be found in (Appendix F).  Revisions to this prototype would be 
made to reflect the findings from the one-on-one interview and focus group to better address our 
objectives.  Additional questions that were asked by either the interviewer or moderator will be 
considered by research team to determine best way to include them in the pilot survey study. 
4.4.6  Data Collection 
4.4.6.1  One-on-one Interview and Focus Group Study Portion 
Participants that take part in either a one-on-one interview or the focus group will be 
asked to sign a consent form prior to being asked any information pertaining to the study.  In the 
one-on-one interview the research team member interviewer will ask the participant to fill our 
questions similar to those found in Section one of the survey prototype found in Appendix F.  
Once these responses were recorded, interviewer would start a digital voice recorder to capture 
all dialect.  Interviewer would take notes as interview took place and would use digital voice 
playback to fill in any missed information after completion of the interview. Collection of focus 
group data would be collected very similarly to that of the one-on-one interviews.  The only 
difference that would occur is that the prototype pilot survey in its entirety would be given to all 
participants.  Once participants complete the prototype pilot survey, moderator will facilitate 
open session for questions, comments, and clarification.  A digital voice recording of this open 
session will be taken and turned into a transcript for research team to review.  Relevant responses 
and notes as determined by research team member would be summarized for review.  Changes to 
the pilot survey prototype will then be made reflect participants, moderator, and interview’s 





4.4.6.2  Pilot Survey Study Portion 
Participants that show up to the survey session will also be asked to sign a consent form 
prior to receiving the survey questionnaire to complete.  The entire survey session will be led by 
two independent survey administrators each of whom were educated about the survey topics and 
instructed on how to run the survey session.  We propose to collect data from a 22-item, paper-
based survey consisting of primarily check box responses and few free text questions.  This 22-
item questionnaire would be revised to reflect those findings from the one-on-one interviews and 
focus groups.  Additionally, study participants are given a space at the end of the survey to 
provide feedback and comments about the survey and/or session.  Study participants will be 
given a paper copy of the survey to record their responses and be directed to turn in their 
completed survey to one of the survey session administrators.   
Data from paper survey are then entered manually into a digital database (i.e., Microsoft 
Excel) by two research team members.  Data will then be matched to determine agreement of 
entered responses to aid with Quality Control.  Any disagreeing results between the two datasets 
entered by the research team members will be adjusted by a different research team member 
through review of paper survey responses.  Each of the survey questionnaires will be assigned a 
questionnaire ID which will allow for rectification of disagree responses.  Free text fields, 
comments, and feedback will be summarized in a list format.  Once Quality Control is conducted 
by the research team members, data will be sent to statisticians for analysis. 
4.4.7  Data Analysis   
 After the data are given to the statistician, descriptive analyses will be completed for all 
survey questions.  For all of the check box questions, frequency and percentage of response will 
be calculated.  However, for those free text questions, inclusive lists of all responses will be 
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developed.  If it is applicable for frequencies and percentages to be reported, the statistician 
would create such list.  Shell tables for these analyses can be found in Appendix G.  It would be 
left up to the statistician’s digression for what type of statistical software (i.e., R Statistical 
Software or SAS) they wanted to use to complete the analysis.  Data will be examined for ceiling 
and/or flooring effects for ordered responses to see if responses would need to be adjusted in the 
larger study.  Additionally, missing values would be tracked for each question.  Depending on 
the percentage of missing values, data imputation may be considered.  Furthermore, for 
Questions 14, 20, and 21 mean response would be calculated.  Questions 14 and 20 will be 
assigned the following values for given responses: 0 = “Unknown or Prefer Not to Answer”, 1 = 
“Disagree”, 2 = “Neither Disagree or Agree”, and 3 = “Agree”.  Similarly, for Question 21, 0 = 
“Unknown or Prefer Not to Answer”, 1 = “I would decline additional genetic testing”, 2 = “I 
would accept additional genetic testing”. 
Under this current pilot study, no subsequent statistical analysis would be complete.  
Although, in the larger-scale study it might be useful to compare differences among responses 
based on age group.  For instance look at responses for patients <50 years of age vs. 50 years or 
older through a chi-square test.  With a larger-scale study, more elaborate statistical analyses can 
be conducted as larger sample size would although for many statistical methods to be adequately 
powered.   
4.5 Discussion 
 
 The need for additional survey studies that target cancer patients’ opinions towards their 
care is evident from our review of the literature.  As genomic sequencing is become more 
regularly used in diagnosing and decisions about treatment options, it makes sense to survey the 
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opinions of cancer patients regarding the topic.  To expand the current literature, we developed a 
protocol for a patients’ opinion study including one-on-one interviews, a focus group, and a pilot 
survey study which would be implemented within the University of Kansas network.  The 
objectives of the study would be to patients’ opinions towards genomic sequencing; and to gain 
some insight to their opinions in using genomic sequencing to determine targeted drug therapy 
options.  Our proposed protocol for implementing our pilot survey study is fairly basic in 
comparison to many pilot survey studies.  However, we believed that it is necessary to take this 
step-wise approach in its development to have a meaningful and influential survey study.  Our 
sampling population is already considered to be heavily burdened and could highly benefit from 
such a study.  Our hope would that information from this pilot study would drive conduction of a 
larger-scale, potentially nationwide, grant-funded survey. 
 When conducting survey studies, there are many logistical issues that must be considered 
for the study to be successful.  If the proposed pilot survey study were to be approved by the 
IRB, we believe that we would be able to successfully reach our targeted sample size of ~32 
participants in our pilot survey study.  Once the one-on-one interviews and focus group portions 
of the study are completed, we have confidence in the patient providers will be willing to take 
part in providing their patients will information about our study as the University of Kansas has a 
mission statement prioritizes research productivity.  Additionally, we trust that our developed 
study material (i.e., “Save the Dated”, initial questions, and survey questionnaire prototype) will 
be easily understood by study participants.  All study material wording has been designed at an 
appropriate reading level (approximately at an eighth grade reading level).  Concurrently, the 
focus group and survey session would be scheduled to take place outside of the normal work 
week for most individuals, and will only require them to spend up to an hour or hour and a half 
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at the determined KU facility location.  Furthermore, the burden of the one-on-one interview to 
the participant is also reduced by scheduling it together with the patient’s next follow-up. 
Although, as with any research study, our proposed pilot survey study contains 
limitations.  Our study is limited in that we were unable to find any published information of any 
type regarding a patient survey implemented at KUMC.  We are also limited in that those 
participants that complete the study are from a convenience sample and likely are interested in 
voicing their opinions.  Hence, the results may be lacking opinions of those that do not 
participate can lead to bias in our results.  Additionally, our questionnaire prototype is not a 
validated.  Though, we are optimistic that the dialect between patients and study portion 
administrators will provide valuable feedback and comments to improve our survey to be 
conducted on a national level.  Despite these limitations, this pilot survey study has the potential 
to provide valuable information regarding patients’ opinions towards genomic sequencing while 
































 The RNA- Sequencing (RNA-Seq), a Next-Generation Sequencing (NGS) technology, 
has greatly changed the landscape of the field of genomics with its accuracy, breadth of data, and 
sensitivity verses previously used technologies such as microarrays.  Throughout this 
dissertation, many of the RNA-Seq analyses are compared to similar types of analyses that were 
completed in microarrays.  This is done as many researchers and scientists alike seek to translate 
analyses methods once used in microarrays to be used in RNA-Seq.  However, in doing so, there 
are many considerations that need to be given and challenges to be addressed.  Unlike microarray 
data which is continuous in nature and most often normally distributed, RNA-Seq data consists 
of discrete data, or count data.  The properties mentioned for microarray data make its analyses 
more straightforward as numerous method’s assumptions can be readily met.   
While the literature is saturated with studies that compare the biological differences 
between microarray and RNA-Seq technologies, there are only few that extend the differences 
between the two technologies in terms of the statistical analyses.  In this dissertation, we sought 
to expand the knowledge of some of the different statistical challenges that arise from RNA-Seq 
data; as well as, address some of the ethical concerns involved in genomic sequencing.  The 
principle findings from each chapter are as follows. In Chapter II’s differential expression study 
a lack of precision amongst selection of similar genes that are differentially expressed when 
comparing differential expression analysis methods from our empirical analysis.  Results from 
our simulation study, which first examined empirical Type I error rate and later empirical power, 
were as expected.  In general, models (i.e, LM, LMM, GLM, GLMM) that were fit according to 
the data (i.e., if the data were paired (𝜌 = 0.3 and 0.5) or unpaired (𝜌 = 0) between 
measurements) had control of the empirical Type I error rate at a level of 0.05 less regardless of 
the distribution (i.e., Bivariate Normal, Bivariate Poisson, or Bivariate Negative Binomial) the 
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RNA-Seq data were simulated from.  In those simulation scenarios where control of the Type I 
error rate was established, we observed that the empirically calculated power increase with 
increases in mean shift and sample size which is a typical relationship.  Those scenarios with 
conservative Type I error rate values significantly lower than 0.05 had extremely low empirical 
power.  Achievement of adequate power depended heavily on the sample size for scenarios 
where data were simulated from the Bivariate Poisson and Bivariate Negative Binomial 
distributions.  Additionally, in Chapter III’s data transformation and clustering method 
assessment, we found that it is highly challenging to transform data to “look” more normal.  
Despite all of the data transformations that were applied, no transformation equated to the exact 
skewness and kurtosis values found in normally distributed data.  Moreover, our results suggest a 
model-based clustering is the most robust approach to clustering analysis when some knowledge 
is previously known about the number of clusters in the data.  Conversely, if the number of 
clusters in unknown, K-Means clustering would perform best in determining most likely clusters.  
Lastly, in Chapter IV no specific findings were observed as the chapter focuses on the setup of a 
pilot survey study.  However, we assume that highly valuable findings would be obtained to 
allow for an extension of the survey to a larger scale.  
Each of the studies presented within this dissertation can be extended in multiple ways in 
the future.  Findings in Chapter II, provokes implementing either a sandwich estimator or 
utilization of the method of moments to better handle the paired structure and limitation of 
current models.  To do so it Kauerman and Carroll (2000) suggest implementation of a robust 
covariance matrix estimator.  In the study in Chapter III, one may want to consider applying the 
data transformations and clustering methods to an actual dataset to see how the performance of 
the methods compare to those results found in our simulation study.  This study also motivates a 
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development of a new algorithm to determine the number of unknown clusters within a dataset.  
This new algorithm would need to consider that range of gene expression values and be tuned to 
handle small effect changes between clusters.  Both of the studies that utilize RNA-Seq data can 
be extended to smaller sample sizes and compared with the current findings.  This is a critical 
expansion of these studies as often times researchers do not have the resources to have larger 
sample sizes in their experiments.  Another general need that is lacking from the realm of RNA-
Seq research in terms of statistical methodology is the application of non-parametric approaches 
to analyses.  A natural extension of the proposed protocol for the pilot survey study would be to 
actually conduct the study and begin the process of obtaining IRB approval, reach out to 
providers from the three mentioned departments within the University of Kansas network, and 
conduct the study portions. 
Throughout the process of completing this dissertation, many lessons have been learned.  
Aside from the findings of the studies in Chapters II and III, this dissertation has greatly 
improved my statistical programming skills, my approach to designing figures and tables, and 
my overall take on conducting meaningful research. Both of the studies in Chapter II and 
Chapter III, gave me the sense that sequencing technology is outpacing the types of statistical 
analyses to be conducted on its data.  We are able to acquire massive amounts of complex data, 
but when attempting to answer research questions there is often opposition between findings 
which are statistically relevant and/or clinically relevant.  Hence, researchers, statisticians, 
bioinformaticians, and other bio-related scientists are tasked to work together to address those 
unanswered research questions, develop new hypotheses, and overcome the challenges that are 




Appendix A: Local False Discovery Rate (FDR) calculation details 
The following calculation is used in the qvaule package in Bioconductor from Storey et. al. 
(2015) to obtain the local False Discovery Rate (lFDR).  
Consider m hypotheses (i.e., 𝐻1, 𝐻2, … , 𝐻𝑚) are conducted where each hypothesis results in a p-
value, 𝑝𝑔, for 𝑔 = 1,…𝑚 (i.e., 𝑝1, 𝑝2,…, 𝑝𝑚).  These null hypothesis is that some g
th gene is not 
differentially expressed.  These p-values corresponding to the tested null hypotheses are 
considered to be statistically significant if 𝑝𝑖 ≤ 0.05.  Results from the testing can be placed into 
the 2 x 2 contingency table below,  
 
(Storey, 2010, Benjamini and Hochberg, 1995).  Here, V is the number of false positives, or 
rather the number of Type I errors; and R is the total count of all significant null hypothesis.   
Using the information from the 2 x 2 contingency table we can determine the FDR 
𝐹𝐷𝑅 = 𝑬 [
𝑉
𝑅
|𝑅 > 0] 𝐏𝐫(𝑅 > 0) 
(Benjamini and Hochberg, 1995).  Though, others have proposed additional extensions of the 
above FDR.  One extension is the lFDR which is used to quantify the probability of 𝐻𝑔 =
𝑡𝑟𝑢𝑒|𝑝 − 𝑣𝑎𝑙𝑢𝑒𝑔 (Efron and Tibshirani, 2002, Efron et al., 2001).  It follows as such from Liao 
et. al. (2004)(Liao et al., 2004): 
Let 
𝑧𝑔 = {
1 𝑖𝑓 𝑡ℎ𝑒 𝑔𝑡ℎ 𝑔𝑒𝑛𝑒 𝑖𝑠 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙𝑙𝑦 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 
0 𝑖𝑓 𝑡ℎ𝑒 𝑔𝑡ℎ 𝑔𝑒𝑛𝑒 𝑖𝑠 𝑛𝑜𝑡 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙𝑙𝑦 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 
 
be modeled as a Bernoulli trial with probability 1 − 𝜋0 , where 𝜋0 =
𝑚𝑜
𝑚1
.  Also, let 𝑓0 and 𝑓1 be 
the density of 𝑝𝑔|𝑧𝑔 = 0 and 𝑝𝑔|𝑧𝑔 = 0, respectively.  Here, 𝑓0~𝑈𝑛𝑖𝑓𝑜𝑟𝑚 (0,1). That said, we 
have 𝑓(𝑦) = 𝜋0 + 1 − 𝜋0𝑓1(𝑦) which is the two component mixture model that all 𝑝𝑔 come 
from. Hence, the  
𝑙𝐹𝐷𝑅(𝑡) ≡ Pr(𝐻𝑔 = 𝑡𝑟𝑢𝑒|𝑝𝑔 = 𝑡) =
𝜋0




Appendix B: Comparison of overlapping Differential Expression (DE) genes after using 
estimations for False Discovery Rate (FDR) as re-evaluation criteria 
 
 Figure II-A1.  Comparison of Differentially Expressed (DE) genes found in unpaired and 
paired methods after re-evaluation.  The Venn diagrams above contain the number of 
Differentially Expressed (DE) genes that were determined by each method.  The overlapping 
portions of the Venn diagrams represent the number of DE genes selected to be the same 
between the compared DE methods.  A) contains comparisons of DE gens found using paired 
designs; and B) contains comparisons of DE genes found using unpaired designs minus results 





 Figure II-A2.  Comparison of Differentially Expressed (DE) genes found using Bayesian 
and Frequentist theoretical backgrounds after re-evaluation.  The Venn diagrams above 
contain the number of Differentially Expressed (DE) genes that were determined by each 
method.  The overlapping portions of the Venn diagrams represent the number of DE genes 
selected to be the same between the compared DE methods.  A) contains comparisons of DE 
gens found using Bayesian methods; and B) contains comparisons of DE genes found using 
Frequentist methods with our results from CuffDiff..  DE genes were determined using re-
evaluation criteria (estimated FDR < 0.2)
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Appendix C: Additional correlation summaries from simulation study 
 
 Figure II-A3.  Correlation variation summary for simulated data from the Bivariate 
Poisson and Bivariate Negative Binomial distributions.  A) depicts the variability of 
correlations in simulated data for 𝜌 = 0, 0.3, and 0.5 from the Bivariate Poisson distribution.  B) 
depicts the variability of correlations in simulated data for 𝜌 = 0, 0.3, and 0.5 from the Bivariate 




Table II-1A.  Correlation summary for simulated data from the Bivariate Normal, 
Bivariate Poisson, and Bivariate Negative Binomial distributions under the alternative with 
shift of 0.5.  Table contains a summary of average correlations from the simulated data for N = 
100, 150, and 200 for correlations 𝜌 = 0, 0.3, and 0.5.  Data were simulated for unequal means 
with mean shift of 0.5 added. 
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Appendix D: Formulas for Evaluation Criteria for Clustering Methods 
For each of our 𝐷 datasets with 𝑁 = 56 samples (i.e., 𝐷 = {𝑑1, 𝑑2, … , 𝑑𝑛}), two types of 
partitions are made 𝑈 and 𝑉 each of which divides 𝐷 into 𝑘 or r mutually disjoint subsets.  
Partition 𝑈:  
 𝐷 = ⋃ 𝑈𝑖
𝑘
𝑖=1  and 𝑈𝑖⋂𝑈𝑗 = ∅   ∀ 𝑖 ≠ 𝑗      𝑈 = {𝑈1, 𝑈2, … , 𝑈𝑘}    
Partition 𝑉: 
𝐷 = ⋃ 𝑉𝑖
𝑘
𝑖=1  and 𝑉𝑖⋂𝑉𝑗 = ∅   ∀ 𝑖 ≠ 𝑗      𝑉 = {𝑉1, 𝑉2, … , 𝑉𝑟} 
Evaluation for clustering agreement is based off identifying pairs (𝑑𝑖, 𝑑𝑗) of data that are the 
from the same or different partition(Rabbany and Zaiane, 2015).  Counts of these pairs are taken 
from the following table: 
 
The ijth element in the table is the intersection of the two partitions (i.e., 𝑛𝑖𝑗 = |𝑈𝑖⋂𝑉𝑗|), and the 
marginal sums are 𝑛𝑖. = ∑ 𝑛𝑖𝑗𝑗  and 𝑛.𝑗 = ∑ 𝑛𝑖𝑗𝑖 .  To determine whether a pair belong to the same 
or different partition, identification of true positives (TP), false positives (FP), true negatives 
(TN), and false negatives (FN) are computed using sums from the table.  Both the Adjusted Rand 
Index (ARI) and the Clustering Error Rate (CER) utilize this table’s information.   
Adjusted Rand Index (ARI) (Hubert and Arabie, 1985): 
Assumes that the above table is randomly constructed with fixed marginal sums.  Rather the size 
of the clusters in the partition are fixed.  With these two assumptions, we get the Adjusted Rand 
Index 













































Clustering Error Rate (CER) (Witten, 2011): 
The Clustering Error Rate that is used in Witten’s manuscript (2001) is 1-Rand Index.  The 
formula for the Rand Index (Rand, 1971) is:  
























































Concordance Index (CI or C-Index) (Harrell et al., 1996): 
To calculate the Concordance Index (CI), we make comparisons between the cluster assignments 
of samples determined by the clustering methods to our simulated cluster assignments.  The steps 
to achieve this are: 
1) Organize simulated cluster assignments into pairs (𝑑𝑖, 𝑑𝑗) where 𝑖 ≠ 𝑗.  Using notation 
from our study (𝑘𝑖, 𝑘𝑗) 
2) If 𝑘𝑖 > 𝑘𝑗, determine if ?̂?𝑖 > ?̂?𝑗 or ?̂?𝑖 = ?̂?𝑗  which determines if the predicted cluster 
assignments are concordant or discordant.  If ?̂?𝑖 > ?̂?𝑗 add 1 to running sum as prediction 
is concordant to observed simulated cluster assignment.  If ?̂?𝑖 = ?̂?𝑗 add 0.5 to running 
sum.  Let the running sum be s. 
3) Tally number of times 𝑘𝑖 > 𝑘𝑗, say n. 
4) Calculate CI as 















University of Kansas Medical Center 
Department of Biostatistics 
5028 Robinson (5th Floor) 
3901 Rainbow Boulevard 
Kansas City, KS 66160 
 
Pilot Study Questionnaire       Questionnaire ID: ##### 
Pilot Study Title: Cancer Patient Opinions Towards Genetic Testing in Cancers 
Thank you for participating in this focus group and consenting to take part in this survey which 
measures cancer patient’s opinion towards genetic sequencing in cancers.  The survey below 
contains three separate sections.  Section 1 contains general questions that will provide 
information about your background.  Section 2 will briefly educate or refresh your knowledge of 
the concepts that you will asked questions about in Section 3.  Lastly, Section 3 is comprised of 
questions to help us obtain patient’s opinions regarding the use of genetic sequencing to aid in 
cancer treatment.  Below Section 3 is space to leave comments and feedback regarding this focus 
group and/or survey.  Be assured that all answers to this survey will be kept confidential.  Once 
you have completed all questions, please turn in survey to administer to receive your 
compensation for you time and participation. 
 
*Please be sure to select a single response for each question.   
Section 1: Background Questions 
1. What is your age? 
□  20 – 29 Years 
 
□  30 – 39 Years 
 
□  40 – 49 Years 
 
□  50 – 59 Years □  60 – 69 Years □  70+ Years 
□  Prefer Not to Answer   
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2. What is your gender? 
□ Female □ Male □  Other 
□  Prefer Not to Answer   
3. What is your race/ethnicity?  
□  White 
 
□  Black or 
        African American 
□  American Indian or 
         Alaska Native 
□  Hispanic or 
          Latino 
□  Asian □  Other 
___________________________ 
□  Unknown   
□  Prefer Not to Answer   









□  Prefer Not to Answer    
5. What is your highest level of education?  
□ Less Than 
       High School 
□ High School / 
        GED 
□ Some College 
 
□ 4 – Year  
        College Degree 
□ Graduate or 
       Professional Degree 
   
□  Prefer Not to Answer    
Questionnaire ID: ##### 
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6. What is your household income level? 
□ $0 - $15,999 □ $16,000 - $24,999 □ $25,000 - $49,999 
□ $50,000 - $99,999 □ $100,000+  
□  Prefer Not to Answer   
7. How many children do you have? 
□ No Children □ 1 Child □ 2 – 3 Children □ 4 – 5 Children 
□ 6+ Children    
□  Prefer Not to Answer    
8. What type of cancer do you currently have? 
 
______________________________________________________________________ 
9. Do you have a family history of cancer? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
 
9a. If you answered “Yes” to question 9 above, what type of cancer(s) are part of 
your family history of cancer? 
 
_____________________________________________________________________ 
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Section 2: Genetic Testing Education 
Genetic information can be viewed as the blue-print for every individual.  This blue-print 
contains specific information that makes individuals have specific characteristic traits (i.e., hair 
color, presence of dimples, hairline, etc.).  The major component of this blue-print is DNA which 
is made up of four base pairs (i.e., Adenine (A), Thymine (T), Cytosine (C), and Guanine (G)) 
which code for genes (Figure IV-S1).  DNA is found in form of chromosomes within the nucleus 
of nearly every cell in the human body.  The DNA within each of the 23 pairs of chromosomes 
guide the cells in the body to grow and develop.  Though when a gene becomes mutated in a 
specific area, it can cause cell to misbehave.  Depending on the mutation, the human body’s 
immune system may respond by killing off the cell.  However, when the immune system does 
not recognize the mutation, the cell divides and copies at rapid rate leading to cancer.  With the 
advancement of technology, researchers are able to look directly at an individual’s DNA and/or 
those mutations that are found in cancerous cells through genetic testing (Figure IV-S2).  Often 
times the information found from genetic testing of cancer can lead to more targeted treatment 
therapies. 
(Designed figure showing relationship between genes, cells, tissues, and the body)   
Figure IV-S1.  Overview of DNA within the human body 
 
Figure IV-S2.  Types of cell copying in the human body.  New cells are continually being 
made in the human body by coping information from older cells.  Occasionally, a mutation of the 
DNA occurs which causes various reactions to the cell.  Panel A displays the immune system’s 
response to a DNA mutation.  Panel B displays the uncontrollable grow (i.e., cancer) that occurs 
when the immune system does not recognize the mutations that occur. 
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Section 3: Patient Opinion Questions 
10.  Please rate your current level of understanding of genetic testing?  
□  None □  Very Poor □  Poor 
□  Fair □  Good □  Very Good 
□  Unknown   
□  Prefer Not to Answer   
11. Have you ever had genetic testing completed for your current cancer? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
12. Have you ever had any genetic testing completed in your past for any reason? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
13. Have any members of your immediate family (i.e., parents and/or grandparents) 
that have had cancer, had genetic testing completed? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
Questionnaire ID: ##### 
161 
 
14. Generally speaking, do you think that conducting genetic testing is ethical?  
□ Disagree □ Neither Disagree or Agree □  Agree 
□  Unknown   
□  Prefer Not to Answer   
15. Has your medical provider talked to you about the possibility of having genetic 
testing completed to determine targeted options for cancer treatment? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
16. Has your medical provider scheduled an appointment for you to have genetic testing 
completed on a sample of your cancer (i.e., your tumor)? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
17. If you answered “No” or “Unknown” to question 15 would you want to have genetic 
testing completed if it were an option to determine targeted cancer treatment? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
□  Answered “Yes” for Question 15   
Questionnaire ID: ##### 
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18. If the results from genetic testing revealed an incidental finding would you want to 
know about it? (An incidental finding is a potential medically relevant finding that 
was found unintentionally or that is unrelated to tested medical condition.) 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
19. If genetic testing revealed that there was a clinical trial testing a new drug that 
would be a treatment option for your cancer, would you consider enrolling? 
□ Yes □ No □  Unknown 
□  Prefer Not to Answer   
20. Do you think patient providers should promote genetic testing to cancer patients?  
□ Disagree □ Neither Disagree or Agree □  Agree 
□  Unknown   
□  Prefer Not to Answer   
21. How do you feel about having additional genetic testing of your germline to 
determine if you have a mutation or many mutations in cancer-predisposing genes? 
□  I would decline additional genetic testing  
□  I would agree to additional genetic testing 
□  Unknown 
□  Prefer Not to Answer 
Questionnaire ID: ##### 
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22. Which of the following, if any, do you feel influenced your responses to any of the 
questions in Section 3?  (Select all that apply) 
□  Lack of Knowledge/Information Regarding Survey Topic  
□  Religious Beliefs 
□  Costs Associated with Genetic Testing 
□  Insurance Concerns 
□  Previous Experience 
□  Other ________________________ 
□  Prefer Not to Answer 
 
 







Thank you for your time and responses.  Please see survey administrator to receive 





Appendix G: Shell Tables and Feedback Space to Complete after Quality Control is 
Completed on Survey Data 
Table IV-A1.  Demographic summary from Section 1 of survey questionnaire  
Table contains summary of responses from Section 1 of survey questionnaire.  Responses are 
given as a frequency and percentage. 
Questions Question Responses 
Response Frequency 
(%) 
1. What is your age? 
20-29 Years  
30-39 Years  
40-49 Years  
50-59 Years  
60-69 Years  
70+ Years  
Prefer Not to Answer  




Prefer Not to Answer  
3. What is your race/ethnicity?  
White  
Black or African 
American 
 
American Indian of 
Alaska Native 
 




Prefer Not to Answer  






Prefer Not to Answer  
5. What is your highest level of 
education? 
Less Than High School  
High School/ GED  
Some College  
4 – Year College Degree  
Graduate or Professional 
Degree 
 











Prefer Not to Answer  
7. How many children do you 
have? 
No Children  
1 Child  
2 – 3 Children  
4 – 5 Children  
6+ Children  
Prefer Not to Answer  
8. What type of cancer do you 
have currently? 
**Responses will be 
listed with their frequency 
 





Prefer Not to Answer  
8a. If you answered “Yes” to 
question 8 above, what type of 
cancer(s) are part of your 
family history of cancer? 
**Top responses will be 
listed with their 
frequency.  Complete list 




Question 8 unique responses with frequency provided in “( )”: 
 




Table IV-A2.  Summary of patient’s opinion responses from Section 3 of survey 
questionnaire  
Table contains summary of responses from Section 1 of survey questionnaire.  Responses are 
given as a frequency and percentage. 




10. Please rate your current level of 
understanding of genetic testing? 
None  




Very Good  
Unknown  
Prefer Not to Answer  
11. Have you ever had genetic testing 




Prefer Not to Answer  
12. Have you ever had any genetic testing 




Prefer Not to Answer  
13. Have any members of your immediate 
family (i.e., parents and/or 
grandparents) that have had cancer, had 




Prefer Not to Answer  
14. Generally speaking, do you think that 
conducting genetic testing is ethical? 
Disagree  
Neither Disagree or Agree  
Agree  
Unknown  
Prefer Not to Answer  
15. Has your medical provider talked to you 
about the possibility of having genetic 
testing completed to determine targeted 








16. Has your medical provider scheduled an 
appointment for you to have genetic 
testing completed on a sample of your 




Prefer Not to Answer  
17. If you answered “No” or “Unknown” to 
question 15 would you want to have 
genetic testing completed if it were an 





Prefer Not to Answer  
Answered “Yes” for 
Question 15 
 
18. If the results from genetic testing 
revealed an incidental finding would 




Prefer Not to Answer  
19. If genetic testing revealed that there was 
a clinical trial testing a new drug that 
would be a treatment option for your 




Prefer Not to Answer  
20. Do you think patient providers should 
promote genetic testing to cancer 
patients? 
Disagree  
Neither Disagree or Agree  
Agree  
Unknown  
Prefer Not to Answer  
21. How do you feel about having 
additional genetic testing of your 
germline to determine if you have a 
mutation or many mutations in cancer-
predisposing genes? 
I would decline additional 
genetic testing 
 









22. Which of the following, if any, do you 
feel influenced your responses to any of 




Regarding Survey Topic 
 
Religious Beliefs  
Costs Associated with 
Genetic Testing 
 
Insurance Concerns  
Previous Experience  
Other  
Prefer Not to Answer  
 
Question 22 written-in responses for “Other” response options: 
 
Table IV-A3.  Mean response of patient’s opinion for select questions 
Questions Question Responses 
Mean 
Response 
14. Generally speaking, do you think that 
conducting genetic testing is ethical? 
Disagree 
 
Neither Disagree or Agree 
Agree 
Unknown 
Prefer Not to Answer 
20. Do you think patient providers should 




Neither Disagree or Agree 
Agree 
Unknown 
Prefer Not to Answer 
21. How do you feel about having 
additional genetic testing of your 
germline to determine if you have a 
mutation or many mutations in cancer-
predisposing genes? 
I would decline additional 
genetic testing 
 
I would agree to additional 
genetic testing 
Unknown 
Prefer Not to Answer 
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